US20040258656A1 - High affinity TGFbeta nucleic acid ligands and inhibitors - Google Patents

Abstract

Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGFβ2. Included in the invention are specific RNA ligands to TGFβ2 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGFβ2 with its receptor.

Description

RELATED APPLICATIONS
• This application is a continuation of U.S. patent application Ser. No. 09/791,301, filed Feb. 23, 2001, entitled “High Affinity TGFβ Nucleic Acid Ligands and Inhibitors,” now U.S. Pat. No. 6,713,616, which is a continuation of U.S. patent application Serial No. 09/363,939, filed Jul. 29, 1999, entitled “High Affinity TGFP Nucleic Acid Ligands and Inhibitors,” now U.S. Pat. No. 6,346,611, which is a continuation-in-part of U.S. patent application Ser. No. 09/046,247, filed Mar. 23, 1998, entitled “High Affinity TGFβ Nucleic Acid Ligands and Inhibitors,” now U.S. Pat. No. 6,124,449, which is a continuation-in-part of U.S. patent application Ser. No. 08/458,424, filed Jun. 2, 1995, entitled “High Affinity TGFβ Nucleic Acid Ligands and Inhibitors,” now U.S. Pat. No. 5,731,424, which is a continuation-in-part of U.S. patent application Ser. No. 07/714,131, filed Jun. 10, 1991, entitled “Nucleic Acid Ligands,” now U.S. Pat. No. 5,475,096, which is a continuation-in-part of U.S. patent application Ser. No. 07/536,428, filed Jun. 11, 1990, entitled “Systematic Evolution of Ligands by EXponential Enrichment,” now abandoned. U.S. patent application Ser. No. 08/458,424 is also a continuation in part of U.S. patent application Ser. No. 07/931,473, filed Aug. 17, 1992, entitled “Methods for Identifying Nucleic Acid Ligands,” now U.S. Pat. No. 5,270,163. U.S. patent application Ser. No. 08/458,424 is also a continuation in part of U.S. patent application Ser. No. 07/964,624, filed Oct. 21, 1992, entitled “Nucleic Acid Ligands to HIV-RT and HIV-1 Rev,” now U.S. Pat. No. 5,496,938. U.S. patent application Ser. No. 08/458,424 is also a continuation in part of U.S. patent application Ser. No. 08/117,991, filed Sep. 8, 1993, entitled “High Affinity Nucleic Acid Ligands Containing Modified Nucleotides,” now abandoned. U.S. patent application Ser. No. 09/363,939 is also a continuation-in-part of U.S. patent application Ser. No. 08/434,465, entitled “Nucleic Acid Ligand Complexes,” filed May 4, 1995, now U.S. Pat. No.6,011,020. The disclosure of each of the foregoing applications, and all patents and publications referred to herein, is incorporated by reference herein in its entirety.[0001]
FIELD OF THE INVENTION
• Described herein are methods for identifying and preparing high affinity nucleic acid ligands that bind human transforming growth factor β2 (TGFβ2). The method utilized herein for identifying such nucleic acid ligands is called SELEX, an acronym for Systematic Evolution of Ligands by EXponential Enrichment. This invention includes high affinity nucleic acids of human TGFβ2. Further disclosed are RNA ligands to TGFβ2. Also included are oligonucleotides containing nucleotide derivatives modified at the 2′ position of the pyrimidines. Additionally disclosed are ligands to TGFβ2 containing 2′-OCH[0002]₃purine modifications that may have higher stability in serum and in animals. This invention also includes high affinity nucleic acid inhibitors of TGFβ2. The oligonucleotide ligands of the present invention are useful in any process in which binding to TGFβ2 is required. This includes, but is not limited to, their use as pharmaceuticals, diagnostics, imaging agents, and immunohistochemical reagents.
BACKGROUND OF THE INVENTION
• Transforming growth factors betas (TGFβs) are part of a superfamily of proteins that includes inhibins, activins, bone morphogenetic and osteogenic proteins, growth/differentiation factors, Mullerian-inhibiting substance, decapentaplegic and 60A ([0003]Drosophila), daf-7 and unc-129 (C. elegans), and vg1 (Xenopus) (Schlunegger and Grutter (1992) Nature 358:430-434). Three TGFβ isotypes exist in mammals that are calledTGFβ 1, TGFβ2, and TGFP3. There is about 80% sequence identity between any pair of mammalian TGFβs. TGFβs bind to at least 5 receptors, but only 2 or 3 of them (types I, II, and possibly V) are signaling receptors. The intracellular signaling pathways activated by TGFβs involve SMAD proteins and are being intensively studied (Padgett et al. (1998) Pharmacol Ther 78:47-52). The signaling receptors are found on a variety of cells. In turn, a variety of cells express TGFβs.
• TGFβs are synthesized as precursors composed of latency-associated protein (LAP) at the amino terminus and mature TGFβ at the carboxyl terminus. The precursor is cleaved and assembles as a homodimer. TGFβs are secreted from cells bound to LAP and latent TGFβ binding proteins (LTBPs). Latent TGFβs are released from LAP and LTBP and become active by a relatively uncharacterized mechanism that may involve proteolysis by plasmin or regulation by thrombospondin (Crawford et al. (1998) Cell 93:1159-70). The mature, released TGFβ homodimer has a combined molecular weight of ˜25000 daltons (112 amino acids per monomer). TGFβ 1 and TGFβ2 bind heparin and there are indications that basic amino acids at position 26 are required for heparin binding (Lyon et al. (1997) Jour. Biol. Chem. 272:18000-18006).[0004]
• The structure of TGFβ2 has been determined using x-ray crystallography (Daopin et al. (1992) Science 257:369-373; Schlunegger and Grutter (1992) Nature 358:430-434) and is very similar to the structure of TGFβ1. TGFβs belong to a structural family of proteins called the “cysteine knot” proteins that includes vascular endothelial growth factor, nerve growth factor, human chorionic gonadotropin, and platelet-derived growth factor. These proteins are structurally homologous, but have only 10-25% primary sequence homology.[0005]
• The biological activities of the TGFβs vary (Moses (1990) Growth Factors from Genes to Clinical Application 141-155; Wahl (1994) J. Exp. Med. 180:1587-1590). In some cases they inhibit cell proliferation (Robinson et al. (1991) Cancer Res. 113:6269-6274) and in other cases they stimulate it (Fynan and Reiss (1993) Crit. Rev. Oncogenesis 4:493-540). They regulate extracellular matrix formation and remodeling (Koli and Arteaga (1996) J. Mammary Gland Bio. and Neoplasia 1:373-380). They are also are very potent immunosuppressants (Letterio and Roberts (1998) Ann. Rev. Immunol. 16:137-161). TGFβs are thought to play a significant role in fibrotic diseases, preventing the immune system from rejecting tumors (Fakhrai et al. (1996) Proc. Natl. Acad. USA 93:2090-2914), cancer cell growth (Koli and Arteaga (1996) J. Mammary Gland Bio. and Neoplasia 1:373-380; Reiss and Barcellos-Hoff (1997) Breast Cancer Res. and Treatment 45:81-85; Jennings and Pietenpol (1998) J. Neurooncol. 36:123-140), and tumor metastasis. They may have ancillary roles in autoimmune and infectious diseases. Inhibition of TGFβ2 by an expressed antisense RNA (Fakhrai et al. (1996) Proc. Natl. Acad. USA 93:2090-2914) and by exogenous antisense oligonucleotides (Marzo et al. (1997) Cancer Research 57:3200-3207) has been reported to prevent glioma formation in rats.[0006]
• The gene for mouse TGFβ2 has been deleted (Sanford et al. (1997) Development 124:2659-2670). Mice lacking TGFβ2 function die near birth and have aberrant epithelial-mesencymal interactions that lead to developmental defects in the heart, eye, ear, lung, limb, craniofacial area, spinal cord, and urogenital tracts. These defects, for the most part, do not overlap abnormalities that have been observed in[0007]TGFβ 1 and TGFP3 knockout mice. TGFβs have also been overexpressed in cell lines or transgeneic mice (Koli and Arteaga (1996) J. Mammary Gland Bio. and Neoplasia 1:373-380; Bottinger et al. 1997 Kidney Int. 51:1355-1360; Bottinger and Kopp (1998) Miner Electrolyte Metab 24:154-160) with a variety of effects.
• A method for the in vitro evolution of nucleic acid molecules with high affinity binding to target molecules has been developed. This method, Systematic Evolution of Ligands by EXponential enrichment, termed SELEX, is described in U.S. patent application Ser. No. 07/536,428, filed Jun. 11, 1990, entitled “Systematic Evolution of Ligands by Exponential Enrichment,” now abandoned, U.S. patent application Ser. No. 07/714,131, filed Jun. 10, 1991, entitled “Nucleic Acid Ligands,” now U.S. Pat. No. 5,475,096 and U.S. patent application Ser. No. 07/931,473, filed Aug. 17, 1992, entitled “Methods for Identifying Nucleic Acid Ligands,” now U.S. Pat. No. 5,270,163 (see also WO91/19813), each of which is herein specifically incorporated by reference. Each of these applications, collectively referred to herein as the SELEX patent applications, describe a fundamentally novel method for making a nucleic acid ligand to any desired target molecule.[0008]
• The SELEX method involves selection from a mixture of candidate oligonucleotides and step-wise iterations of binding, partitioning and amplification, using the same general selection theme, to achieve virtually any desired criterion of binding affinity and selectivity. Starting from a mixture of nucleic acids, preferably comprising a segment of randomized sequence, the SELEX method includes steps of contacting the mixture with the target under conditions favorable for binding, partitioning unbound nucleic acids from those nucleic acids which have bound to target molecules, dissociating the nucleic acid-target complexes, amplifying the nucleic acids dissociated from the nucleic acid-target complexes to yield a ligand-enriched mixture of nucleic acids, then reiterating the steps of binding, partitioning, dissociating and amplifying through as many cycles as desired to yield high affinity nucleic acid ligands to the target molecule.[0009]
• The basic SELEX method may be modified to achieve specific objectives. For example, U.S. patent application Ser. No. 07/960,093, filed Oct. 14, 1992, entitled “Method for Selecting Nucleic Acids on the Basis of Structure,” now abandoned, describes the use of SELEX in conjunction with gel electrophoresis to select nucleic acid molecules with specific structural characteristics, such as bent DNA (See U.S. Pat. No. 5,707,796). U.S. patent application Ser. No. 08/123,935, filed Sep. 17, 1993, entitled “Photoselection of Nucleic Acid Ligands,” now abandoned, describes a SELEX based method for selecting nucleic acid ligands containing photoreactive groups capable of binding and/or photocrosslinking to and/or photoinactivating a target molecule. U.S. patent application Ser. No. 08/134,028, filed Oct. 7, 1993, entitled “High-Affinity Nucleic Acid Ligands That Discriminate Between Theophylline and Caffeine,” now abandoned, describes a method for identifying highly specific nucleic acid ligands able to discriminate between closely related molecules, termed “Counter-SELEX” (See U.S. Pat. No. 5,580,737). U.S. patent application Ser. No. 08/143,564, filed Oct. 25, 1993, entitled “Systematic Evolution of Ligands by EXponential Enrichment: Solution SELEX,” now abandoned, (See also U.S. Pat. No. 5,567,588) and U.S. patent application Ser. No. 08/792,075, filed Jan. 31, 1997, entitled “Flow Cell SELEX,” now U.S. Pat. No. 5,861,254, describe SELEX-based methods which achieve highly efficient partitioning between oligonucleotides having high and low affinity for a Target molecule. U.S. patent application Ser. No. 07/964,624, filed Oct. 21, 1992, entitled “Nucleic Acid Ligands to HIV-RT and HIV-1 Rev,” now U.S. Pat. No. 5,496,938, describes methods for obtaining improved Nucleic Acid Ligands after the SELEX process has been performed. U.S. patent application Ser. No. 08/400,440, filed Mar. 8, 1995, entitled “Systematic Evolution of Ligands by EXponential Enrichment: Chemi-SELEX,” now U.S. Pat. No. 5,705,337,describes methods for covalently linking a ligand to its target.[0010]
• The SELEX method encompasses the identification of high-affinity nucleic acid ligands containing modified nucleotides conferring improved characteristics on the ligand, such as improved in vivo stability or delivery. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions. Specific SELEX-identified nucleic acid ligands containing modified nucleotides are described in U.S. patent application Ser. No. 08/117,991, filed Sep. 8, 1993, entitled “High Affinity Nucleic Acid Ligands Containing Modified Nucleotides,” now abandoned, that describes oligonucleotides containing nucleotide derivatives chemically modified at the 5- and 2′-positions of pyrimidines, as well as specific RNA ligands to thrombin containing 2′-amino modifications (See U.S. Pat. No. 5,660,985). U.S. patent application Ser. No. 08/134,028, supra, describes highly specific nucleic acid ligands containing one or more nucleotides modified with 2′-amino (2′-NH2), 2′-fluoro (2′-F), and/or 2′-O-methyl (2′-OMe). U.S. patent application Ser. No. 08/264,029, filed Jun. 22, 1994, entitled “Novel Method of Preparation of Known and[0011]Novel 2′ Modified Nucleosides by Intramolecular Nucleophilic Displacement,” now abandoned, describes oligonucleotides containing various 2′-modified pyrimidines. PCT/US98/00589 (WO 98/18480), filed Jan. 7, 1998, entitled “Bioconjugation of Oligonucleotides” describes a method for identifying bioconjugates to a target comprising nucleic acid ligands derivatized with a molecular entity exclusively at the 5′-position of the nucleic acid ligands.
• The SELEX method encompasses combining selected oligonucleotides with other selected oligonucleotides and non-oligonucleotide functional units as described in U.S. patent application Ser. No. 08/284,063, filed Aug. 2, 1994, entitled “Systematic Evolution of Ligands by Exponential Enrichment: Chimeric SELEX,” now U.S. Pat. No. 5,637,459 and U.S. patent application Ser. No. 08/234,997, filed Apr. 28, 1994, entitled “Systematic Evolution of Ligands by Exponential Enrichment: Blended SELEX,” now U.S. Pat. No. 5,683,867, respectively. These applications allow the combination of the broad array of shapes and other properties, and the efficient amplification and replication properties, of oligonucleotides with the desirable properties of other molecules. The full text of the above described patent applications, including but not limited to, all definitions and descriptions of the SELEX process, are specifically incorporated herein by reference in their entirety.[0012]
BRIEF SUMMARY OF THE INVENTION
• The present invention includes methods of identifying and producing nucleic acid ligands to transforming growth factor beta (TGFβ2) and the nucleic acid ligands so identified and produced. In particular, RNA sequences are provided that are capable of binding specifically to TGFβ2. Also included are oligonucleotides containing nucleotide derivatives modified at the 2′ position of the pyrimidines. Specifically included in the invention are the RNA ligand sequences shown in Tables 5, 7, 8, 11, 13, 14, 16-19 and FIG. 9 (SEQ ID NOS:21-121 and 128-193). Also included in this invention are RNA ligands of TGFβ2 that inhibit the function of TGFβ2. Also described herein are 2′-OMe-modified nucleic acid ligands of[0013]TGFβ 1, shown in Table 22 (SEQ ID NOS:194-216).
• Further included in this invention is a method of identifying nucleic acid ligands and nucleic acid ligand sequences to TGFβ2, comprising the steps of (a) preparing a candidate mixture of nucleic acids, (b) contacting the candidate mixture of nucleic acids with TGFβ2, (c) partitioning between members of said candidate mixture on the basis of affinity to TGFβ2, and (d) amplifying the selected molecules to yield a mixture of nucleic acids enriched for nucleic acid sequences with a relatively higher affinity for binding to TGFβ2.[0014]
• More specifically, the present invention includes the RNA ligands to TGFβ2, identified according to the above-described method, including those ligands shown in Tables 5, 7, 8, 11, 13, 14, 16-19 and FIG. 9 (SEQ ID NOS:21-121 and 128-193). Also included are nucleic acid ligands to TGFβ2 that are substantially homologous to any of the given ligands and that have substantially the same ability to bind TGFβ2 and inhibit the function of TGFβ2. Further included in this invention are nucleic acid ligands to TGFβ2 that have substantially the same structural form as the ligands presented herein and that have substantially the same ability to bind TGFβ2 and inhibit the function of TGFβ2.[0015]
• The present invention also includes other modified nucleotide sequences based on the nucleic acid ligands identified herein and mixtures of the same.[0016]
BRIEF DESCRIPTION OF THE FIGURES
• FIG. 1 shows a flow chart summarizing the various SELEX experiments done with TGFβ2. The length of the arrowheads corresponds to the round number shown to the left. Connected arrowheads indicate branches in the SELEX experiments where a pool was used to start a new branch. Under each arrowhead the fold improvement in affinity is also shown.[0017]
• FIG. 2 shows activity of TGFβ2 following amine coupling on a BIAcore carboxymethylcellulose (CM5) chip. A CM5 chip was loaded with TGFβ2 using NHS-EDC coupling as described in the Materials and Methods at about 18, 718, and 1692 response units for flow cell (FC) 1, 2, and 3, respectively. FC-4 was left blank as a control and was used to normalize the signals from the other FCs. The chip was then exposed to 10 nM of either (FIG. 2A) latency associated peptide (LAP) or (FIG. 2B) TGFβ soluble receptor III (sRUD at 20:l/min in binding buffer. Data were collected for an association and a dissociation phase as shown. The signal from FC-4 was subtracted from the other FCs.[0018]
• FIG. 3 shows affinity improvement during the spr SELEX. A CM5 chip was loaded with TGFβ2 using NHS-EDC coupling as described in the Materials and Methods at about 18, 718, and 1692 response units for flow cell (FC) 1, 2, and 3, respectively. FC-4 was left blank as a control and was used to normalize the signals from the other FCs. The chip was then exposed to 1:M of RNA pools from the SELEX rounds (Rd) as shown at 20:l/min in binding buffer. Data were collected for an association and a dissociation phase as shown. The signal from FC-4 was subtracted from the other FCs.[0019]
• FIG. 4 shows nitrocellulose filter binding curves with pools from the spr SELEX. High specific activity internally labeled RNA was used from rounds (R) as shown. Labeled RNA was incubated with various concentrations of TGFβ2 in the presence of ˜100,000 fold molar excess unlabelled tRNA. Bound RNA was partitioned by nitrocellulose filtration and quantitated. Data were analyzed as described in the Materials and Methods.[0020]
• FIG. 5 shows nitrocellulose filter binding curves with various pools. High specific activity internally labeled RNA was used from rounds (R) as shown. Labeled RNA was incubated with various concentrations of TGFβ2 (no competitor tRNA was used). Bound RNA was partitioned by nitrocellulose filtration and quantitated. Data were analyzed as described in the Materials and Methods.[0021]
• FIG. 6 shows specificity of the bioactivity of[0022]lead TGFβ 1 and TGFβ2 aptamers and comparison with commercial antibody preparations. RNA was either synthesized by phosphoramidite chemistry (NX22283) or by in vitro transcription. Indicator cells (mink lung epithelial cells) were incubated with either TGFβ1, TGFβ2 or TGFβ3 and dilutions of RNA or antibody as described. The extent of cell proliferation was measured by³H-thymidine incorporation and the data were analyzed as described. The points represent an average of n=2-6 and error bars are standard errors. Symbols designated by TGFβ1, TGFβ2 or TGFβ3 indicate data obtained from cells treated with either TGFβ1, TGFβ2 or TGFβ3, respectively. MAB and pAB designate monoclonal and polyclonal antibodies, respectively. Random, NX22283 and 40-03 designate the use of random RNA, the TGFβ2 or the TGFβ1 lead aptamer, respectively. The aptamer 40-03 was described in the TGFβ1 patent (U.S. Pat. No. 6,124,449, entitled “High-Affinity TGFβ Nucleic Acid Ligands and Inhibitors”).
• FIG. 7 shows boundaries of TGFβ2 ligands 14-1, 21-21 and 21-4. RNA aptamers were end labeled at the 5′ end (3′B) or at the 3′ end (5′B), partially hydrolyzed at high pH, and partitioned for binding to TGFβ2 by nitrocellulose filtration as described in the Materials and Methods. The amounts of TGFβ2 used for binding partitioning is as shown. Recovered RNA was analyzed on high resolution sequencing gels and visualized by autoradiography. Unselected hydrolyzed RNA was used as a marker (Alk. hydr.) to align the banding pattern to the sequence of each ligand. The observed boundary bands are shown with (*) and their position in the sequence pattern is shown by arrowheads. No protein and input lanes show the background binding to nitrocellulose and the starting unhydrolyzed RNA. The observed boundaries for each ligand is summarized at the bottom of the figure.[0023]
• FIG. 8 shows the putative structures of TGFβ2 aptamers. The minimal required sequences were fit into similar structures.[0024]Ligand 14i-1t5-41 and 21a-4(ML-110) were transcribed in vitro and contained extra bases at their 5′ ends (shown in lower case) to allow efficient in vitro transcription. Bold-faced letters indicate positions that are identical to invariant positions of the biased SELEX with the 21-21 sequence.
• FIG. 9 shows the molecular description of NX22323 40k PEG. rG =2′-OH G; rA =2′-OH A; FU =2′-FU; FC=2′-FC.[0025]
• FIG. 10 shows the putative structure of lead truncate ligand CD70. Lower case letters indicate positions requiring 2′-OH.  indicates GU base pairing.[0026]
• FIG. 11 shows the pharmacokinetics of TGFβ aptamer in sprague dawley rats.[0027]
DETAILED DESCRIPTION OF THE INVENTION
• This application describes high-affinity nucleic acid ligands to TGFβ2 identified through the method known as SELEX. SELEX is described in U.S. patent application Ser. No. 07/536,428, entitled “Systematic Evolution of Ligands by EXponential Enrichment,” now abandoned, U.S. patent application Ser. No. 07/714,131, filed Jun. 10, 1991, entitled “Nucleic Acid Ligands,” now U.S. Pat. No. 5,475,096 and U.S. patent application Ser. No. 07/931,473, filed Aug. 17, 1992, entitled “Methods for Identifying Nucleic Acid Ligands,” now U.S. Pat. No. 5,270,163 (see also WO91/19813). These applications, each specifically incorporated herein by reference, are collectively called the SELEX patent applications. Nucleic Acid Ligands to TGFβ have been identified through the SELEX method. These TGF, Nucleic Acid Ligands are described in U.S. patent application Ser. No. 08/458,423, filed Jun. 2, 1995, entitled, “High Affinity TGF, Nucleic Acid Ligands and Inhibitors,” now U.S. Pat. No. 5,731,144 and U.S. patent application Ser. No. 09/046,247, filed Mar. 23, 1998, entitled “High Affinity TGFβ Nucleic Acid Ligands and Inhibitors,” and U.S. patent application Ser. No. 09/275,850, filed Mar. 24, 1999, entitled “Truncation SELEX Method.” These applications are specifically incorporated herein in their entirety.[0028]
• Certain terms used to described the invention herein are defined as follows:[0029]
• “Nucleic Acid Ligand” as used herein is a non-naturally occurring nucleic acid having a desirable action on a target. Nucleic Acid Ligands are also referred to herein as “aptamers.” A desirable action includes, but is not limited to, binding of the target, catalytically changing the target, reacting with the target in a way which modifies/alters the target or the functional activity of the target, covalently attaching to the target as in a suicide inhibitor, and facilitating the reaction between the target and another molecule. In the preferred embodiment, the desirable action is specific binding to a target molecule, such target molecule being a three dimensional chemical structure other than a polynucleotide that binds to the nucleic acid ligand through a mechanism which predominantly depends on Watson/Crick base pairing or triple helix binding, wherein the nucleic acid ligand is not a nucleic acid having the known physiological function of being bound by the target molecule. Nucleic acid ligands include nucleic acids that are identified from a candidate mixture of nucleic acids, said nucleic acid ligand being a ligand of a given target by the method comprising: a) contacting the candidate mixture with the target, wherein nucleic acids having an increased affinity to the target relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and c) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids.[0030]
• “Candidate Mixture” is a mixture of nucleic acids of differing sequence from which to select a desired ligand. The source of a candidate mixture can be from naturally-occurring nucleic acids or fragments thereof, chemically synthesized nucleic acids, enzymatically synthesized nucleic acids or nucleic acids made by a combination of the foregoing techniques. In a preferred embodiment, each nucleic acid has fixed sequences surrounding a randomized region to facilitate the amplification process.[0031]
• “Nucleic Acid” means either DNA, RNA, single-stranded or double-stranded and any chemical modifications thereof Modifications include, but are not limited to, those which provide other chemical groups that incorporate additional charge, polarizability, hydrogen bonding, electrostatic interaction, and fluxionality to the nucleic acid ligand bases or to the nucleic acid ligand as a whole. Such modifications include, but are not limited to, 2′-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5-iodo-uracil, backbone modifications, methylations, unusual base-pairing combinations such as the isobases isocytidine and isoguanidine and the like. Modifications can also include 3′ and 5′ modifications such as capping.[0032]
• “SELEX” methodology involves the combination of selection of nucleic acid ligands which interact with a target in a desirable manner, for example binding to a protein, with amplification of those selected nucleic acids. Iterative cycling of the selection/amplification steps allows selection of one or a small number of nucleic acids which interact most strongly with the target from a pool which contains a very large number of nucleic acids. Cycling of the selection/amplification procedure is continued until a selected goal is achieved. In the present invention, the SELEX methodology is employed to obtain nucleic acid ligands to TGFβ2. The SELEX methodology is described in the SELEX patent applications.[0033]
• “Target” means any compound or molecule of interest for which a ligand is desired. A target can be a protein, peptide, carbohydrate, polysaccharide, glycoprotein, hormone, receptor, antigen, antibody, virus, substrate, metabolite, transition state analog, cofactor, inhibitor, drug, dye, nutrient, growth factor, etc. without limitation. In this application, the target is TGFβ2.[0034]
• In its most basic form, the SELEX process may be defined by the following series of steps:[0035]
• 1) A candidate mixture of nucleic acids of differing sequence is prepared. The candidate mixture generally includes regions of fixed sequences (i.e., each of the members of the candidate mixture contains the same sequences in the same location) and regions of randomized sequences. The fixed sequence regions are selected either: (a) to assist in the amplification steps described below, (b) to mimic a sequence known to bind to the target, or (c) to enhance the concentration of a given structural arrangement of the nucleic acids in the candidate mixture. The randomized sequences can be totally randomized (i.e., the probability of finding a base at any position being one in four) or only partially randomized (e.g., the probability of finding a base at any location can be selected at any level between 0 and 100 percent).[0036]
• 2) The candidate mixture is contacted with the selected target under conditions favorable for binding between the target and members of the candidate mixture. Under these circumstances, the interaction between the target and the nucleic acids of the candidate mixture can be considered as forming nucleic acid-target pairs between the target and those nucleic acids having the strongest affinity for the target.[0037]
• 3) The nucleic acids with the highest affinity for the target are partitioned from those nucleic acids with lesser affinity to the target. Because only an extremely small number of sequences (and possibly only one molecule of nucleic acid) corresponding to the highest affinity nucleic acids exist in the candidate mixture, it is generally desirable to set the partitioning criteria so that a significant amount of the nucleic acids in the candidate mixture (approximately 5-50%) are retained during partitioning.[0038]
• 4) Those nucleic acids selected during partitioning as having the relatively higher affinity to the target are then amplified to create a new candidate mixture that is enriched in nucleic acids having a relatively higher affinity for the target.[0039]
• 5) By repeating the partitioning and amplifying steps above, the newly formed candidate mixture contains fewer and fewer weakly binding sequences, and the average degree of affinity of the nucleic acids to the target will generally increase. Taken to its extreme, the SELEX process will yield a candidate mixture containing one or a small number of unique nucleic acids representing those nucleic acids from the original candidate mixture having the highest affinity to the target molecule.[0040]
• The SELEX patent applications describe and elaborate on this process in great detail. Included are targets that can be used in the process; methods for partitioning nucleic acids within a candidate mixture; and methods for amplifying partitioned nucleic acids to generate enriched candidate mixture. The SELEX patent applications also describe ligands obtained to a number of target species, including both protein targets where the protein is and is not a nucleic acid binding protein.[0041]
• The SELEX method further encompasses combining selected nucleic acid ligands with lipophilic or non-immunogenic, high molecular weight compounds in a diagnostic or therapeutic complex as described in U.S. patent application No. 08/434,465, filed May 4, 1995, entitled “Nucleic Acid Ligand Complexes,” now U.S. Pat. No. 6,011,020. VEGF nucleic acid ligands that are associated with a Lipophilic Compound, such as diacyl glycerol or dialkyl glycerol, in a diagnostic or therapeutic complex are described in U.S. patent application Ser. No. 08/739,109, filed Oct. 25, 1996, entitled “Vascular Endothelial Growth Factor (VEGF) Nucleic Acid Ligand Complexes,” now U.S. Pat. No. 5,859,228. VEGF nucleic acid ligands that are associated with a Lipophilic Compound, such as a glycerol lipid, or a non-immunogenic, high molecular weight Compound, such as polyalkylene glycol, are further described in U.S. patent application Ser. No. 08/897,351, filed Jul. 21, 1997, entitled “Vascular Endothelial Growth Factor (VEGF) Nucleic Acid Ligand Complexes,” now U.S. Pat. No. 6,051,698. VEGF nucleic acid ligands that are associated with a non-immunogenic, high molecular weight compound or lipophilic compound are also further described in PCT/US 97/18944 (WO98/18480), filed Oct. 17, 1997, entitled “Vascular Endothelial Growth Factor (VEGF) Nucleic Acid Ligand Complexes”. Each of the above described patent applications which describe modifications of the basic SELEX procedure are specifically incorporated by reference herein in their entirety.[0042]
• In certain embodiments of the present invention it is desirable to provide a complex comprising one or more nucleic acid ligands to TGFβ2 covalently linked with a non-immunogenic, high molecular weight compound or lipophilic compound. A complex as used herein describes the molecular entity formed by the covalent linking of the nucleic acid ligand of TGFβ2 to a non-immunogenic, high molecular weight compound. A non-immunogenic, high molecular weight compound is a compound between approximately 100 Da to 1,000,000 Da, more preferably approximately 1000 Da to 500,000 Da, and most preferably approximately 1000 Da to 200,000 Da, that typically does not generate an immunogenic response. For the purposes of this invention, an immunogenic response is one that causes the organism to make antibody proteins. In one preferred embodiment of the invention, the non-immunogenic, high molecular weight compound is a polyalkylene glycol. In the most preferred embodiment, the polyalkylene glycol is polyethylene glycol (PEG). More preferably, the PEG has a molecular weight of about 10-80K. Most preferably, the PEG has a molecular weight of about 20-45K. In certain embodiments of the invention, the non-immunogenic, high molecular weight compound can also be a nucleic acid ligand.[0043]
• In another embodiment of the invention it is desirable to have a complex comprised of a nucleic acid ligand to TGFβ2 and a lipophilic compound. Lipophilic compounds are compounds that have the propensity to associate with or partition into lipid and/or other materials or phases with low dielectric constants, including structures that are comprised substantially of lipophilic components. Lipophilic compounds include lipids as well as non-lipid containing compounds that have the propensity to associate with lipid (and/or other materials or phases with low dielectric constants). Cholesterol, phospholipid, and glycerol lipids, such as dialkylglycerol, diacylglycerol, and glycerol amide lipids are further examples of lipophilic compounds. In a preferred embodiment, the lipophilic compound is a glycerol lipid.[0044]
• The non-immunogenic, high molecular weight compound or lipophilic compound may be covalently bound to a variety of positions on the nucleic acid ligand to TGFβ2, such as to an exocyclic amino group on the base, the 5-position of a pyrimidine nucleotide, the 8-position of a purine nucleotide, the hydroxyl group of the phosphate, or a hydroxyl group or other group at the 5′ or 3′ terminus of the nucleic acid ligand to TGFβ2. In embodiments where the lipophilic compound is a glycerol lipid, or the non-immunogenic, high molecular weight compound is polyalkylene glycol or polyethylene glycol, preferably the non-immunogenic, high molecular weight compound is bonded to the 5′ or 3′ hydroxyl of the phosphate group thereof In the most preferred embodiment, the lipophilic compound or non-immunogenic, high molecular weight compound is bonded to the 5′ hydroxyl of the phosphate group of the nucleic acid ligand. Attachment of the non-immunogenic, high molecular weight compound or lipophilic compound to the nucleic acid ligand of TGFβ can be done directly or with the utilization of linkers or spacers.[0045]
• A “linker” is a molecular entity that connects two or more molecular entities through covalent bonds or non-covalentlinteractions, and can allow spatial separation of the molecular entities in a manner that preserves the functional properties of one or more of the molecular entities. A linker can also be known as a “spacer.”[0046]
• The complex comprising a nucleic acid ligand to TGFβ2 and a non-immunogenic, high molecular weight compound or lipophilic compound can be further associated with a lipid construct. Lipid constructs are structures containing lipids, phospholipids, or derivatives thereof comprising a variety of different structural arrangements which lipids are known to adopt in aqueous suspension. These structures include, but are not limited to, lipid bilayer vesicles, micelles, liposomes, emulsions, lipid ribbons or sheets, and may be complexed with a variety of drugs and components which are known to be pharmaceutically acceptable. In the preferred embodiment, the lipid construct is a liposome. The preferred liposome is unilamellar and has a relative size less than 200 nm. Common additional components in lipid constructs include cholesterol and alpha-tocopherol, among others. The lipid constructs may be used alone or in any combination which one skilled in the art would appreciate to provide the characteristics desired for a particular application. In addition, the technical aspects of lipid constructs and liposome formation are well known in the art and any of the methods commonly practiced in the field may be used for the present invention.[0047]
• The SELEX method further comprises identifying bioconjugates to a target. Copending PCT patent application No. PCT/US98/00589 (WO 98/18480), filed Jan. 7, 1998, entitled “Bioconjugation of Oligonucleotides” describes a method for enzymatically synthesizing bioconjugates comprising RNA derivatized exclusively at the 5′-position with a molecular entity, and a method for identifying bioconjugates to a target comprising nucleic acid ligands derivatized with a molecular entity exclusively at the 5′-position of the nucleic acid ligands. A bioconjugate as used herein refers to any oligonucleotide which has been derivatized with another molecular entity. In the preferred embodiment, the molecular entity is a macromolecule. As used herein, a macromolecule refers to a large organic molecule. Examples of macromolecules include, but are not limited to nucleic acids, oligonucleotides, proteins, peptides, carbohydrates, polysaccharides, glycoproteins, lipophilic compounds, such as cholesterol, phospholipids, diacyl glycerols and dialkyl glycerols, hormones, drugs, non-immunogenic high molecular weight compounds, fluorescent, chemiluminescent and bioluminescent marker compounds, antibodies and biotin, etc. without limitation. In certain embodiments, the molecular entity may provide certain desirable characteristics to the nucleic acid ligand, such as increasing RNA hydrophobicity and enhancing binding, membrane partitioning and/or permeability. Additionally, reporter molecules, such as biotin, fluorescein or peptidyl metal chelates for incorporation of diagnostic radionuclides may be added, thus providing a bioconjugate which may be used as a diagnostic agent.[0048]
• The methods described herein and the nucleic acid ligands identified by such methods are useful for both therapeutic and diagnostic purposes. Therapeutic uses include the treatment or prevention of diseases or medical conditions in human patients. Therapeutic uses may also include veterinary applications.[0049]
• Diagnostic utilization may include both in vivo or in vitro diagnostic applications. The SELEX method generally, and the specific adaptations of the SELEX method taught and claimed herein specifically, are particularly suited for diagnostic applications. SELEX identifies nucleic acid ligands that are able to bind targets with high affinity and with surprising specificity. These characteristics are, of course, the desired properties one skilled in the art would seek in a diagnostic ligand.[0050]
• The nucleic acid ligands of the present invention may be routinely adapted for diagnostic purposes according to any number of techniques employed by those skilled in the art or by the methods described in PCT/US98/00589 (WO 98/18480). Diagnostic agents need only be able to allow the user to identify the presence of a given target at a particular locale or concentration. Simply the ability to form binding pairs with the target may be sufficient to trigger a positive signal for diagnostic purposes. Those skilled in the art would also be able to adapt any nucleic acid ligand by procedures known in the art to incorporate a labeling tag in order to track the presence of such ligand. Such a tag could be used in a number of diagnostic procedures. The nucleic acid ligands to TGFβ2 described herein may specifically be used for identification of the TGFβ2 protein.[0051]
• SELEX provides high affinity ligands of a target molecule. This represents a singular achievement that is unprecedented in the field of nucleic acids research. The present invention applies the SELEX procedure to the specific target of[0052]TGFβ 1. In the Example section below, the experimental parameters used to isolate and identify the nucleic acid ligands to TGFβ2 are described.
• In order to produce nucleic acids desirable for use as a pharmaceutical, it is preferred that the nucleic acid ligand (1) binds to the target in a manner capable of achieving the desired effect on the target; (2) be as small as possible to obtain the desired effect; (3) be as stable as possible; and (4) be a specific ligand to the chosen target. In most situations, it is preferred that the nucleic acid ligand have the highest possible affinity to the target.[0053]
• In co-pending and commonly assigned U.S. patent application Ser. No. 07/964,624, filed Oct. 21, 1992 ('624), methods are described for obtaining improved nucleic acid ligands after SELEX has been performed. The '624 application, entitled “Nucleic Acid Ligands to HIV-RT and HIV-1 Rev,” now issued as U.S. Pat. No. 5,496,938, is specifically incorporated herein by reference.[0054]
• In the present invention, SELEX experiments were performed in order to identify RNA ligands with specific high affinity for TGFβ2 from degenerate libraries containing 33, 34 or 40 random positions (33N, 34N or 40N) (Table 1). This invention includes the specific RNA ligands to TGFβ2 shown in Tables 5, 7, 8, 11, 13, 14, 16-19 and FIG. 9 (SEQ ID NOS:21-121 and 128-193), identified by the methods described in Example 1. This invention further includes RNA ligands to TGFβ2 which inhibit TGFβ2 function, presumably by inhibiting the interaction of TGFβ2 with its receptor. The scope of the ligands covered by this invention extends to all nucleic acid ligands of TGFβ2, modified and unmodified, identified according to the SELEX procedure. More specifically, this invention includes nucleic acid sequences that are substantially homologous to the ligands shown in Tables 5, 7, 8, 11, 13, 14, 16-19 and FIG. 9 (SEQ ID NOS:21-121 and 128-193). By substantially homologous it is meant a degree of primary sequence homology in excess of 70%, most preferably in excess of 80%, and even more preferably in excess of 90%, 95% or 99%. The percentage of homology as described herein is calculated as the percentage of nucleotides found in the smaller of the two sequences which align with identical nucleotide residues in the sequence being compared when 1 gap in a length of 10 nucleotides may be introduced to assist in that alignment. A review of the sequence homologies. of the ligands of TGFβ2, shown in Tables 5, 7, 8, 11, 13, 14, 16-19 and FIG. 9 (SEQ ID NOS:21-121 and 128-193) shows that some sequences with little or no primary homology may have substantially the same ability to bind TGFβ2. For these reasons, this invention also includes nucleic acid ligands that have substantially the same structure and ability to bind TGFβ2 as the nucleic acid ligands shown in Tables 5, 7, 8, 11, 13, 14, 16-19 and FIG. 9 (SEQ ID NOS:21-121 and 128-193). Substantially the same ability to bind TGFβ2 means that the affinity is within one or two orders of magnitude of the affinity of the ligands described herein. It is well within the skill of those of ordinary skill in the art to determine whether a given sequence—substantially homologous to those specifically described herein—has substantially the same ability to bind TGF,.[0055]
• This invention also includes nucleic acid ligands that have substantially the same postulated structure or structural motifs. Substantially the same structure or structural motifs can be postulated by sequence alignment using the Zukerfold program (see Zuker (1989) Science 244:48-52). As would be known in the art, other computer programs can be used for predicting secondary structure and structural motifs. Substantially the same structure or structural motif of nucleic acid ligands in solution or as a bound structure can also be postulated using NMR or other techniques as would be known in the art.[0056]
• One potential problem encountered in the therapeutic, prophylactic, and in vivo diagnostic use of nucleic acids is that oligonucleotides in their phosphodiester form may be quickly degraded in body fluids by intracellular and extracellular enzymes such as endonucleases and exonucleases before the desired effect is manifest. Certain chemical modifications of the nucleic acid ligand can be made to increase the in vivo stability of the nucleic acid ligand or to enhance or to mediate the delivery of the nucleic acid ligand. See, e.g., U.S. patent application Ser. No. 08/117,991, filed Sep. 8, 1993, entitled “High Affinity Nucleic Acid Ligands Containing Modified Nucleotides,” now abandoned and U.S. patent application Ser. No. 08/434,465, filed May 4, 1995, entitled “Nucleic Acid Ligand Complexes,” now U.S. Pat. No. 6,011,020, which are specifically incorporated herein by reference. Modifications of the nucleic acid ligands contemplated in this invention include, but are not limited to, those which provide other chemical groups that incorporate additional charge, polarizability, hydrophobicity, hydrogen bonding, electrostatic interaction, and fluxionality to the nucleic acid ligand bases or to the nucleic acid ligand as a whole. Such modifications include, but are not limited to, 2′-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5-iodo-uracil, backbone modifications, phosphorothioate or alkyl phosphate modifications, methylations, unusual base-pairing combinations such as the isobases isocytidine and isoguanidine and the like. Modifications can also include 3′ and 5′ modifications such as capping.[0057]
• Where the nucleic acid ligands are derived by the SELEX method, the modifications can be pre- or post-SELEX modifications. Pre-SELEX modifications yield nucleic acid ligands with both specificity for their SELEX Target and improved in vivo stability. Post-SELEX modifications made to 2′-OH nucleic acid ligands can result in improved in vivo stability without adversely affecting the binding capacity of the nucleic acid ligand. The preferred modifications of the nucleic acid ligands of the subject invention are 5′ and 3′ phosphorothioate capping and/or 3′-3′inverted phosphodiester linkage at the 3′ end. In one preferred embodiment, the preferred modification of the nucleic acid ligand is a 3′-3′ inverted phosphodiester linkage at the 3′ end. Additional 2′-fluoro (2′-F) and/or 2′-amino (2′-NH[0058]₂) and/or 2′-O methyl (2′-OMe) and/or 2′-OCH₃modification of some or all of the nucleotides is preferred. Described herein are nucleic acid ligands that were 2′-F modified and incorporated into the SELEX process. Also described herein are nucleic acid ligands that were 2′-OCH₃modified after the SELEX process was performed.
• Other modifications are known to one of ordinary skill in the art. Such modifications may be made post-SELEX (modification of previously identified unmodified ligands) or by incorporation into the SELEX process.[0059]
• As described above, because of their ability to selectively bind TGFβ2, the nucleic acid ligands to TGFβ2 described herein are useful as pharmaceuticals. This invention, therefore, also includes a method for treating TGFβ2-mediated pathological conditions by administration of a nucleic acid ligand capable of binding to TGFβ2.[0060]
• Therapeutic compositions of the nucleic acid ligands may be administered parenterally by injection, although other effective administration forms, such as intraarticular injection, inhalant mists, orally active formulations, transdermal iontophoresis or suppositories, are also envisioned. One preferred carrier is physiological saline solution, but it is contemplated that other pharmaceutically acceptable carriers may also be used. In one preferred embodiment, it is envisioned that the carrier and the ligand constitute a physiologically-compatible, slow release formulation. The primary solvent in such a carrier may be either aqueous or non-aqueous in nature. In addition, the carrier may contain other pharmacologically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation. Similarly, the carrier may contain still other pharmacologically-acceptable excipients for modifying or maintaining the stability, rate of dissolution, release, or absorption of the ligand. Such excipients are those substances usually and customarily employed to formulate dosages for parental administration in either unit dose or multi-dose form.[0061]
• Once the therapeutic composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder. Such formulations may be stored either in a ready to use form or requiring reconstitution immediately prior to administration. The manner of administering formulations containing nucleic acid ligands for systemic delivery may be via subcutaneous, intramuscular, intravenous, intranasal or vaginal or rectal suppository.[0062]
• The following Examples are provided to explain and illustrate the present invention and are not intended to be limiting of the invention. Example 1 describes the various materials and experimental procedures used in Examples 2-5. Example 2 describes the isolation and characteristics of Nucleic Acid Ligands that bind human TGFβ2. Example 3 describes the Nucleic Acid Ligands isolated by the SELEX method using a biased round O library, the sequences of TGFβ2 Nucleic Acid Ligands isolated from the biased SELEX process, and the binding of Nucleic Acid Ligands isolated from the biased SELEX process. Example 4 describes substitutions of 2′-OH purines with 2′OCH[0063]₃purines in NX22284 and NX222385. Example 5 describes the pharmacokinetic properties of NX22323. Example 6 describes 2′-OMe modification oflead TGFβ 1 truncate ligand CD70.
EXAMPLESExample 1Experimental Procedures
• Materials and Methods[0064]
• Monoclonal and polyclonal antibodies that recognize human TGFβ1, TGFβ2 or TGFβ3 were purchased from R&D Systems, Inc. (Minneapolis, Minn.). DNA oligonucleotides were purchased from Operon, Inc. (Alameda, Calif.) or Oligos, Etc. (Redding Center, Conn.). The BIAcore 2000 and IAsys plus instruments are products of Biacore, Inc. (Paramus, N.J.) and Affinity Sensors, Inc. (Cambridge, U. K.), respectively. Nitrocellulose filters and filtering manifolds were obtained from Millipore (Bedford, Mass.). Mink lung epithelial cells (#CCL64) were purchased from the American Type Culture Collection (Rockville, Md.). The cloning vectors pCR-Script and pUC9 were obtained in-house or from Stratagene, Inc. (La Jolla, Calif.) or Life Technologies, Inc. (Gaithersburg, Md.), respectively.[0065]E colistrains were obtained from Stratagene. The QIAprep spin miniprep kit was from QIAgen, Inc. (Chatsworth, Calif.). The Big Dye sequencing kit and model 377 sequencer can be purchased from Applied Biosystems (Foster City, Calif.). T7 RNA polymerase andThermus aquaticusDNA polymerase were purchased from Enzyco, Inc. (Denver, Colo.) and Perkin Elmer (Norwalk, Conn.), respectively. All restriction enzymes were purchased from New England Biolabs.E. coliRNase H was obtained from Boehringer Mannheim. All synthetic nucleic acids with a name that begins with “NX” were synthesized at NeXstar Pharmaceuticals, Inc. (Boulder, Co.) using an ABI model 394 DNA/RNA synthesizer (Applied Biosystems). Yeast tRNA (type X-SA) and porcine intestinal mucosca-derived heparin (molecular weight 5000), were purchased from Sigma (St. Louis, Mo.) and Calbiochem (La Jolla, Calif.), respectively.
• Preparation of[0066]Round 0 Nucleic Acid Library
• The initial (round 0) library of ribonucleic acid molecules that was used to isolate TGFβ2 nucleic acid ligands was generated as follows. Two DNA oligonucleotides (40[0067]N7 round 0 DNA template and 5′N7 primer) were annealed and filled in with Klenow to produce a 40N7 round 0 DNA transcription template (Table 1). This template was transcribed using T7 RNA polymerase, 3mM 2′-fluoro uridine and cytosine, 1mM 2′-hydroxyl guanosine and adenine, and a³²P-ATP as described in (Fitzwater and Polisky (1996) Meth. Enz. 267:275-301). This resulted in around 0 40N7 nucleic acid pool with the following sequence which has 5′ and 3′ “fixed” regions and a 40 base long random sequence region:

  5′-GGGAGGACGAUGCGG-40N-CAGACGACUCGCCCGA-3′	round	0 40N7 nucleic acid	(SEQ ID NO:6)
  5′fixed region   random region   3′fixed region

  A = 2′-OH A; C = 2′-F C; G = 2′-OH G; U = 2′-F U

  (Table 1)

• Spot SELEX[0068]
• Spot SELEX was performed as described in U.S. patent application No. 08/477,527, filed Jun. 7, 1995, entitled “High Affinity Nucleic Acid Ligands of Cytokines,” now U.S. Pat. No. 5,972,599, which is hereby incorporated by reference in its entirety, using nucleic acid that was internally labeled using α-[0069]³²P ATP. The conditions and progress of this SELEX experiment are summarized in Table 3. Briefly, human TGFβ2 (or no protein) was applied to a 13 mm diameter nitrocellulose filter and allowed to absorb but not completely dry. The filter was incubated with RNA in Dulbecco's phosphate-buffered saline, 1 mM MgCl₂and then washed as summarized in Table 3. Filter-bound and protein-bound nucleic acid was visualized and quantitated on an Instant Imager (Packard Instrument Co., Downers Grove, Ill.) and the protein-bound nucleic acid was eluted in 50% phenol, 4 M urea for 45 minutes at 65° C. Eluted nucleic acid was ethanol precipitated and then reverse transcribed using avian myeloblastosis virus reverse transcriptase and subjected to the polymerase chain reaction using 5′N7 and 3′N7 primers for 15 cycles. This resulting transcription template was transcribed with T7 RNA polymerase in the presence of 2′-fluoro pyrimidine nucleotides, 2′-OH purine ribonucleotides, and α-³²P-ATP, and carried to the next spot round. The pool from the first spot round was also transcribed as above in the absence of α-³²P-ATP for use inround 2 of the surface plasmon resonance biosensor SELEX.
• Surface Plasmon Resonance Biosensor SELEX[0070]
• Rounds 2-spr through 9-spr were done using surface plasmon resonance biosensor technology on a BIAcore model 2000 instrument. For this experiment 1XDPBS, 1 mM MgCl[0071]₂, 0.005% P20 surfactant (cat#BR-1000-54, Biacore, Inc., Piscataway, N.J.) was used as the running buffer. TGFβ2 was amine coupled onto a CM5 BIACORE chip (Biacore, Inc., Piscataway, N.J.) using the Biacore amine coupling kit (cat#BR-1000-50, Biacore, Inc., Piscataway, N.J.) per manufacturer's instructions. Briefly, TGFβ2 aliquots (3 μl, in 4 mM HCl at 100 μg/ml) were diluted in 30 μl of 10 mM CH₃COONa, pH 5.0 and injected on an EDC-NHS activated chip at 25° C., 5 μl/min, in different volumes to achieve different loading levels, as measured in response units (RU). Following coupling, the chip was washed with 3 M NaCl for about 1.5 min at 10 μl/min. Under these experimental conditions, TGFβ2 loading of 15 RU/μl could be achieved. TGFβ2 was loaded inflow cells 1, 2, and 3 , whileflow cell 4 was kept blank for control and background subtractions. Before use, the chip was tested for activity by testing binding of LAP and or soluble receptor III (R&D Systems, Minneapolis, Minn.) at 37° C. At the end of each test injections the chip was regenerated using 1 min wash with 10 mM NaOH. For SELEX rounds, RNA pools, generated by in vitro transcription without any labeled nucleotides, were in running buffer and were injected over the TGFβ2 loaded CM5 chips at 5 μl/min at 37° C. The concentration and volume of the RNA pools used at each round are as shown in Table 4. At each round the RNA pools were applied in 40 μl injections and each injection cycle was followed by a dissociation phase where the chip was washed with DPBS, 1 mM MgCl₂at 20 μl/min while three 100 μl fractions (5 min each) were collected. Following the last injection-dissociation cycle, the chip was treated with 0.25% SDS and the eluted RNA was collected as the final fraction. The third fractions of each injection cycle and the SDS elution were pooled and amplified by RT/PCR to generate the template pool for the next SELEX round.
• Resonant Mirror Optical Biosensor SELEX[0072]
• Rounds 10-rm through 13-rm were done using an IASYS plus resonant mirror optical biosensor instrument. Round 9-spr from the surface plasmon resonance SELEX was used as the starting material. For this experiment, 1XDPBS, 1 mM MgCl[0073]₂, 0.005% P20 surfactant (cat#BR-1000-54, Biacore, Inc., Piscataway, N.J.) were used as the running buffer. TGFβ2 was amine coupled onto a CMD IASYS cuvette (Affinity Sensors, Cambridge, UK) according to the manufacturer's protocol. Briefly, the CMD cuvette was activated with 0.2 M EDC, 0.05 M NHS for 10 minutes, and TGFβ2 was coupled by injection 35 μl of 0.4 μM TGFβ2, 10 mM CH₃COONa, pH 5.5 in 35 μl of 10 mM CH₃COONa, pH 5.5. The coupling reaction was at 25° C. for about 10 minutes and resulted in about 2,000 Arcsec of signal. Unreacted sites were capped by exposing the cuvette in 1 M ethanolamine for 1-2 minutes. Following coupling and capping the cuvette was exposed to 3 M NaCl for 1-2 minutes and was ready for use. The cuvettes were routinely tested for activity by measuring binding of LAP and or soluble receptor III (R&D Systems, Minneapolis, Minn.) at 37° C. At the end of each test injection the chip was regenerated using a 1 minute wash with 50 mM NaCO₃. For SELEX rounds, RNA pools, generated by in vitro transcription without any labeled nucleotides, were in running buffer. They were injected in the TGFβ2 loaded CMD cuvette and incubated for 27-60 minutes (Table 6) under 100% steering at 37° C. Following binding, the RNA was replaced with buffer and bound RNA was observed to dissociate from the cuvette surface. Dissociation was allowed for 30-150 minutes (Table 6) at 37° C. while the buffer was exchanged several times to avoid evaporation. Following dissociation, the remaining RNA was eluded with H₂O or 0.25% SDS and the RNA was amplified as above and carried to the next SELEX round.
• SELEX using Filter Partitioning and Polyanion Competition[0074]
• For rounds 9b through 22a, SELEX using filter partitioning was performed essentially as described in (Fitzwater and Polisky (1996) Meth. Enz. 267:275-301) except that 1) heparin or yeast tRNA was included to compete off ligands that bound nonspecifically, 2) the binding buffer was HBSMCK (50 mM HEPES, pH 7.4,140 mM NaCl, 1 mM MgCl[0075]₂, 1 mM CaCl₂, 3 mM KCl), 3) extensive efforts were undertaken to reduce filter binding sequences (preadsorbtion of nucleic acid onto filters after elution and transcription, blocking of filters with tRNA and bovine serum albumin prior to partitioning, addition of 0.5 M urea to the wash buffer) and 4) the transcripts were initiated with a 5:1 molar mixture of guanosine:2′-fluoro-nucleotides. Initiation with guanosine allows nucleic acids to be used in SELEX or bioactivity assays without radiolabeling and alleviates a phosphatase step if the nucleic acid is to be 5′-end radiolabeled for binding studies.
• Round 8-spr from the surface plasmon resonance SELEX was used as the starting material. From rounds 9b to 14i, the SELEX process was performed using protein-excess conditions. The concentrations of nucleic acid and protein were equimolar in round 15c. Nucleic acid-excess conditions were used from rounds 16a to 22a (Table 2). Competitors (yeast tRNA and heparin) were used from rounds 9b to 14i. Filters were washed with 10-15 ml HBSMCK buffer from rounds 9b to 12d and increasing amounts (5-50 ml) of HBSMCK, 0.5 M urea from rounds 13i to 22a.[0076]
• Sequencing of Nucleic Acid Ligand Pools[0077]
• Nucleic acid pools were sequenced as described in (Fitzwater and Polisky (1996) Meth. Enz. 267:275-301).[0078]
• Screening Nucleic acid Ligand Pools using Ligand-Specific Reverse Transcription-Polymerase Chain Reactions[0079]
• Nucleic acids from the various pools was reverse transcribed with clone-“specific” primers (ML-85 for[0080]ligand 14i-1 and ML-81 forligand 21a-21) for 12, 15 or 18 cycles. Mixtures of pure nucleic acid ligands andround 0 40N7 nucleic acid that contained 10%, 3%, 1%, 0.3%, or 0.1% ligand were processed in the same manner and served to quantitate signals from RT-PCR of the nucleic acid pools.
• Cloning, Screening and Sequencing of Nucleic Acid Ligands[0081]
• Nucleic acid ligands were cloned using two methods. In one method the ligands were directly cloned into pCR-Script according to the manufacturer's instructions and transformed into[0082]E. colistrain XL-1 Blue MRF′ Kan. In the other method the double-stranded DNA transcription template was amplified by PCR using primers ML-34 and ML-78, digested with BamHI and EcoRI restriction enzymes, and cloned into Bam-HI and EcoRI-digested pUC9. The ligation was transformed intoE. colistrain DH5α. Colonies were selected on ampicillin plates and screened for inserts by PCR using vector-specific primers (RSP and FSβ2). Typically 90%-1 00% of the clones had inserts. Some colonies or nucleic acid pools were also screened using 14i-1, 21a-4 or 21a-21 ligand-specific primers (ML-79, ML-81 and ML-85, respectively) in an attempt to identify clones that were different from those already isolated.
• Plasmid minipreps from the transformants were prepared using the QIAprep spin miniprep kit (QIAGEN, Inc., Valencia, Calif.) or PERFECT prep plasmid DNA kit (5′3′, Inc., Boulder, Co.). Sequencing reactions were performed with the Big Dye kit and a sequencing primer (RSβ2). The sequencing products were analyzed on an ABI model 377 sequencer.[0083]
• Nucleic Acid Ligand Boundaries[0084]
• The boundaries (5′ and 3′ end) of the smallest ligand that can bind TGFβ2 was determined essentially as described in (Fitzwater and Polisky (1996) Meth. Enz. 267:275-301). The protein concentrations used were 0, 1 nM, and 10 nM and the nucleic acid/protein ratio was 1. The binding buffer used in this experiment was HBSMC, 0.01% HSA. Binding reactions were incubated at 37° C. for 30 minutes, filtered through 0.45 μm, nitrocellulose filters (15 mm),and then washed with 15 ml HBSMC. The RNA was recovered by phenol-urea extraction, eluted RNA was ethanol precipitated in the presence of glycogen, resuspended in H[0085]₂O, supplemented withequal volume 2× formamide dye, and analyzed on 8% acrylamide, 8 M urea sequencing gels. Truncated RNAs that were bound to TGFβ2 were visualized and developed on a FUJIX BAS 1000 phosporimager (FUJI Medical Systems, USA).
• Nucleic Acid Ligand truncation[0086]
• Truncated versions of full length nucleic acid ligands were generated in three ways. In one method,[0087]E. coliRNase H andhybrid 2′-OCH₃RNA/DNA oligonucleotides (5′N7 cleave, 3′N7 cleave; Table 1) were used to cleave nucleic acids at a specific site. Truncation SELEX is described in U.S. patent application Ser. No. 09/275,850, filed Mar. 24, 1999, entitled “Truncation SELEX Method,” which is hereby incorporated by reference in its entirety. In a second method, overlapping DNA oligonucleotides encoding the desired ligand sequence were annealed, extended by Klenow DNA polymerase, and then transcribed. In a third method, ligands were chemically synthesized with the desired sequence.
• Binding of Nucleic Acid Ligands to Human TGFβ's[0088]
• The binding activity of individual ligands was determined by measuring the equilibrium dissociation constants using nitrocellulose partitioning of labeled RNA as a function of protein concentration. RNA was body-labeled or guanylated and then 5′-end labeled with γ-[0089]³²P ATP and T4 polynucleotide kinase. Binding reactions were set at various protein concentrations (typically varied in either 3-fold or 10-fold increments) while maintaining the labeled RNA concentration constant at less than 0.1 nM, and incubated at 37° C. for 10 minutes. Protein-RNA complexes were partitioned away from uncomplexed RNA, by filtering the binding reactions through a nitrocellulose/cellulose acetated mixed matrix (0.45 μm pore size filter disks, type HA; Millipore, Co., Bedford, Mass.). For filtration, the filters were placed onto a vacuum manifold (12-well, Millipore, or 96-well BRL) and wetted by aspirating 1-5 ml of binding buffer. The binding reactions were aspirated through the filters, washed with 1-5 ml of binding buffer and counted in a scintillation counter (Beckmann).
• To obtain the monophasic equilibrium dissociation constants of RNA ligands to hTGFβ2 the binding reaction:[0090]
• K[0091]_D
• R:P→R+P[0092]
• R=RNA[0093]
• P=Protein[0094]
• K[0095]_D=dissociation constant
• is converted into an equation for the fraction of RNA bound at equilibrium:[0096]
• q=(f/2R_T)(P_T+R_T+K_D−((P_T+R_T+K_D)²−4P_TR_T)^1/2)
• q=fraction of RNA bound[0097]
• P[0098]_T=total protein concentration
• R[0099]_Ttotal RNA concentration
• f=retention efficiency of RNA-protein complexes[0100]
• The average retention efficiency for RNA-TGFβ2 complexes on nitrocellulose filters is 0.3-0.8. K[0101]_dvalues were obtained by least square fitting of the data points using the software Kaleidagraph (Synergy Software, Reading, Pa.).
• Competition between Ligands[0102]
• [0103]³²P-labeled test ligands at a concentration of 1 nM were mixed with increasing concentrations of unlabeled NX22283 (SEQ ID NO:114). Then, an amount of TGFβ2 estimated to be near the K_dof the test ligands was added (1 nM for NX22283, 1 nM for 21a-21, 3 nM for 21a-4, and 10 nM for 14i-1). The reactions were incubated, filtered, washed and counted as for a binding reaction.
• Off-Rate of NX22283[0104]
• 1 nM[0105]³²P-labeled NX22283 was mixed with 10 nM TGFβ2, incubated for 5 minutes to allow the protein to bind to the nucleic acid, and then a 1000-fold excess (1 μM) of unlabeled NX22283 was added. At various time points the reactions were filtered and washed to measure the amount of³²P-labeled NX22283 that remained bound.
• Biased SELEX[0106]
• A library of sequences was constructed based on the sequence of the 34-mer truncate (NX22284) of[0107]nucleic acid ligand 21a-21. The sequence of the DNA template (34N7.21a-21 (SEQ ID NO:7)) is shown in Table 1. The randomized region is 34 bases long. At each position the randomized region consists of 62.5% of the NX22284 sequence and 12.5% of the other 3 nucleotides. Thus the randomized region is mutagenized at each position (37.5%), but at the same time is biased toward the sequence of NX22284. The fixed regions (5N7, 3′N7) were the same as used for the primary SELEXs.
• To generate 34N7.21[0108]a-21 round 0 nucleic acid, the DNA template was amplified by PCR using the 5′N7 (SEQ ID NO:2) and 3′N7 (SEQ ID NO:3) primers (Table 1). This PCR product was transcribed as described above in the filter partitioning SELEX section. This resulted in a 34N7.21a-21round 0 nucleic acid pool with the sequence shown in Table 1 (SEQ ID NO:10).
• Filter partitioning as described above and in Fitzwater and Polisky (1996) (Meth. Enz. 267:275-301) with no competitors was used to enrich nucleic acids ligands that bound to human TGFβ2 the best. The protein concentration was reduced from 150-300 nM to 50 pM. The nucleic acid concentration was reduced from 1 μM to 1 nM. The nucleic acid/protein ratio ranged from 0.25 to 125. The round 5a pool of ligands was cloned into pUC9 and sequenced as described above.[0109]
• Bioactivity of TGFβ2 Nucleic Acid Ligands[0110]
• The bioactivity of TGFβ2 nucleic acid ligands was measured with mink lung epithelial cells. Proliferation of these cells is inhibited by TGFβ2. Human TGFβ2 was titrated on the cells and[0111]³H-thymidine incorporation was measured. The point at which³H-thymidine incorporation by the cells was inhibited by 90-100 % was determined (typically 1-4 pM). This inhibitory amount of TGFβ2 along with varying amounts of nucleic acid ligand (typically 0.3 or 1 nM to 1 or 3 μM, in 3 fold increments) was used. Typically, cells were plated at 10E5/ml in 96-well plates in 100 μl MEM, 10 mM HEPES pH 7.4, 0.2% FBS. Following a 4 hour incubation at 37° C., when cells were well attached to the well surface, TGFβ2 was added at 1-4 pM with or without nucleic acid ligands as follows: the ligands were diluted across the 96 well plate in 3-fold dilution steps and then TGFβ2 was added at 1-4 pM to all wells except controls. The cells were incubated for 16-18 hours prior to addition of³H-thymidine, and then incubation was continued for 20 additional hours following³H-thymidine addition at 0.25 μCi per well. After incubation, the cells were lysed with 1% Triton X-100 and harvested onto GF/B filter plates in a Packard 96 well plate harvester, and³H-thymidine incorporation in cellular DNA was quantitated by scintillation counting in MicroScint (Packard, Mariden, Conn.) in a Packard Top-Count. Data were plotted as % of maximum³H-thymidine incorporation vs RNA concentration, and were fitted by the software Kaleidagraph (Synergy Software, Reading, Pa.) to the equation m3*(m0+m1+(m2)−((m0+m1+(m2))*(m0+m1+(m2))−4*(m0)*( m2))){circumflex over ( )}0.5)/(2*(m2)); where m0 is the concentration of competitor RNA; m1 is the IC50, m2 is the concentration of TGFβ2, and m3 is the plateau value of the fraction of maximum³H-thymidine incorporation. K_ivalues were determined from IC₅₀values according to the equation K_i=IC₅₀/(1+([T]/K_dT), where [T] is the molar concentration of TGFβ2 present in the assay and K_dTis the concentration of TGFβ2 causing 50% inhibition of MLEC proliferation as determined by TGFβ2 titration experiments. This assay was also used to determine the isotype specificity of RNA ligands where the three TGFβ isotypes were independently used as inhibitors of MLEC replication.
• Pharmacokinetic Properties of NX22323[0112]
• The pharmacokinetic properties of TGFβ2 ligand NX22323 were determined in Sprague-Dawley rats. NX22323 was suspended in sterile PBS and stored at ≦−20° C. Prior to animal dosing NX22323 was diluted with sterile PBS, to a final concentration of 0.925 mg/ml (18 μM, based on the oligonucleotide molecular weight and the ultraviolet absorption at 260 nm with an extinction coefficient of 0.037 mg of oligo/ml). Sprague-Dawley rats (n=2) were administered a single dose of NX22323 by intravenous bolus injection through the tail vein. Blood samples (approximately 400 μL) were obtained by venipuncture under isofluorane anesthesia and placed in EDTA-containing tubes. The EDTA-treated blood samples were immediately processed by centrifugation to obtain plasma and stored frozen ≦−20° C. Time points for blood sample collection ranged from 5 to 2880 minutes.[0113]
• Standards and quality control samples prepared in blank rat plasma and plasma samples were analyzed by a double hybridization assay. To prepare plasma samples for hybridization analysis, 25 μL of plasma sample (or a dilution in plasma of the sample) was added to 100 μL of 4×SSC, 0.5% sarkosyl. A 25 μL aliquot was then mixed with 25 μL of 4×SSC, 0.5% sarkosyl containing 24 μM capture oligonucleotide conjugated to magnetic beads and 28 μM detect oligonucleotide conjugated to biotin in a covered 96-well microtiter plates. The mixture was allowed to incubate at 45° C. for 1 hour. Unbound oligonucleotide was removed and 0.1 ng streptavidin alkaline phosphatase/μL NTT Buffer (0.8 M NaCl, 20 mM Tris pH 7.5, 0.5% Tween 20) added to each well followed by a 30 minute incubation at room temperature. The streptavidin alkaline phosphatase was removed and the plate was washed twice with 200 μl NTT Buffer. The NTT Buffer was removed and replaced with 50 μL DEA buffer (0.02% sodium azide, 1 mM MgCl[0114]₂, 1% diethanolamine (Tropix, Inc., Bedford, Mass.), pH 10). Then 34 μL/ml 25 mM chemiluminescent substrate for alkaline phosphatase (Tropix, Inc., Bedford, Mass.), and 20% Sapphire chemiluminescence amplifier (Tropix, Inc., Bedford, Mass.) in DEA buffer (50 μL/well) was added. The plate was incubated for 20 minutes at room temperature and read on a luminometer. A standard curve of NX22323 was fit using a variable slope sigmoidal dose response non linear regression equation (PRISM, version 2.00, GraphPad, San Diego, Calif.). Sample and quality control concentrations were extrapolated from the standard curve and corrected for dilution.
• The average plasma concentration at each time point was calculated and utilized in the pharmacokinetic analysis. Both noncompartmental and compartmental pharmacokinetic analysis were carried out using WinNonlin version 1.5 (Scientific Consulting, Inc.). In the noncompartmental analysis, the following parameters were calculated; the maximum concentration extrapolated at zero time (Cmax), the area under the curve from zero to the last time point (AUClast), the area under the curve from zero to infinite time (AUCINF), the terminal phase half life (Beta t½), the clearance rate (Cl), the mean residence time calculated from zero to infinite time (MRTINF), the volume of distribution at steady state (Vss), and the volume of distribution during elimination (Vz). In the case of compartmental analysis, the following parameters were calculated based on the minimum number of monoexponetial equations to adequately fit the data: the maximum concentration extrapolated at zero time (Cmax), the area under the curve from zero to infinite time (AUCINF), the distribution phase half life (Alpha t[0115]{fraction (1/2×)}), terminal phase half life (Beta t½), the exponential constant for the distribution phase (A), the exponential constant for the terminal phase (B), the clearance rate (Cl), the mean residence time calculated from zero to infinite time (MRTINF), and the volume of distribution at steady state (Vss).
Example 2Isolation of Nucleic Acid Ligands that Bind Human TGFβ2
• Several SELEX experiments on TGFβ2 have been attempted as summarized in FIG. 1. Several partitioning methods were applied at various stages of the SELEX progress including standard filtration through nitrocellulose, spot , surface plasmon resonance biosensor (BLAcore), resonant mirror biosensor (lasys), polystyrene beads, and polyacrylamide gel shift. The combination of spot SELEX, surface plasmon resonance biosensor SELEX, and filter partitioning SELEX (with competitors) described here had the best overall improvement in affinity (˜>1000 fold) and thus is described in detail. In addition, a branch of this SELEX that utilized resonant mirror biosensor technology is also described.[0116]
• Spot SELEX Conditions[0117]
• Spot SELEX was chosen to initiate the SELEX process on human TGFβ2 because it would allow a large amount of protein and nucleic acid to interact. The conditions used are shown in Table 3. The results of[0118]round 1 were acceptable. The background was very low and the signal to noise ratio was 5. At this point the population from the first round was used for the surface plasmon SELEX in addition to continuing with the spot partition method. Ten rounds of spot SELEX were completed as summarized in Table 3 and a modest improvement in the affinity of the pool of about 30 fold was observed. These pools were not analyzed further.
• Surface Plasmon Resonance Biosensor (spr) SELEX[0119]
• Surface plasmon resonance biosensors were chosen as a partitioning medium because they provide very low background nucleic acid binding to the sensor, so that higher degrees of enrichment can be obtained. In addition binding and elution of nucleic acid can be monitored and quantitated in real time.[0120]
• TGFβ2 was coupled to a BLAcore biosensor using amine coupling chemistry. TGFβ2 coupled in this manner binds latency-associated protein, and recombinant soluble TGFβ receptors. FIG. 2 shows typical sensograms obtained with LAP and recombinant sRIII where we observed k[0121]_onand k_offrates indicative of avid binding. During this SELEX experiment as summarized in Table 4, a binding signal was first observed on the biosensor in round 6, increased up toround 9, and then decreased inrounds 10 and 11. FIG. 3 shows sensograms with 0, 4-spr, 6-spr, 8-spr and 9-spr. FIG. 4 shows typical filter binding curves, in the presence and absence of competitor tRNA, with representative pools from the spr SELEX and from these data it seems thatround 9 binds in a biphasic manner with a high affinity and low affinity K_dof 30 and 160 nM, respectively.
• In bioactivity assays the K[0122]_iof the round 0 pool was about 2.6 μM and the K_iof the round 9-spr pool was about 711 nM (see below). Sequence analysis of representative pools indicated that such pools maintained significant complexity up toround 8 while afterround 9 such pools were strongly biased towards a single sequence.
• Round 8-spr was cloned and sequenced. A total of 69 clones representing 51 different sequences were analyzed. Four sequences (# 8.2, 8.3, 8.9 and 8.48; see Table 5) were represented more than once and accounted for 21 of the 69 clones. All four of these sequences bound TGFβ2 and were 2 or 3 base variants of a clone (14i-1) isolated from the filter SELEX (see below). Twenty three other sequences were nonbinding or filter-binding sequences (see Table 5) and 25 clones were not tested for binding.[0123]
• Resonant Mirror (rm) Optical Biosensor SELEX[0124]
• Since the affinity of nucleic acid pools selected on the surface plasmon resonance biosensor peaked at round 9-spr, resonant mirror (rm) optical biosensor technology was tested to determine if it could advance the affinity of nucleic acid ligands any further. Resonant mirror optical biosensor technology offers many of the same advantage as surface plasmon biosensor technology, but in addition the binding is done in a cuvette under equilibrium conditions rather than over the surface of a chip under flow conditions. Within the cuvette the binding can be extended for long time periods. Therefore the nucleic acid/protein binding reaction can be more stringent and selective.[0125]
• For resonant mirror SELEX, TGFβ2 was coupled to two biosensor cuvettes using amine coupling chemistry. In one cuvette the TGFβ2 was inactivated by SDS denaturation and this cuvette served to assess background. The other cuvette containing active TGFβ2 was used for the SELEX. Beginning with round 9-spr, five rounds were done using resonant mirror optical biosensor technology. The conditions used for and the results of the resonant mirror SELEX are shown in Table 6.[0126]
• Biosensor signals were observed for each round. The binding of the nucleic acid pools from rounds 10-rm to 12-rm was assessed (Table 6; FIG. 5). The pool K[0127]_dimproved modestly up to round 12-rm with no further improvement in the subsequent rounds. The round 12-rm pool binds biphasically with high and low affinity K_dof ˜2 nM and ˜150 nM, respectively.
• In bioactivity assays the K[0128]_iof the round 13-rm pool was about 505 nM. Round 13-rm was chosen for subcloning and sequence analysis. Of 15-clones that were sequenced, all 15 (Table 7) were 1 to 5 base variants of a clone (14i-1) which was originally isolated from the filter SELEX (see below).
• Filter Partitioning SELEX[0129]
• Round 8-spr was used as the starting material for a filter SELEX. The properties of round 8-spr were studied and it was found that 1) a significant fraction bound to a nitrocellulose filter (10%), 2) significant nucleic acid binding (defined here as signal/noise>2) to TGFβ2 was not detectable using nucleic acid-excess conditions, and 3) in the presence or absence of polyanionic competitors there was a significant decrease in the binding of[0130]round 0, but not round 8-spr to TGFβ2. These findings had implications that are addressed below.
• Use of a Competitor[0131]
• The binding of round 8-spr nucleic acid to TGFβ2 in the presence of a polyanionic competitor (yeast tRNA) was studied at various ratios of competitor to nucleic acid. It was found that a 75,000 fold excess of tRNA over round 8-spr nucleic acid resulted in 50% inhibition of binding, whereas a 6,000 fold excess of tRNA over the[0132]round 0 nucleic acid pool resulted in 50% inhibition of binding. Heparin also competed with RNA for binding to TGFβ2, but about 10-fold more heparin was needed to inhibit RNA binding to TGFβ2 to the same degree as that observed using tRNA. By including a 100,000-fold excess of yeast tRNA over RNA in a TGFβ2/RNA binding experiment, a 100-fold difference in binding betweenround 0 and round 8-spr was detected, whereas a 3-fold difference was observed in the absence of any competitor. Thus in the presence of an appropriate amount of competitor, the binding of selected nucleic acid pools is unaffected, whereas the binding ofround 0 nucleic acid is reduced substantially. When competitors are not included in studying the binding of TGFβ2 to nucleic acid the affinity of nucleic acids selected using the SELEX process can be grossly underestimated. In this regard TGFβ2 is similar to other “professional” nucleic acid binding proteins (e.g., restriction enzymes, polymerases, transcription factors, etc.), in that it possesses both a low affinity, nonspecific and a high affinity, specific nucleic acid binding activity. The difference between these 2 binding modes can be revealed in the presence of competitors. Competitors are often used in the study of transcription factors. For example, it can be difficult to detect specific binding of a crude extract containing a transcription factor to oligonucleotides representing their cognate site in gel-shift experiments, unless a competitor, such as poly [dI-dC]  poly [dI-dC], is included in the binding reaction.
• Nonspecific binding can involve the binding of multiple proteins per nucleic acid, often at low affinity sites, giving a false appearance of high affinity. A protein can bind at multiple sites on a nucleic acid or protein aggregates may form on a single protein bound to a nucleic acid. TGFβ2 is well known to be “sticky.” In the absence of a competitor of nonspecific interactions, TGFβ2 may form large networks and complexes of nucleic acid and protein involving primarily nonspecific interactions. Gel shift analysis of TGFβ2, in the absence of competitor, supports these ideas because TGFβ2 does not form distinct (one to one) complexes with nucleic acid in gels, but instead either remains in the well at the top of a gel or forms smears that may represent large heterogeneous nucleic acid/protein complexes.[0133]
• Besides the implications for doing binding curves, the nucleic acid -binding properties of TGFβ2 may have implications for SELEX. For example the high level of nonspecific binding of nucleic acid by TGFβ2 may have interfered with previous SELEXs by obscuring specific interactions or preventing the isolation of nucleic acid/protein complexes that involved only specific binding interactions. That is, if mixtures of specific and nonspecific nucleic acid interactions exist in nucleic acid/TGFβ2 complexes that form, then the selection for specific interactions may be difficult, if the nonspecific interactions are not eliminated. Lack of progress in some previous SELEX experiments may have been due to efficient competition by the large excess (>10[0134]¹²-10¹⁴) of low affinity nucleic acids that contain nonspecific binding sites with a smaller number (˜10-1000) of high affinity nucleic acids that contain specific binding sites, especially in early rounds of SELEX.
• Use of Protein-Excess or Nucleic Acid-Excess Conditions[0135]
• Given the discussion above, a question arises as to which type of SELEX condition is better for a protein such as TGFβ2, protein-excess or nucleic acid-excess. Protein-excess conditions may tend to encourage nonspecific interactions. However as long as the competitor/nucleic acid ratio is high enough to eliminate enough nonspecific interactions, but retain specific interactions, this may not be an issue. One advantage to using protein excess is the bound to background ratios are better and background is lower, which would results in better levels of enrichment.[0136]
• Nucleic acid-excess conditions may not discourage nonspecific interactions because within nucleic acid pools used for SELEX the ratio of nonspecific to specific binding nucleic acids (which is what is most important) would be the same no matter what the nucleic acid concentration is. In addition nucleic acid-excess would reduce the competitor/nucleic acid ratio which would tend to increase nonspecific interactions. As discussed above the ratio of tRNA to nucleic acid must be at least 100,000 in early round of the filter SELEX in order for affinity enrichment to be efficient. This can be technically difficult in early rounds of SELEX when the nucleic acid concentration is typically higher. One advantage to using excess nucleic acid is that more members of a given sequence would be represented in a pool. However if there had been enough enrichment (e.g., using a method such as surface plasmon resonance SELEX) prior to filter SELEX there will probably be multiple representatives of a given sequence and this would not be an issue.[0137]
• Filter SELEX Conditions[0138]
• The conditions used at each round of the filter SELEX are shown in Table 15. Multiple conditions (up to 12) were used in each round varying nucleic acid/protein ratios, competitor/nucleic acid ratios, filter washing buffers, and filter washing volumes. Typically conditions that resulted in the lowest background (<1%) and a significant bound/background ratio (>2) were processed for the next round. Only data for SELEX rounds that were used in the next round are shown in Table 15.[0139]
• The SELEX began by using an amount of tRNA competitor (100,000-fold excess) that was determined in the SELEX reaction to inhibit binding of round 8-spr to TGFβ2 by about 60%. SELEX reactions with competitor were done for round 9b through 14i. The inclusion of tRNA in[0140]round 9 also dramatically reduced binding of round 8-spr nucleic acid to nitrocellulose filters from ˜10-15% to ˜1%. The higher the “background” binding is in a SELEX reaction, the lower the maximum possible enrichment. Thus inclusion of tRNA in the early rounds of the filter SELEX may have had a dual benefit. It not only may have eliminated nonspecific binding of TGFβ2 to nucleic acid, but also allowed more enrichment by reducing background. At round 15c lower affinity competitors were no longer effective at reducing binding of nucleic acid and were not used. This is presumably because the nucleic acid pool bound TGFβ2 with adequate specificity and affinity. Therefore from round 16 to 22, the presumed specific nucleic acids were allowed to compete with each other by using more traditional nucleic acid -excess conditions.
• The background increased to unacceptable levels in rounds 15c and 16a. Gel shift partitioning was investigated as an alternative partitioning procedure at this point but did not work. By modifying the washing conditions the background was reduced to 0.2% in round 17a. After round 18b it was possible to do SELEX rounds at protein concentrations below 1 nM and under nucleic acid-excess conditions. It was also found that nucleic acid concentrations above 1-5 nM also helped to reduce background in some rounds.[0141]
• In summary, during the filter SELEX, the concentration of the protein was reduced 30,000-fold, from 300 nM in round 9b to 10 pM in round 22a. The background binding to filters was reduced from 10% to 0.1%. Nucleic acid pools that bound to TGFβ2 only when protein-excess conditions (˜100 protein/i nucleic acid) were used were selected to bind under high nucleic acid/protein (>100/l) or competitor/nucleic acid (>10[0142]⁷/l)-excess conditions.
• Binding of Nucleic Acid Pools from Filter SELEX[0143]
• The binding of TGFβ2 to selected nucleic acid pools improved steadily, but slowly and erratically. There was an improvement in the binding of round 10b (K[0144]_d=˜100 nM) compared to the starting pool (round 8-spr; K_d=˜500 nM). The affinity of round 11a was the same as 10b and that of round 12d improved modestly to ˜40 nM. Rounds 13i and 15c bound TGFβ2 approximately the same (K_d=˜30), whileround 14i may have bound worse (K_d=˜75). Round 16a nucleic acid (K_d=˜10 nM) bound slightly better than round 15c. There was ˜2-fold improvement in affinity of the nucleic acid pool from rounds 16a to 17a (K_d=˜5 nM). The K_dof round 18a nucleic acid (˜5 nM) was equivalent to round 17a nucleic acid. There was another slight increase in affinity from round 18b to 19a (K_d=˜2-3 nM). The affinity ofrounds 20a, 21a and 22a plateaued at about 1 nM. The SELEX was stopped at round 22a because the bound to background ratio was below 2 and it would have been technically difficult to reduce the protein concentration to 1-3 pM inround 23.
• In summary the K[0145]_dimproved from ˜500 nM in round 9b to ˜1 nM inround 21a, resulting in an overall improvement of ˜500-fold in the filter SELEX and >10,000-fold in the entire SELEX. The average improvement per round was only about 1.6-fold. This rate of improvement is slow compared to an average SELEX experiment, which may take ˜5 rounds using only surface plasmon resonance technology or ˜10 rounds using only filter partitioning.
• Inhibition of Bioactivity by Nucleic Acid Pools[0146]
• [0147]Rounds 0, 9-spr, 13-rm, 14i, 18b and 19a, and latency-associated protein (LAP) were tested on mink lung epithelial cells for their ability to reverse TGFβ2-mediated inhibition of³H-thymidine incorporation. The results are that the K_iof the round 9-spr pool was about 711 nM. The K_i's of theround 14i, 18b, 19a and 21a pools were about 231 nM, 309 nM, 154 nM and 10 nM, respectively. The K_i′ of LAP was about 0.5 nM.
• From these results it can be concluded that inhibitors of TGFβ2 were enriched in the later rounds of the TGFβ2 SELEX. In addition there is a continuous correlation between the affinity measured in vitro and the inhibitory activity measured in vivo:[0148]
• LAP<round 19A<[0149]round 14i<round 13-rm<round 8-spr<round 0.
• Sequencing of Nucleic Acid Ligand Clones Isolated from Filter SELEX[0150]
• Based on several criteria (pool K[0151]_d, filter-binding background, bound to noise background, inhibitory activity in cell assay, and absence of aberrant products during the RT-PCR steps of SELEX) round 21a was subcloned for sequence analysis. Forty eight clones were sequenced fromround 21a (Table 8). Two unique sequences represented byclones 21a-4 and 21a-21 (the first number refers to the SELEX round a clone was initially isolated from and the second number is a clone number) were identified. Several clones were minor variants (1-6 bases different) ofclones 21a-4 and 21a-21. One hundred more clones were screened by PCR using primers specific forclones 21a-4 and 21a-21. Of these, 90 wereclone 21a-21-like, 9clone 21a-4-like and 1 was a third unique sequence (21a-48), which was shown to be a nitrocellulose filter-binding sequence. In conclusion, round 21a consists almost entirely of two sequences and variations of those sequences. This was not surprising because round 21a was the second to last round and the bulk affinity of the nucleic acid pools had not improved much from round 19a to 21a.
• Since the sequence diversity of[0152]round 21a was restricted, 3 other rounds (14i, 16a, 18a) were also sequenced. Only one more novel sequence (14i-1 and variants) was isolated. Two filter-binding sequences were also isolated (16a-1 and a variant of 21a-48). Therefore, as with rounds 8-spr, 13-rn and 21a, these 3 rounds also did not contain diverse TGFβ2-binding nucleic acid ligands.
• The sequences of 14i-1, 21a-4, and 21a-21 are shown in Table 8. The affinity of the sequences for human TGFβ2 is about 10 nM, 3 nM and 1 nM respectively. Therefore these 3 sequences are ligands that bind human TGFβ2 with high affinity.[0153]
• The ligands were tested for inhibitory bioactivity. The K[0154]_i's of 14i-1, 21 a-4 and 21a-21 are about 200 nM, 30 nM and 10 nM respectively. Thus these ligands are also inhibitory ligands. As for the pools the binding affinity correlates well with the inhibitory activity. This is not surprising since it is likely the TGFβ2 ligands bind near the heparin binding site which is very close to the TGFβ receptor binding region. The inhibitory activity ofligand 21a-21 was also compared to that of antibodies.
• Clones were isolated and sequenced from six rounds (8-spr, 13-rm, 14i, 16a, 18a and 21a). The number of each type of sequence is summarized Table 9. Out of 264 clones analyzed by sequencing and 100 clones analyzed by a PCR-based analysis using ligand-specific primers (Table 10), only 3 different TGFβ2 ligand sequences (and minor variants) were obtained. Fifteen sequences were filter binding sequences and 36 were nucleic acids that do not bind well to filters or TGFβ2. The degree of restriction in sequence diversity observed in this SELEX is very unusual. Generally one can isolate dozens of different nucleic acid ligands and usually it is possible to find high affinity rounds were one ligand represents <10% of the population.[0155]
• Since sequencing and screening of 6 rounds of SELEX that are as much as 13 rounds apart did not result in a diverse set of sequences the properties of the pools were investigated further to determine where the sequence diversity was restricted. Selected nucleic acid pools were sequenced and semi-quantitative RT-PCR on nucleic acid pools using ligand-specific primers was done. The results are shown in (Table 10). Taken together with the sequencing results, it appears that a restriction in sequence diversity during the SELEX process may have occurred near rounds 6-spr or 7-spr.[0156]
• [0157]Clone 14i-1 is first detectable in round 6-spr, becomes most frequentnear round 14i, and decreases in frequency in later rounds.Clone 21a-4 is first detectable by sequencing inround 14i, is most abundant in round 16a, and decreases in frequency byround 21a. However 21a-4 may exist in prior rounds (RT-PCR analysis of pools using a primer specific forclone 21a-4 was not done.).Clone 21a-21 was rare inround 14i (<1/104 clones by sequencing; estimate <1/200-500 clones by RT-PCR), became more frequent in round 16a, and composes most of round 18b and 21a.
• It appears the surface plasmon resonance biosensor SELEX resulted in a high degree of diversity restriction, which has been observed before using this technology. The reason why various later rounds would consist of virtually one sequence is not clear. Perhaps only a very small number of sequences bind TGFβ2 under the selection conditions used. Perhaps a change in selection conditions such as the inclusion of competitors at[0158]round 9 or the switch from protein-excess binding reactions to nucleic acid-excess binding reactions at round 16 resulted in the emergence ofclone 21a-21 as the predominant clone byround 21a. It seems as though the selection pressures were significant because the predominant ligand in a pool changed in as few as 2 rounds.
• The pattern of changes in the population of nucleic acid ligands can be explained by analogy to the theory of natural selection. In an early SELEX round, a variety of sequences will exist. Strong selective pressure may narrow the sequence variation considerably, to the point that a single sequence is predominant. However rare ligands still exist that can be selected in future rounds or during significant changes in selective pressure. This is true in any SELEX experiment, but the TGFβ2 SELEX experiment described here may be an extreme example. In spite of the restriction on sequence diversity, better binding ligands could eventually be isolated. Note that[0159]ligand 21a-21 was first identified by sequencing in round 16a. Thus rare, high affinity nucleic acid ligands may exist even in round 22 that would only become predominant under the correct selection conditions. One approach for isolating such rare sequences might be to specifically deplete late rounds of SELEX of known sequences (e.g., by hybrid selection, restriction enzyme digestion of PCR products, site-directed RNase H cleavage of nucleic acid), an approach that this TGFβ2 SELEX is well suited for since essentially only 5 different sequences (3 ligands and 2 filter binding sequences) were present in later rounds. Isolating a sequence that is present in <1/1000 clones might be easy using depletion methods, but would be tedious using sequencing or PCR screening methods.
• These results raise questions about when a SELEX is done and how to judge whether it is done. In this SELEX, standard criteria for judging when a SELEX is done such as K[0160]_dimprovement, and sequencing of clones or bulk nucleic acid pools may not be good criteria for judging if the SELEX had proceeded as far as it could. Often there are technical limitations (background, reaction volumes, loss of low amounts of protein to large surfaces) that determine when a SELEX must be terminated and these are artificially limiting. Perhaps a “depletion SELEX” round should be done at the end of every SELEX to attempt enrichment of ligands that would be difficult to isolate by currently used methods.
• Specificity of Human TGFβ2 Ligands[0161]
• For nucleic acid ligands to be most useful in the applications claimed herein they should be highly specific for a particular subtype of TGFβ. The specificity of human TGFβ2 ligands was investigated by in several ways.[0162]
• The specificity of TGFβ2 ligands was examined using the cell culture bioactivity assay where the specificity of the TGFβ2 (described here) and TGFβ1 (see U.S. patent application Ser. No. 09/046,247, filed Mar. 23, 1998, entitled “High Affinity TGFβ Nucleic Acid Ligands and Inhibitors,” now U.S. Pat. No. 6,124,449, which is incorporated herein by reference in its entirety) aptamers was compared to the specificity of antibodies. Two types of antibodies were used namely, monoclonal antibodies and immunopurified polyclonal antibodies. It was found (FIG. 6) that the TGFβ2 ligand NX22283 inhibited TGFβ2 protein bioactivity (K[0163]_i==10 nM), but not TGFβ1 (K_i=>1000 nM) or TGFβ3 bioactivity (K_i=>1000 nM). The TGFβ2 ligand NX22283 inhibits the TGFβ2 bioactivity with a potency equivalent to that of a monoclonal antibody while the most potent inhibitor of TGFβ2 bioactivity in this experiment was an affinity-purified polyclonal antibody.
• The specificity of a TGFβ2 ligand for TGFβ2 compared to TGFβ3 was also analyzed in nucleic acid binding assays. The affinity of[0164]round 0 40N7 nucleic acid or the full-length TGFβ2 ligand 21a-21 to human TGFβ2 protein was >10 [M or 1 nM, respectively. The affinity ofround 0 nucleic acid orligand 21a-21 to human TGFβ3 protein was >10 μM or >30 μM, respectively. Therefore the TGFβ2 ligand does not bind significantly to TGFβ3.
• It was found that the TGFβ1 ligand 40-03 (1 (see U.S. patent application Ser. No. 09/046,247, filed Mar. 23, 1998, entitled “High Affinity TGFβ Nucleic Acid Ligands and Inhibitors,” now U.S. Pat. No. 6,124,449), bound to TGFβ3 although 1000-fold worse. These results indicate there may be one or more amino acids in common between TGFβ1 and TGFβ3 that are not found in TGFβ2 so that a TGFβ1 ligand can bind TGFβ1 and TGFβ3 but not TGFβ2 and so that the[0165]TGFβ2 ligand 21a-21 binds TGFβ2 but not TGFβ1 or TGFβ3. Indeed, as shown in Table 12, there are 19 amino acids out of 122 that are found in TGFβ2, but not in TGFβ1 or TGF03. Three of these differences (Lys-25, Arg-26, and Lys-94 in TGFβ2) are within a putative heparin binding region and may be important for determining the binding specificity of TGFβ ligands.
• Truncation of Nucleic Acid Ligands[0166]
• It is desirable to obtain the smallest “truncate” of a full length nucleic acid ligand so that it can be synthesized efficiently at the least cost. The goal of this study was to obtain ligands that are less than half their original length (<35 bases), yet retain about the same affinity as the full length ligand. Several approaches were used to identify truncates of the three TGFβ2 ligands.[0167]
• RNase H and[0168]hybrid 2′-OCH₃RNA/DNA oligonucleotides (5′N7 cleave, 3′N7 cleave; Table 1) were used to remove the 5′ and 3′ fixed sequences from 2′-F pyrimidine, 2′-OH purine nucleic acid ligands as described in U.S. patent application Ser. No. 09/275,850, filed Mar. 24, 1999, entitled “Truncation SELEX Method,” which is hereby incorporated by reference in its entirety.
• Second, the “boundaries” of the ligands were identified using a previously described method (Fitzwater and Polisky (1996) Met. in Enzymol. 267:275-301). Boundaries define the 5′ and 3′ ends of the smallest truncate. However boundary determination does not identify internal deletions that can be made. Also because of the nature of the boundary determination method, if a boundary falls within a run of pyrimidines or is too close to either end, then which nucleotide is the boundary must be determined by other methods (e.g., generation of ligands beginning or ending with each candidate boundary position followed by analysis of their binding to TGFβ2).[0169]
• A third method used relied on plausible structural motifs to define hypothetical sequence boundaries. Synthetic oligonucleotides corresponding to these boundaries were synthesized and were tested for binding to TGFβ2.[0170]
• A fourth approach for identifying TGFβ2 ligand truncates was to look at the location of sequence variations in each ligand. In[0171]ligands 21a-4 and 21a-21 the changes that occurred in sequence variants were distributed randomly throughout their sequences. However inligand 14i-1, the sequence changes in variants were highly localized. This implied that the variable region ofligand 14i-1 could tolerate changes without affecting binding and that the whole variable region may be dispensable.
• A fifth approach was to make internal deletions based on predicted structures. Portions of putative bulges, loops, or base pair(s) within predicted stems can be deleted. The success of this method depends critically on how close the structural model is to the real structure. For 21a-21 the most stable structure was found to be incorrect. Only when a structure closer to the real structure was identified (by using the biased SELEX method) could internal deletions of 21a-21 successfully be made.[0172]
• Truncation of[0173]Ligand 14i-1
• Using the RNase H truncation method it was determined that[0174]ligand 14i-1 requires the 5′ but not the 3′ fixed sequence (Table 13). Consistent with this result, when both the 5′ and 3′ fixed sequences were removed,ligand 14i-1 did not bind TGFβ2.
• Conventional boundary experiments defined the 3′ end of[0175]ligand 14i-1 (FIG. 7) to be within positions 39-45. In the same experiment we failed to observe a clear boundary at the 5′ end of this ligand. Of the 60 sequence variants ofligand 14i-1, 54 have nucleotide changes that occur within the last 16 bases at the 3′ end of the selected sequence region. Most of the variants have single base changes, but a few have as many as 6 bases changed. Such changes may or may not affect binding. If they affect binding then that region is important for binding. More likely, since there are so many changes in so many clones within that region, those bases are probably not important. It was surmised they may be able to be deleted, possibly along with the adjacent 3′ fixed region, without affecting binding. This idea was confirmed by two experiments:
• 1) The binding of 8 sequences that varied within the 16 base region and had different sequence changes was tested. They all bound as well to TGFβ2 as the 14i-1 ligand.[0176]
• 2) A 38 base long truncate of 14i-1 (14i-1t5-41; Table 13) that lacked the 3′ fixed region and the 16 base variable region bound to TGFβ2 as well as the full length (71 base long) ligand.[0177]
• Four sequences that removed additional bases from the ends of 14i-1 beyond those removed in 14i-1t5-41 were made [(14i-1t5-38, 14i-1t5-35, 14i-1(ML-87), and 14i-1(ML-89]. Also one internal deletion of 14i-1t5-41 was made [14i-1(ML-86)]. None of these bound to TGFβ2 (Table 13). Taken as a whole these experiments showed that the boundaries of[0178]ligand 14i-1 fall within positions 5-7 at the 5′ end and 39-41 at the 3′ end. All these results define truncate forligand 14i-1 that is 38 bases long (Table 13).
• Truncation of[0179]Ligand 21a-4
• Using the RNase H truncation method it was determined that[0180]ligand 21a-4 requires the 5′ but not the 3′ fixed sequence (Table 14). When both the 5′ and 3′ fixed sequences were removedligand 21a-4 did not bind TGFβ2.
• The boundaries of[0181]ligand 21a-4 (FIG. 7) are atpositions U 11 in the 5′ fixed region and within positions 52-56 on the 3′ end, defining a truncate that is between 42-46 bases long (Table 8). This is consistent with RNase H truncation results which show 21a-4 requires the 5′ end but not the 3′ end to bind TGFβ2.
• By examining hypothetical structures, the boundaries for 21a-4 were predicted to occur at position G12 at the 5′ end and position C48 at the 3′ end. These positions agree well with the region defined by the boundary method. A 37 base long truncate of 21a-4 (excluding sequences required to initiate transcription), beginning at position 12 and ending at position 48 [(21a-4(ML-110); Table 14)], bound as well to TGFβ2 as the[0182]full length 21a-4 ligand.
• One sequence that removes 4 additional bases from the 3′ end of 21a-4(ML1 10) was made that is called 21a-4(ML-1 11). The binding of2la-4(ML-111) was reduced 30-fold compared to 21a-4(ML-110). Also three internal deletions of 21a-4(ML-1 10) were made [21a-4(ML-92, ML-108, and ML-109)]. None of these bound well to TGFβ2 (Table 14). A sequence [21a-4(ML-91)] that added 2 bases to the 3∝end of 21a-4(ML111) did not have any improved binding compared to 21a-4(ML-110). Thus, the smallest truncate of[0183]ligand 21a-4 identified, that retains binding, is 42 bases long.
• Truncation of[0184]Ligand 21a-21
• Using the RNase H truncation method it was concluded that[0185]ligand 21a-21 requires the 3′ but not the 5′ fixed sequence (Table 11). However, when both the 5′ and 3′ fixed sequences were removed,ligand 21a-21 bound TGFβ2. This seems paradoxical since removal of the 3′ end alone eliminates binding. However, the data can be interpreted to mean that the 3′ deletion folds in a structure that does not bind to TGFβ2, while the truncate that lacks both ends does not fold into a dead end structure. Indeed Mfold structure predictions indicate this may be the case.
• The boundaries of[0186]ligand 21a-21 (FIG. 7) are at position G21 on the 5′ end and within positions 50-55 on the 3′ end, defining a truncate that is 30-35 bases long. The results are consistent with RNAse H truncation data which shows that 21a-21 requires neither the 5′ nor the 3′ end to bind TGFβ2. The truncate identified by boundaries falls completely within that defined by RNase H truncation.
• Synthetic sequences based on putative structures were also tested as summarized in Table 11. Results from these experiments are in agreement with the RNAse H and conventional boundary experiments.[0187]
• Several additional end truncates and internal deletions of 21a-21(ML-95) were made (Table 11). The 9 end truncates included 21a-21(ML-96), 21a-21(ML-97), 21a-21(ML-103) 21a-21(ML-104) 21a-21(ML-105), NX22286, NX22301, NX22302, and NX22303. Of these only NX22301, which removes one base at the 5′ end, binds as well as 21a-21(ML-95). Internal deletions included 21a-21 (ML-99), 21a-21 (ML-101), 21a-21 (ML-102), 21a-21(ML-114), 21a-21(ML-115), 21a-21(ML-116), 21a-21(ML-118), 21a-21(ML-120), 21a-21(ML-122), 21a-21(ML-128), 21a-21(ML-132), 21a-21(ML-134), 21a-21(ML-136), and 21a-21(ML-138). Of these 14 internal deletions, only 21a-21(ML-130) bound about as well as 21a-21(ML-95).[0188]
• Three sequences [21a-21(ML-94), NX22283, and NX22285), were made that are longer than 21a-21(ML-95). Of these only NX22285 may have bound (marginally) better than 21a-21(ML-95). Thus, the shortest ligand identified that binds TGF2 is the 34-mer NX22284.[0189]
• NX22283 and NX22284, which are synthetic analogs of the transcribed[0190]ligands 21a-21(ML-94) and 21a-21(ML-95), respectively, bound with identical affinity to TGFβ2 (Table 11). The synthetic nucleic acids also have the same inhibitory bioactivity as their transcribed analogs; on the other hand, the short, 30-base long NX22286 and its transcribedanalog 21a-21 (ML-96) do not bind TGFβ2 and they do not inhibit TGFβ2 bioactivity. Therefore synthetic nucleic acids have the same properties as their transcribed counterparts.
• To summarize, truncated 14i-1, 21a-4, and 21a-21 ligands were identified that bind TGFβ2 as well as the full length ligands and are 38, 37 (excluding 5 bases added to improve transcription yield), and 32 bases long, respectively. Twenty four sequences were made in an attempt to shorten the NX22284 truncated ligand (8 single base deletions and 16 multiple base deletions). Only 2 of them, (2la-21(ML-130) and NX22301, bind to TGFβ2. Therefore it appears that the sequence and spacing of structural elements in NX22284 must be maintained for binding to occur.[0191]
• Competition Between Ligands for Binding TGFβ2[0192]
• Examination of the ability of different ligands to compete with each other for binding to a protein can indicate whether the ligands bind to a similar (or overlapping) or distinctly different regions on the protein.[0193]
• The ability of NX22283, a truncate of[0194]ligand 21a-21 (Table 14), to compete with 4 ligands (14i-1, 21a-4, 21a-21, and NX22283) was tested. The results were that NX22283 competed best with itself, then with 21a-21, 21a-4, and 14i-1, in decreasing effectiveness. Thus, the ability of NX22283 to compete correlates with how related its sequence is to the sequence of the test ligand. NX22283 is most closely related to itself and competes best with itself. NX22283 is a truncate of 21a-21, and competes with 21a-21 second best. The sequence of 21a-4 may be distantly related to 21a-21 and NX22283 competes with 21a-4 third best. The sequence ofligand 14i-1 is not related to NX22283, and NX22283 is least capable of competing with 14i-1.
• The concentration range of NX22283 required to inhibit 50% of the binding of the other ligands was 10-fold. Since these differences in the amount of NX22283 it took to compete off the other ligands can be attributed to differences in their affinity there is probably only one type of binding region for these ligands on TGFβ2. However, there may be one or more similar sites per homodimer of TGFβ2. If there were two distinct types of nucleic acid binding sites on TGFβ2 (as is the case for the HIV-l gag protein; Lochrie et al. (1997) Nucleic. Acids Res. 25:2902-2910) it should take >1000 times as much competitor (i.e., the difference between the K[0195]_dofround 0 nucleic acid and the K_dof NX22283) to compete off a ligand binding at a second distinct site, because presumably a ligand that has high affinity at one site would have low affinity for a distinct site. This was not observed.
• Off-Rate of NX22283[0196]
• The half-life for NX22283-TGFβ2 complex was measured in 2 experiments to be 0.5 or 3 minutes. Almost all of the ligand dissociated from TGFβ2 in 60-75 minutes. Although these times may seem short, they are typical of in vitro off-rate measurements for nucleic acid ligands that have been isolated by filter partitioning SELEX.[0197]
Example 3Nucleic Acid Ligands Isolated by the SELEX Method using aBiased Round 0 Library
• A biased SELEX is one in which the sequences in a nucleic acid pool are altered to bias the result toward a certain outcome. The primary goals of a “biased” SELEX are to obtain ligands that have a higher affinity and to determine what the putative secondary structure of a ligand may be. The starting,[0198]round 0 nucleic acid library (called 34N7.21a-21) used for the TGFβ2 biased SELEX had the same 5′ and 3′ fixed regions (5′N7 and 3′N7) as the prior TGFβ2 SELEX (Table 1). It was made as a 2′-F pyrimidine, 2′-OH purine nucleic acid. However, as described in the “Materials and Methods” section, the random region was 34 bases long. Within the randomized region 62.5% of the nucleotides at each position correspond to the NX22284 sequence. The remaining 37.5% correspond to the other three nucleotides. Thus each position is mutagenized and the sequence of the pool is biased toward the NX22284 sequence. Selection for ligands that bind to TGFβ2 using such a pool should allow variants of NX22284 to be isolated, some of which may not have been present in theoriginal 30N7 round 0 pool.
• The bulk K[0199]_dof theround 0 34N7.21a-21 pool was about 870 nM (Table 15) using protein-excess binding conditions. This is at least 10-fold better than for theunbiased round 0 40N7 pool, as would be expected. Thisround 0 nucleic acid pool also bound under nucleic acid-excess conditions in small scale SELEX type reactions, although poorer than in protein-excess reactions, as would be expected. The progress of the biased SELEX is shown in Table 15.
• The conditions used in the biased SELEX and the results are shown in Table 15. A total of 9 rounds were done. Attempts were made to obtain higher affinity ligands by using competitors, starting at[0200]round 4. Both yeast tRNA (low affinity) and NX22284 (high affinity) were used as competitors. Both are nonamplifiable during the PCR step of SELEX. The “A” series was done without competitors while the “B” series was done with competitors.
• The binding of the nucleic acid pools to TGFβ2 was measured for[0201]rounds 0 to 8 (Table 15) and found to improve from ˜870 nM for theround 0 nucleic acid library to ˜1 nM for the round 5a nucleic acid pool. Competition seemed to have little consistent effect on affinity improvement in this SELEX experiment. Probably competition should have been initiated with NX22284 atround 1. Peak improvement in the pool affinity plateaued inrounds 5, 6 and 7, and 8. Therefore round 5a, the earliest round with the best affinity, was subcloned and sequenced.
• Sequences of TGFβ2 Nucleic Acid Ligands Obtained from a Biased SELEX.[0202]
• As shown in Table 16, 25 unique sequences were obtained. One to nine changes from the starting sequence were found. All of the clones were 34 bases long within the selected sequence, consistent with studies (see“truncation of[0203]ligand 21a-21” above) where it was difficult to delete any internal bases.
• Covariance between pairs of positions was analyzed by eye and by using the consensus structure matrix program (Davis et al. (1995) Nucleic Acids Research 23:4471-4479). Covariance was observed between 2 different areas implying the existence of 2 stems in the structure. The pattern of covariance suggests the structural model shown in FIG. 8 or a similar variant of that structure (e.g., some base pairing could occur within the loop). This predicted structure is the third most stable structure predicted by the Mfold program (Zuker (1989) Science 244:48-52). A curious example of possible covariance is observed at[0204]positions 15 and 25 in the loop region. A15 and G25 were observed to covary to C15 and U25 in 2 clones (#18 and #29).Ligand 21a-4 also has the C/U combination at the bottom of its putative loop.
• Of 34 bases, 11 are “invariant” among these 25 clones (Table 16). All of the invariant positions are predicted to occur in the loop and bulge regions except C34, the last nucleotide. The last base of all 3 truncated TGFβ2 ligands (FIG. 8) is a C. Removal of this C results in loss of binding. If invariant positions indicate regions where TGFβ2 binds the NX22284 ligand, then binding may occur primarily in the bulge and stem loop regions. The stems must be base paired, but can vary in sequence implying that the structure of the stems may be more important than their sequence. The stem may be a structure used to present the bulge, loop and C34 nucleotides in the proper orientation to bind TGFβ2.[0205]
• Clone 5a-11 from the biased SELEX is similar to clone 21-4 from the primary SELEX, particularly at positions that are invariant in clones from the biased SELEX, thus reinforcing the new structural model and the importance of the invariant positions. It has not been possible to fit[0206]ligand 14i-1 into a similar structure. Perhaps it represents a second sequence motif capable of binding TGFβ2.
• Binding of Nucleic Acid Ligands Isolated from the Biased SELEX[0207]
• The binding of clones from the biased SELEX was compared to the binding of[0208]full length ligand 21a-21. The majority of the clones bound as well to TGFβ2 as 21a-21 (Table 16). One clone (#20) bound about 6-fold worse and one clone (#13) bound about 5-fold better thanfull length ligand 21a-21. The average K_dof the clones (weighting clones found more than once) is 1.2 nM, which agrees with the round 5a pool K_dof ˜1 nM. Thus the ligands that were isolated in this manner were not vastly different in affinity from the starting sequence.
• One would expect there to be an optimal number of changes that results in higher affinity ligands. Clones with only a few changes might be expected to bind about the same as the starting sequence, clones with a threshold number of changes may bind better, and clones with too many changes may bind worse. Indeed there may be a correlation between the number of changes and the affinity. Clones with 1 to 4 changes tend to bind the same or worse than[0209]ligand 21a-21. Clones with 5-8 changes tend to bind better thanligand 21a-21. The worst binder (#20) was the one with the most changes (9). The ligand that bound to TGFβ2 the best (clone #13) had 7 changes relative to the starting sequence.
• When the clones that bound better and those that bound worse are aligned (Table 17) it appears that an A at[0210]position 5 may be important for higher affinity binding since the ligands that bind to TGFβ2 best all have an A atposition 5 and all clones with an A atposition 5 bind at least as well as 21a-21. In contrast clones with a U, C or G atposition 5 tend to bind worse than 21a-21. With regard to the pattern of base pair changes in the putative stems there is no single change that correlates with better binding. In addition, the better binders do not consistently have GC-rich stems. However the pattern of changes in the stems of the poor binders does not overlap with that seen in the stems of the better binders. Thus, various stem sequences may result in better binding for subtle reasons.
• A point mutant that eliminated binding of the full length 21-21 transcript (21a-21 (ML-107); Table 11) changes U at position 6 to G. A G was found at position 6 in three clones from the biased SELEX (#4, 9 and 35), one of which (clone #4) has only one other base change while the others had additional changes. All three clones from the biased SELEX that have a G at position 6 bind TGFβ2. Thus it would seem that the U6G change alone eliminates binding, but this binding defect can be reversed when combined with other sequence changes.[0211]
• To summarize, some changes (such as A at position 5) may act independently and be able to confer better binding alone, while others changes (e.g, at position 6 and in the stems) may influence binding in a more unpredictable way that depends on what other changes are also present.[0212]
• Presumably sequences that lack an “invariant” nucleotide would not bind to TGFβ2. Some of the invariant bases have been deleted and others have been changed (Table 11). None of these 10 altered sequences [21a-4(ML-111); 21a-21(ML-96, 97, 101, 102, 103, 104, 105, 120, NX22286] bind to TGFβ2.[0213]
Example 4Substitutions of 2′-OH Purines with 2′-OCH₃Purines in NX22284
• Substitutions of 2′-OH purines with 2′-OCH[0214]₃purines sometimes results in nucleic acid ligands that have a longer half life in serum and in animals. Since the nucleic acid ligands described here are ultimately intended for use as diagnostics, therapeutics, imaging or histochemical reagents the maximum number of 2′-OH purines that could be substituted with 2′-OCH₃purines in ligand NX22284 was determined. NX22284 is a 34-mer truncate of the 70 base long 21a-21TGFβ2 ligand (Table 18). NX22284 has 17 2′-OH purines and binds about 2-fold worse thanligand 21a-21.
• Initially an all 2′-OCH[0215]₃purine substituted sequence was synthesized (NX22304). Another sequence has all 2′-OH purines substituted with 2′-OCH₃purines except six purines at its 5′ end. Neither bound to TGFβ2 or had measurable bioactivity (Table 18).
• Therefore a set of sequences was synthesized (NX22356-NX22360; Table 18) such that groups of 3 or 4 2′-OH purines were substituted with 2′-OCH[0216]₃purines. The binding of NX22357 was reduced about 2-fold and the bioactivity was reduced 10-fold. The binding and bioactivity of NX22356, NX22258 and NX22360 were unaffected. In contrast the binding of NX22359 was reduced over 100-fold and its bioactivity was reduced over 30-fold. Therefore the sequence of NX22359 was “deconvoluted” one base at a time in order to determine which individual purines in NX22359 cannot be 2′-OCH₃purines. NX22374, NX22375 and NX22376 are deconvolutions of NX22359. All three of these sequences had greatly reduced binding and bioactivity. This suggests that G20, A22, and A24 cannot be 2′-OCH₃purines.
• NX22377 was designed to determine if a sequence with an intermediate number of 2′-OCH[0217]₃purines could bind TGFD2 and retain bioactivity. NX22377 has 10 2′-OCH₃purines out of 17 (representing the 2′-OCH₃purines in NX22356, NX22357 and NX22360). The binding and bioactivity of NX22377 are identical to NX22284.
• NX22417 was designed to test the possibility that G20, A22 and A24 must be 2′-OH purines in order to retain binding and bioactivity. In NX22417 G20, A22 and A24 are 2′-OH purines while the other 14 purines are 2′-OCH[0218]₃. NX22417 binds to TGFβ2 as well as NX22284, but its bioactivity is reduced about 10 fold. Since substitution of G20 (NX22374) or A24 (NX22376) alone had a less severe effect than substitution of A22 (NX22375), nucleic acids were synthesized that had all 2′-OCH₃purines except position A22 (see NX22384) or G20 and A22 (see NX22383). NX22383 and NX22384 did not bind or inhibit TGFβ2, again suggesting that at least 3 purines atpositions 20, 22 and 24 must be 2′OH to retain binding and bioactivity.
• NX22384 was analyzed by mass spectroscopy to ensure its lack of binding and inhibitory activity was not due to incomplete deprotection or an incorrect sequence. The results are that NX22383 may be 0.5-0.9 daltons more than the predicted molecular weight and therefore is very likely to be what it should be.[0219]
• Since NX22357 bound to TGFβ2 slightly worse than NX22284, but had a 10-fold reduced bioactivity, it was possible that one or more of the three 2′-OCH[0220]₃purines in NX22357 (G5, A8, A11) may also be required for bioactivity. This notion was tested by synthesizing NX22420 and NX22421. NX22421 has all three of these bases (G5, A8 and Al 1) as 2′-OH purines (along with G20, A22 and A24, which require 2′-OH groups). NX22420 has A8 (along with G20, A22 and A24) as 2′-OH purines. NX22421 has G5, A8, and A11 (along with G20, A22 and A24) as 2′-OH purines. A8 was retained as a 2′-OH purine in both NX22420 and NX22421 because it was invariant among the clones from the biased SELEX and therefore it was inferred that A8 might be less tolerant to change at the 2′ ribose position (as was the case for G20, A22 and A24). Indeed both NX22420 and NX22421 had approximately the same binding and inhibitory activity as NX22284. In summary, the NX22284 sequence can retain maximal binding and inhibitory activity when four purines (A8, G20, A22 and A24) are 2′-OH and the other purines are 2′-OCH₃. Note that all four of these positions were invariant among the clones isolated using the biased SELEX method.
• While studies were being done on substituting the 2′-OH purines of NX22284, two shorter versions of NX22284 (21a-21 [ML-130] and 21a-21 [ML-134]; Table 11) were dis that bound well to TGFβ2 as transcripts. The 2′-OCH[0221]₃purine substitution pattern of NX22420 was transferred to these sequences. NX22426 is the 2′-OCH₃purine analog of 2la-21(ML-134) and NX22427 is the 2′-OCH₃purine analog of2la-21(ML-130). NX22426 bound well to TGFβ2, but had 25-fold reduced bioactivity. NX22427 may have slightly better binding and inhibitory activity than NX22284.
• In summary, the human TGFβ2 ligand isolated by using combined spot, spr and filter SELEX methods which have the best combination of affinity, short length, and inhibitory activity is NX22427, a 32-mer with 12 2′-OCH[0222]₃purines out of a total of 16 purines.
• Substitutions of 2′-OH Purines with 2′-OCH[0223]₃Purines in NX22385
• Some of the ligands that were isolated using the biased SELEX method (e.g., clone 13) bound better to TGFβ2.[0224]
• To compare the properties of a[0225]truncated clone 13 to truncated 21a-21, NX22385 was synthesized. NX22385 (Table 19) is a 34 base long, 2′-F pyrimidine, 2′-OH purine version of biasedSELEX clone #13. It binds about 2.5-fold better than NX22284, the corresponding 34 base long truncate of 21a-21, but its inhibitory activity is about 4-fold worse.
• For reasons mentioned in the previous section it was of interest to determine if the properties of a truncated clone 13t when synthesized as a 2′-F pyrimidine, 2′-OCH[0226]₃purine nucleic acid. Two 2′-OCH₃purine versions of NX22385 (NX22424 and NX22425; Table 19) were synthesized based on the 2′-OCH₃pattern of NX22420, a truncate of 21a-21. In both nucleic acids A8, G20, A22 and A24 wer retained as 2′-OH purines, as in NX22420. In NX22424, the purines that are unique to clone 13 (A5, A6 and G12) are 2′-OH purines. In NX22425, those purines are 2′-OCH₃purines. Analogs of NX22424 and NX22425 were also synthesized in which A24 (NX22386) or G20 and A24 (NX22387) are 2′-OCH₃purines. NX22386 and NX22387 were expected to serve as negative controls since 2′-OCH₃G20 or A24 version of NX,22284 were inactive. As expected NX22386 and NX22387 did not bind-or inhibit TGFβ2. NX22424 and NX22425 bound to TGFβ2 as well as NX22284, but were reduced >100-fold in bioactivity ( Table 19). Therefore, while other sequences that bind as well as NX22284 were isolated, no other sequence was identified that have better bioactivity.
Example 5Pharmacokinetic Properties of NX22323
• NX22323 is a 5′-polyethylene glycol-modified version of NX22284 (see Table 11; FIG. 9). The plasma concentrations of NX22323 were measured in rats over a 48 hour time period and are shown in FIG. 11 with the corresponding pharmacokinetic parameters in Tables 20 and 21. These data demonstrate biphasic clearance of NX22323 from plasma with an initial clearance half life (αT[0227]_1/2) of 1 hour and a terminal clearance half life (βT_1/2) of 8 hours. The volume of distribution at steady state was approximately 140 mL/kg suggesting only minor distribution of the aptamer with the majority remaining in plasma and extracellular water. The clearance rate determined by compartmental analysis was 0.40 mL/(min*kg). This value was consistent with other aptamers with similar chemical composition (5′-PEG 40K, 3′-3′ dT, 2′F pyrimidine, 2′-OH purine nucleic acid). These data support daily administration of NX22323 for efficacy evaluation.
Example 62′-O-Methyl Modification of Lead Truncate Ligand CD70
• TGFβ1 nucleic acid ligands are disclosed in U.S. patent application Ser. No. 09/275,850, filed Mar. 24, 1999, entitled “Truncation SELEX Method,” which is incorporated herein by reference. A lead aptamer was generated by truncation SELEX by hybridization (see Table 11,[0228]Family 4, Ligand #70 in U.S. patent application Ser. No. 09/275,850), herein called CD70. CD70 derivative oligonucleotides were synthesized containing 2′-OMe modifications at various positions as summarized in Table 22 (SEQ ID NOS:194-216). The results suggest that 13 out of 16 purines can be substituted with their 2′-OMe counterparts without any loss of activity. The molecule with the maximum 2′-OMe modifications (CD70-m13) is also bioactive (Table 22). FIG. 10 shows a putative structure of CD70-m13 and the positions of that require the presence of 2′-OH nucleotides. Of interest is the A position at the 3′ end of the molecule which according to the proposed structure does not participate in a secondary structure. Deletion of this single stranded A affects somewhat the binding activity of the molecule but it completely eliminates its bioactivity (Table 22). The 2′-OH bases and the 3′ final A are in close proximity in the proposed structure. This suggests a domain of the molecule responsible for target binding. Under these circumstances, it is expected that the loop shown at the top of the proposed structure (FIG. 10) may not be necessary for binding. This was confirmed by replacing such a loop with a PEG linker and showing that such modified molecules retain binding (Table 22). The PEG linker was conjugated to the aptamer as shown in U.S. patent application Ser. No. 08/991,743, filed Dec. 16, 1997, entitled “Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes,” which is hereby incorporated by reference in its entirety. The shortest binding aptamer identified from these experiments is CD70-m22, a 34-mer (including the PEG linker).

  TABLE 1
  Sequences used during SELEX.
  (all are shown in a 5′ to 3′ direction, and separated by a blank every 10 bases)

  Sequences involved in SELEX process:
  (P0; DNA template for round 0 of spot SELEX)
  TCGGGCGAGT CGTCTGNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN	50	(SEQ ID NO:1)
  NNNNNNCCGC ATCGTCCTCC C	71

  A = dA; C = dC; GdG; T = dT; N + 25% each of dA, dC, dG, or dT

  (5′N7; primer used in PCR steps of SELEX)
  TAATACGACT CACTATAGGG AGGACGATGC GG	32	(SEQ ID NO:2)
  A = dA; C = dC; G = dG; T = dT
  (3′N7; primer used in RT and PCR steps of SELEX)
  TCGGGCGAGT CGTCTG	16	(SEQ ID NO: 3)
  A = dA; C = dC; G = dG; T = dT
  (Transcription template for round 0 of spot SELEX)
  TAATACGACTCACTATAGGGAGGACGATGCGG-40N-CAGACGACTCGCCCGA	88 bp	(SEQ ID NO:4)
  ATTATGCTGAGTGATATCCCTCCTGCTACGCC-40N-GTCTGCTGAGCGGGCT		(SEQ ID NO:5)

  A = dA; C = dC; G = dG; T = dT; N = 25% each of dA, dC, dG, or dT

  (R0 40N7; nucleic acid library for round 0 of spot
  SELEX)
  GGGAGGACGA UGCGGNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN	50	(SEQ ID NO:6)
  NNNNNCAGAC GACUCGCCCG A	71

  A = 2′-OH A; C = 2′-F C; G = 2′-OH G; N = 25 % each of 2′-OH A, 2′-F C,

  2′-OH G, and 2′-F U; U = 2′-F U

  (34N7.21a-21 DNA template for round 0 of biased SELEX)
  GGGAGGACGA TGCGGNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNC	50	(SEQ ID NO:7)
  AGACGACTCG CCCGA	65

  A = dA; C = dC; G = dG; T = dT, N = 62.5% NX22284 sequence as DNA and 12.5%

  of the other 4 nucleotides (dA, dC, dG, or dT) at each position

  (Transcription template for round 0 of biased SELEX)
  TAATACGACTCACTATAGGGAGGACGATGCGG-34N-CAGACGACTCGCCCGA	82 bp	(SEQ ID NO:8)
  ATTATGCTGAGTGATATCCCTCCTGCTACGCC-34N-GTCTGCTGAGCGGGCT		(SEQ ID NO:9)

  A = dA; C = dC; G = dG; T = dT, N = 62.5% NX22284 sequence as DNA and 12.5%

  of the other 4 nucleotides (dA, dC, dG, or dT) at each position

  (34N7.21a-21 nucleic acid library for round 0, biased
  SELEX)
  GGGAGGACGA UGCGGNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNC	50	(SEQ ID NO:10)
  AGACGACUCG CCCGA	65

  A = 2′-OH A; C = 2′-F C; G = 2′-OH G; N = 62.5% NX22284 sequence and 12.5%

  of other 4 nucleotides (2′-OH A, 2′-F C, 2′-OH G, or 2′-F U) at each

  position; U = 2′-F U

  Sequences used for subcloning, screening, sequencing
  ligand
  (ML-34; used for subcloning)
  CGCAGGATCC TAATACGACT CACTATA	27	(SEQ ID NO:11)
  A = dA; C = dC; G = dG; T = dT
  (ML-78; used for subcloning)
  GGCAGAATTC TCATCTACTT AGTCGGGCGA GTCGTCTG		(SEQ ID NO:12)
  A = dA; C = dC; G = dG; T = dT

  (RSP1; vector-specific primer used to screen transformants for ligand inserts)

  AGCGGATAAC AATTTCACAC AGG	23	(SEQ ID NO:13)
  A = dA; C = dC; G = dG; T = dT

  (FSP2; vector-specific primer used to screen transformants for ligand inserts)

  GTGCTGCAAG GCGATTAAGT TGG	23	(SEQ ID NO:14)
  A = dA; C = dC; G = dG; T = dT
  (RSP2; primer for sequencing ligands)
  ACTTTATGCT TCCGGCTCG	19	(SEQ ID NO:15)
  A = dA; C = dC; GdG; T = dT
  Sequences used to detect specific ligands
  (ligand 14i-1 specific primer; ML85)
  GCCAAATGCC GAGAGAACG	19	(SEQ ID NO:16)
  A = dA; C = dC; G = dG; T = dT
  (ligand 21a-4 specific primer; ML-79)
  GGGGACAAGC GGACTTAG	18	(SEQ ID NO:17)
  A = dA; C = dC; G = dG; T = dT
  (ligand 21a-21 specific primer; ML-81)
  GGGAGTACAG CTATACAG	18	(SEQ ID NO:18)
  A = dA; C = dC; G = dG; T = dT
  Sequences used for RNAse H cleavage
  (5′N7 cleave)
  CCGCaugcuc cuccc	15	(SEQ ID NO:19)

  a = 2′-OCH3A; c = 2′-OCH3C; C = dC; g = 2′-OCH3G; G = dG; u = 2′-OCH3U

  (3′N7 cleave)

  ucgggcgagu cgTCTG

  16

  (SEQ ID NO:20)

  a = 2′-OCH3A; c = 2′-OCH3C; C = dC; g = 2′-OCH3G; G = dG; u = 2′-OCH3U;

  T = dT

• [0229]

  TABLE 2
  Conditions and results of filter SELEX

  Rounda	[RNA]b, nM	[TGFβ2], nM	RNAb/protein	[Competitor]	% Bound	% Background	Bound/Background	Kd (nM)

  9b	1nM	100 nM	0.01	100 μM tRNA	4.2	1.1	4	nd
  10b
  	1nM	30 nM	0.03	100 μM tRNA	4.3	0.13	33	100
  11a	1nM	30 nM	0.03	100 μM tRNA	1.5	0.2	8	75
  12d	0.2nM	20 nM	0.01	250 μM tRNA	2.2	0.3	7	40
  13i	0.4nM	10 nM	0.04	10 μM tRNA	2.6	0.16	16	30
  14i	0.1nM	10 nM	0.01	10 μM heparin	14.5	0.55	20	75
  15c	10nM	10 nM	1.0	0	8.8	2.2	4	30
  16a	55nM	10 nM	5.5	0	9.6	2.1	5	10
  17a	30nM	3nM	10	0	1.9	0.17	11	5
  18b	15nM	3nM	5	0	2.3	0.6	4	5
  19a	7 nM	0.1 nM	70	0	0.17	0.05	3	2
  20a	0.33 nM	0.03nM	11	0	0.1	0.04	3	1
  21a	0.63 nM	0.03nM	21	0	0.3	0.1	3	1
  22a	0.07 nM	0.01nM	7	0	0.12	0.09	1	1

• [0230]

  TABLE 3
  Conditions and results of Spot SELEX

  	Protein	RNA	Washes1	Signal/
  Rd	(pmoles)	(pmoles)	(μl/min)	Noise	% Input	Incubation	Pre-adsorb2

  1	*200	2000	2 (500/10)	4.90	ND3	4 hrs, 20° C.	No
  2	*200	1500	2 (1000/10)	1.80	ND	0.5 hrs, 37° C.	5 layers, 0.75 hrs
  3	*200	1500	2 (1000/10)	5.50	ND	1 hr, 37° C.	5 layers, 1 hr
  4	200	1000	2 (1000/10)	11.20	0.18	1 hr, 37° C.	5 layers, 2.5 hrs
  	*67	1000	2 (1000/10)	3.70	0.06	1 hr, 37° C.	5 layers, 2.5 hrs
  	22	1000	2 (1000/10)	1.58	0.03	1 hr, 37° C.	5 layers, 2.5 hrs
  5	67	100	2 (1000/20)	26.00	1.30	1 hr, 37° C.	10 layers, 0.75 hrs
  	*22	100	2 (1000/20)	11.00	0.56	1 hr, 37° C.	10 layers, 0.75 hrs
  	7.3	100	2 (1000/20)	2.70	0.10	1 hr, 37° C.	10 layers, 0.75 hrs
  6	22	50	2 (1000/20)	20.70	1.00	1 hr, 37° C.	10 layers, 0.75 hrs
  	*7.3	50	2 (1000/20)	4.00	0.20	1 hr, 37° C.	10 layers, 0.75 hrs
  	2.4	50	2 (1000/20)	1.20	0.06	1 hr, 37° C.	10 layers, 0.75 hrs
  7	22	7	3 (1000/50)	24.00	1.30	1 hr, 37° C.	10 layers, 1.5 hrs
  	*7.3	7	3 (1000/50)	7.50	0.40	1 hr, 37° C.	10 layers, 1.5 hrs
  	2.4	7	3 (1000/50)	1.50	0.07	1 hr, 37° C.	10 layers, 1.5 hrs
  8	*7.3	3	2 (1000/60)	77.00	0.41	0.75 hr, 37° C.	10 layers, 1.5 hrs
  	2.4	3	2 (1000/60)	8.50	0.04	0.75 hr, 37° C.	10 layers, 1.5 hrs
  	0.7	3	2 (1000/60)	1.00	ND	0.75 hr, 37° C.	10 layers, 1.5 hrs
  9	*7.3	1	2 (1000/20)	87.00	0.23	1 hr, 37° C.	10 layers, 1.5 hrs
  	2.4	1	2 (1000/20)	4.00	0.01	1 hr, 37° C.	10 layers, 1.5 hrs
  	0.7	1	2 (1000/20)	2.50	0.006	1 hr, 37° C.	10 layers, 1.5 hrs
  10	7.3	<1 (no tRNA)	2 (1000/20)	13.70	ND	0.5 hr, 37° C.	10 layers, 1.5 hrs
  	7.3	<1 (101tRNA)4	2 (1000/20)	10.50	ND	0.5 hr, 37° C.	10 layers, 1.5 hrs
  	7.3	<1 (102tRNA)	2 (1000/20)	5.00	ND	0.5 hr, 37° C.	10 layers, 1.5 hrs
  	7.3	<1 (103tRNA)	2 (1000/20)	1.80	ND	0.5 hr, 37° C.	10 layers, 1.5 hrs

• [0231]

  TABLE 4
  Conditions and results surface plasmon resonance biosensor (spr) SELEX.
  Progress of BIA SELEX with TGFβ2

  TGFβ2, RU1

  [RNA],

  Injections

  Fractions

  Fraction

  RU after

  Rd	FC1	FC2	FC3	FC4	μM2	(vol, μL)3	(min each)4	FW5	SDS6

  2	1293	874	294	0	4	4 (40)	3 (5)	3rd & SDS	˜100
  3	1176	1178	1181	0	15	4 (40)	3 (5)	3rd & SDS	˜50-100
  4	3010	2037	1767	0	10	6 (40)	3 (5)	3rd & SDS	˜80
  5	5520	5334	4265	0	5	6 (40)	3 (5)	3rd & SDS	˜100-150
  6	4075	3143	298	0	5	6 (40)	3 (5)	3rd & SDS	˜75-100
  7	3773	2616	2364	0	2	6 (40)	3 (5)	3rd & SDS	˜330-220
  8	2574	1842	1461	0	5	4 (40)	3 (5)	3rd & SDS	˜60-105
  9	3180	2029	1688	0	3	4 (40)	3 (5)	3rd & SDS	˜77-114
  10	344	718	1692	0	1	4 (40)	6 (10)	6th & SDS	˜50
  11	217	675	386	0	5	2 (40)	6 (10)	6th & SDS	˜50-62

• [0232]

  TABLE 5
  Sequences isolated fromround 8 of surface plasmon resonance SELEX.

  NAMEa	SEQ ID NO.	SEQUENCEb	BINDINGc
  8.1 (1)	21	GGGAGGACGAUGCGG UCCUCAAUG-AUCUU---------UCCUGUUUAUGCUCCC CAGACGACUCGCCCGA	FILTER
  8.2 (1)	22	GGGAGGACGAUGCGG AAGUAACGUUUA AGUAAAAUUCGUUCUCUCGGU_AUUUGGC CAGACGACUCGCCCGA	TGFβ2
  8.3 (14)	23	GGGAGGACGAUGCGG AAGUAACGUUGA_AGUAAAAUUCGUUCUCUCGGC_AUUUGGC CAGACGACUCGCCCGA	TGFβ2
  8.5 (1)	24	GGGAGGACGAUGCGG UCCUAACCAUCACAAUCUCAAUUCUUAUAUUUUCCCGCCC CAGACGACUCGCCCGA	NONE
  8.6 (1)	25	GGGAGGACGAUGCGG --AAACCAAAAGACCACAUCUCCAUACUCACGCUCUGCCC CAGACGACUCGCCCGA	NONE
  8.8 (1)	26	GGGAGGACGAUGCGG AUAGAUCGGUCCGAUAAGUCUUUCAUCUUUACCUGGCCCC CAGACGACUCGCCCGA	NONE
  8.9 (4)	27	GGGAGGACGAUGCGG AAGUAACGUUGA_AGUAAAAUUCGUUCUCUCGGU_AUUUGGC CAOACGACUCGCCCGA	TGFβ2
  8.11 (1)	28	GGGAGGACGAUGCGG ACGAUCCUUUCCUUAACAUUUCAUCAUUUCUCCUGUGCCC CAGACGACUCGCCCGG	FILTER
  8.12 (1)	29	GGGAGGACGAUGCGG UCCAUCAACAAUCUUAUCAUUAUGUUUUUCCUUCCCGCCC CAGACGACUCGCCCGA	NONE
  8.13 (1)	30	GGGAGGACGAUGCGG UCCUCUGAGCCGAUCUUCUUCACUACUUCUUUUUCUGCCC CAGACGACUCGCCCGA	FILTER
  8.15 (2)	31	GGGAGOACGAUGCGG UUCCUCAAUUCUUCCAUCUUCAUAAUGUUUCCCUUUGCCC CAGACGACUCGCCCGA	FILTER
  8.18 (1)	32	GGGAGGACGAUGCGG UCUACCCUUUAGCAGUAUUUGUUUCCAUCGUUGUUUGCCC CAGACGACUCGCCCGG	NONE
  8.20 (1)	33	GGGAGGACGAUGCGG UCUCAACGAAGAACAUCGUUGGAUACUGUUUGUCCCGCCC CAGACGACUCGCCCGA	NONE
  8.21 (1)	34	GGGAGGACGAUGCGG UUCAGUUUCCUUCAGUUUUCGUUUCUAAUUCUUGUGUCCC CAGACGACUCGCCCGA	FILTER
  8.22 (1)	35	GGGAGGACGAUGCGG ----------AGCGGAUUAAUUAGUCUGACUUCUUGUCCC CAGACGACUCGCCCGA
  8.23 (1)	36	GGGAGGACGAUGCGG AGACAUCUUUGUCUCGAUUAGUCAUGUUCCUUACCUGCCC CAGACGACUCGCCCGA	NONE
  8.24 (1)	37	GGGAGGACGAUGCGG --UCCUCUAGCAAGCAGCUUCUCAUCUUAUUUUUCCGCCC CAGACGACUCGCCCGA
  8.25 (1)	38	GGGAGGACGAUGCGG UGCACAGUGAUGGAUGACAUUGUAUAACGGUAUOCGUCCC CAGACGACUCGCCCGA
  8.26 (1)	39	GGGAGGACGAUGCGG -ACCUAUCUUUCUUCCAAGUCAUAGUUUUACUUCCCGCCC CAGACGACUCGCCCGA	FILTER
  8.28 (1)	40	GGGAGGACGAUGCGG AUGAGACCUAAUCAUCGAUCCGCUAUCUAAAACCUCACCC CAGACGACUCGCCCGA	NONE
  8.29 (1)	41	GGGAGGACGAUGCGG UCCUCAGACAAAUCUUUCUUGAAUCUUUCCUUAACUGCCC CAGACGACUCGCCCGA	FILTER
  8.31 (1)	42	GGGAGGACGAUGCGG -ACCGAUUCUCCAACUUGACAUUUAUUCCUCUUUCUGCCC CAGACGACUCGCCCGA	FILTER
  8.33 (1)	43	GGGAGGACGAUGCGG UCCUCUGAGCCAAUCUUCUUCGCUACUUCUUUUUCUGCCC CAGACGACUCGCCCGA	FILTER
  8.34 (1)	44	GGGAGGACGAUGCGG AUUCUUUCUCCAACGCUUUUCACUACCUACAUUUCUGCCC CAGACGACUCGCCCGA	FILTER
  8.35 (1)	45	GGGAGGACGAUGCGG AUCCUAUCCUCUGAAUAUCAUUAAAUCAUCUUCUCCGCCC CAGACGACUCGCCCGA	NONE
  8.36 (1)	46	GGGAGGACGAUGCGG UUCAAUCAUCUUCACUCU-CAUUUCCUUUUUCCUACUCCC CAGACGACUCGCCCGA	FILTER
  8.38 (1)	47	GGGAGGACGAUGCGG CGAUAGAAUCUAGUCGUUCUAGAUGAUCUGGUACGUGCCC CAGACGACUCGCCCGA
  8.39 (1)	48	GGGAGGACGAUGCGG UAGUAAUCCUUGUCUUCCAUUUCUCUUUACCCUUUUGCCC CAGACGACUCGCCCGA	FILTER
  8.40 (1)	49	GGGAGGACGAUGCGG ----CCCAUUAGUCCUCAUUAGU------CCCCUGUGCCC CAGACGACUCGCCCGA	NONE
  8.41 (1)	50	GGGAGGACGAUGCGG CAUCUUAUCCUCCAUCAGUUACUCUUCGUUAUUCCCGCCC CAGACGACUCGCCCGA
  8.45 (1)	51	GGGAGGACGAUGCGG UCC-AAAUCCUCUUCCCAUGUUAGCAUUCAGCCUUGUCCC CAGACGACUCGCCCGA
  8.46 (1)	52	GGGAGGACGAUGCGG -UUCCGACAAUUUCCUCCACCAUUAGAUUUCUUGCUGCCC CAGACGACUCGCCCGA
  8.47 (1)	53	GGGAGGACGAUGCGG UCUUGAUCCUCCUUUGUGUCUUUCUUUGUCUUCCCUGCCC CAGACGACUCGCCCGA
  8.48 (2)	54	GGGAGGACGAUGCGG AAGUAACGUUGA_AGUAAAAUUCGUUCUCUCGGU_AUU-GGC CAGACGACUCGCCCGA	TGFβ2
  8.49 (1)	55	GGGAGGACGAUGCGG -UCCGAUCAGUUCCUUCGAUUAAUCUUCUUUCCUGCCCCC CAGACGACUCGCCCGA
  8.51 (1)	56	GGGAGGACGAUGCGG AAUCCUUCUCCCUGAUGAAUAUGACCUUUUUCUUGCUCCC CAGACGACUCGCCCGA
  8.52 (1)	57	GGGAGGACGAUGCGG AUGAUCUUUAAUGUCUGGUUUGAGGUCAAUGCGGGUGCCC CAGACGACUCGCCCGA
  8.56 (1)	58	GGGAGGACGAUGCGG AGAUGGUACUCCAUCUCCUUUAUGUGCCCAUCGCUGUCCC CAGACGACUCGCCCGA
  8.57 (1)	59	GGGAGGACGAUGCGG UCCUC-GAUUCU---------AAUUUACUCCUUUUUCCCC CAGACGACUCGCCCGA
  8.61 (1)	60	GGGAGGACGAUGCGG UCUACCCUUUAGCAGUAUUUGUUUCCAUCGUUGUUUGCCC CAGACGACUCGCCCGA
  8.62 (1)	61	GGGAGGACGAUGCGG -CACAAUAUUCUCCUCUACUUCCACGUAUUUUCCUGUCCC CAGACGACUCGCCCGA
  8.64 (1)	62	GGGAGGACGAUGCGG UCCUCAACCUUAGACUUUCAUUUCUUCAGUUCUUCUGCCC CAGACGACUCGCCCGA
  8.65 (1)	63	GGGAGGACGAUGCGG UAGUGGUCUGUCAAAGGAAUAGCUAGUAGUGUUUGGUCCC CAGACGACUCGCCCGA
  8.69 (1)	64	GGGAGGACGAUGCGG CAUCUUCCUUAGCAUACCAGUUUAUUCCUUUCCCUGUCCC CAGACGACUCGCCCGA
  8.71 (1)	65	GGGAGGACGAUGCGG AGCGACAGUAUAGUUAGUACUCUAGCUCUAGUGCUGUCCC CAGACGACUCGCCCGA
  8.72 (1)	66	GGGAGGACGAUGCGG ACCUCUCAUGAUCAGCAUCUCGCGUAAUCACGGUUCACCC CAGACGACUCGCCCGA
  8.74 (1)	67	GOGAGGACGAUGCGG UCCGUACUCCAUUUCCUAUUUGAUUCCUUUUCCUCUGCCC CAGACGACUCGCCCGA
  8.75 (1)	68	GGGAGGACGAUGCGG AACCCACGACCUUACCUUAAUCAUGUAUUUCUCUCUGCCC CAGACGACUCGCCCGA
  8.76 (1)	69	GGGAGGACGAUGCGG ------AGAUAAUGAGUGACGGUGAUUAUAGAUGCUGCCC CAGACGACUCGCCCGA
  8.79 (1)	70	GGGAGGACGAUGCGG UUCCUCAAUUCUUCCAUCUUCAUAAUGUUUCCCUUUGCCC CAGACGACUCGCCCGA
  8.80 (1)	71	GGGAGGACGAUGCGG UUCCU-------UCCAACGUUAUCUACUUUCU----GCCC CAGACGACUCGCCCGA

• [0233]

  TABLE 6
  Conditions and results of resonant mirror (rm) optical
  biosensor SELEX.
  Progress of IASYS SELEX with TGFβ2

  TGFβ2,

  Disso-

  Arcsec1

  [RNA],

  Vol,

  Binding

  ciation

  Rd	C1	C2	μM2	μL3	(min)4	(min)5	Elution6

  10	1777	0	1	50	27	29	water
  11	1777	0	10	50	30	60	water
  12	1777	0	10	50	60	150	water
  13	1893	0	0.05	50	37	73	water&SDS
  14	1721	0	3.5	50	30	35	water&SDS

• [0234]

  TABLE 7
  Sequences isolated fromround 13 of resonant mirror SELEX

  	SEQ ID
  NAMEa	NO.	SEQUENCEb
  14i-1	72	GGGAGGACGAUGCGG AAGUAACGUUGUAGUAAAAUUCGUUCUCUCGG-CAUUUGGC CAGACGACU-CGCCCGA
  13.20 (1)	73	GGGAGGACGAUGCGG AAGUAACGUUAUAGUAAAAUUCGUUCUCUCGG-UAUU GGC CAGACGACU-CGCCCGA
  13.22 (2)	74	GGGAGGACGGUGCGG AAGUAACGUUGUAGUAAAAUUCGUUCUCUCGG-CGUUUGGC CAGACGACU-CGCCCGA
  13.24 (2)	75	GGGAGGACGAUGCGG AAGUAACGUUGUAGUAAAAUUCGUUCUCUCGG-CGUUUGGU CAGACGACU-CGCCCGA
  13.30 (1)	76	GGGAG ACGAUGCGG AAGUAACGUUGUAGUAAAAUUCGUUCUCUCGG-CAUUUGGC CAGACGACU-CGCCCGA
  13.32 (1)	77	GGGAGGACGAUGCGG AAGUAACGUUGAAGUAAAAUUCGUUCUCUCUG-CGUUUGGU CAGACGACU-CGCCCGA
  13.34 (1)	78	GGGAGGACGAUGCGG AAGUAACGUUGAAGUAAAAUUCGUUCUCCUGG-UA UUGGC CAGACGACU-CGCCCGA
  13.36 (2)	79	GGGAGGACGAUGCGG AAGUAACGUUGAAGUAAAAUUCGUUCUCUCGG-CAUUUGGC CAGACGACU-CGCCCGA
  13.40 (1)	80	GGGAGGACGAUGCGG AAGUAACGUUGUAGUAAAAUUCGUUCUCUUGG-CAUUU GC CAGACGACU-CGCCCGA
  13.42 (1)	81	GGGAGGACGAUGCGG AAGUAACGUUAAAGUAAAAUUCGUUCUCUCGG-CGUUUGGC CAGACGACU-CGCCCGA
  13.44 (1)	82	GGGAGGACGAUGCGG AAGUAACGUUGAAGUAAAAUUCGUUCUCUCGG-CGUUUGGC CAGACGACU-CGCCCGA
  13.48 (1)	83	GGGAGGACGAUGCGG AAGUAACGUUGUAGUAAAAUUCGUUCUCUCGG-UAUUUGGC CAGACGACU-CGCCCGA
  13.50 (1)	84	GGGAGGACGAUGCGG AAGUAACGUUGUAGUAAAAUUCGUUCUCUUGG-UCUU GGC CAGACGACU-CGCCCGA
  13.54 (1)	85	GGAGGACGAUGCG  AAGUAACGUUGUAGUAAAAUUCGUUCUCUCGGGCAUUUGG  CAGACGACUUCGCCCGA

• [0235]

  TABLE 8
  Sequences and boundaries of TGFβ2 ligands isolated fromrounds 14 and 21 of filter SELEX.

  	SEQ ID		Kd	Ki
  NAMEa	NO.	SEQUENCEb	(nM)	(nM)

  14i-1	72	GGGAGGACGAUGCGGAAGUAACGUUGUAGUAAAAUUCGUUCUCUCGGCAUUUGGCCAGACGACUCGCCCGA	10	230
  21a-4	86	GGGAGGACGAUGCGGCGUUGUUUAGUCGUAUGUAUAUACUAAGUCCGCUUGUCCCCAGACGACUCGCCCGA	3	30
  21a-21	87	GGGAGGACGAUGCGG-UUCAGGAGGUUAUUACAGAGUCUGUAUAGCUGUACUCCCCAGACGACUCGCCCGA	1	10
  region:		5′ fixed                    selected                     3′ fixed

• [0236]

  TABLE 9
  Number of sequences isolated using the SELEX process.

  SELEX round

  Sequence	8-spr	13-rm	14i	16a	18b	21a	TOTAL

  14i-1	0	0	75	2	0	0	77
  14i-1variants	21	15	22	2	0	0	60
  21a-4	0	0	0	0	0	3	3
  21a-4variants	0	0	4	7	0	2	13
  21a-21	0	0	0	1	11	38	50
  21a-21variants	0	0	0	2	4	4	10
  unidentified	36	0	0	0	0	0	36
  filter-binding	12	0	1	1	0	1	15
  TOTAL	69	15	102	15	15	48	264

• [0237]

  TABLE 10
  Characteristics of nucleic acid pools isolated using
  the SELEX method.

  Rounda	Sequence of poolb	% of poolc	% of transformantsd	% ofclonese
  0	random	14i-1: <0.03
  6-spr	random	14i-1: ˜1
  8-spr	slightly nonrandom	14i-1: ˜5		14i-1: 30
  				other: 70
  9-spr	nonrandom
  9-rm	can read sequence ofligand 14i-1
  10-rm	can read sequence ofligand 14i-1
  11-rm	can read sequence ofligand 14i-1
  12-rm	can read variants ofligand 14i-1 sequence
  13-rm	can read variants ofligand 14i-1sequence	14i-1: 10-100		14i-1: 100
  		21a-21: <0.1
  14i				14i-1: 93
  				21a-4: 4
  		21a-21: 0.2-0.5		21a-21: 0
  				other: 3
  16a				14i-1: 27
  				21a-4: 47
  		21a-21: 3-100		21a-21: 20
  				other: 6
  18b		21a-21: 3-100		21a-21: 100
  21a
  			21a-4: 9	21a-4: 10
  		21a-21: 3-100	21a-21: 90	21a-21: 84
  			other: 1	other: 6

• [0238]

  TABLE 11
  Truncates of human TGFβ2nucleic acid ligand 21a-21.

  					BIO-
  		SEQ			AC-
  		ID			TIV-
  NAME	SEQUENCEa	NO:	BINDINGb	LENGTHc	ITYd

  21a-21

  GGGAGGACGAUGCGGUUCAGG_AGGUUAUUACAGAGUCUGUAUAGCUGUACUCCCC AGACGACU

  87

  0.5

  70

  1

  	CGCCCGA

  21a-21

  GGGAGGACGAUGCGGUUCAGGAGGG_UAUUACAGAGUCUGUAUAGCUGUACUCCCCAGACGACUC

  88

  250

  34

  (U6G)	GCCCGA

  21a-21Δ5′	GGUUCAGGAGGUUAUUACAGAGUCUGUAUAGCUGUACUCCCCAGACGACUCGCCCGA	89	0.5	56
  21a-21Δ3′	GGGAGGACGAUGCGGUUCAGGAGGUUAUUACAGAGUCUGUAUAGCUGUACUCCCCA	90	100	56
  21a-21Δ5′,3′	GGUUCAGGAGGUUAUUACAGAGUCUGUAUAGCUGUACUCCCCA	91	0.5	42	1
  21a-21	GGAGGUUAUUACAGAGUCUGUAUAGCUGUACUCCCC	92	0.5	36
  (ML-94)
  21a-21	GGAGGUUAUUACAGAGUCUGUAUAGCUGUACUCC	93	1	34
  (ML-95)
  21a-21	GGAGGUUAUUACAGAGUCUGUAUAGCUGUA	94	1000	30
  (ML-96)
  21a-21	GGAGGUUAUUACAGAGUCUGUAUAGC	95	1000	26
  (ML-97)
  21a-21	GGAGCUUAUUACAGAGUCUGUAUAGC CUCC	96	1000	30
  (ML-99)
  21a-21	GGAGGUUAUU AGAGUCU AUAGCUGUACUCC	97	1000	30
  (ML-101)
  21a-21	GGAGGUUAUU AGAGUCU AUAGC CUCC	98	1000	26
  (ML-102)
  21a-21	GGAGGUUAUUACAGAGUCUGUAUAGCUGUACUC	99	50	33
  (ML-103)
  21a-21	GGAGGUUAUUACAGAGUCUGUAUAGCUGUACU	100	70	32
  (ML-104)
  21a-21	GGAGGUUAUUACAGAGUCUGUAUAGCUGUAC	101	1000	31
  (ML-105)
  21a-21	GGAGGUUAUUACAGAGUCUGUAUAGC GUACUCC	102	1000	33
  (ML-114)
  21a-21	GGAGGUUAUUACAGAGUCUGUAUAGCUGU CUCC	103	1000	33
  (ML-115)
  21a-21	GGAGGUUAUUACAGAGUCUGUAUAGCU ACUCC	104	1000	32
  (ML-116)
  21a-21	GGAGGUUAU ACAGAGUCUGUAUAGCUGUACUCC	105	1000	33
  (ML-118)
  21a-21	GGAGGUUAUUACAGA UCUGUAUAGCUGUACUCC	106	1000	33
  (ML-120)
  21a-21	GGAGGUUAUUACA AGU UGUAUAGCUGUACUCC	107	1000	32
  (ML-122)
  21a-21	GGAGGUUAUUACAGAGU UGUAUAGCUGUACUCC	108	1000	33
  (ML-128)
  21a-21	GG GGUUAUUACAGAGUCUGUAUAGCUGUAC CC	109	2	32
  (ML-130)
  21a-21	GGAGGUUAUUAC GAGUCUGUAUAGC GUACUCC	110	1000	32
  (ML-132)
  21a-21	GGAGA UAUUACAGAGUCUGUAUAGCUGUACUCC	111	10	33
  (ML-134)
  21a-21	GG GGUUAUU CAGAGUCUGUAUAGCUG AC CC	112	10000	30
  (ML-136)
  21a-21	GG GGUUAUUA AGAGUCUGUAUAGCU UAC CC	113	10000	30
  (ML-138)
  NX22283	GGAGGUUAUUACAGAGUCUGUAUAGCUGUACUCCCC [3′T]	114	0.6	36	0.5
  NX22284	GGAGGUUAUUACAGAGUCUGUAUAGCUGUACUCC [3′T]	115	1	34	1
  NX22285	GGAGGUUAUUACAGAGUCUGUAUAGCUGUACUCCCCA	116	2	37
  NX22286	GGAGGUUAUUACAGAGUCUGUAUAGCUGUA	117	130	30	>20
  NX22301	GAGGUUAUUACAGAGUCUGUAUAGCUGUACUCC [3′T]	118	1	33	2
  NX22302	AGGUUAUUACAGAGUCUGUAUAGCUGUACUCC [3′T]	119	100	32
  NX22303	GGUUAUUACAGAGUCUGUAUAGCUGUACUCC [3′T]	120	>100	31	>100
  NX22323	PEG-GGAGGUUAUUACAGAGUCUGUAUAGCUGUACUCC [3′T]	121	nt	34	3

• [0239]

  TABLE 12
  Alignment of human transforming growth factor β amino acid sequences.

  	SEQ ID NO.

  TGFβ1:	ALDTNYCFSS TEKNCCVRQL YIDFRKDLGWKWIHEPKGYH ANFCLGPCPY IWSLDTQYSK 60	122
  TGFβ2:	ALDAAYCFRN VQDNCCLRPL YIDFKRDLGWKWIHEPKGYN ANFCAGACPY LWSSDTQHSR 60	123
  TGFβ3:	ALDTNYCFRN LEENCCVRPL YIDFRQDLGWKWVHEPKGYY ANFCSGPCPY LRSADTTHST 60	124
  TGFβ2 specific:	AA      VQD   L        KR              N     A A       S     R
  TGFβ1:	VLALYNQHNP GASAAPCCVP QALEPLPIVY YVGRKPKVEQ LSNMIVRSCK CS 112	125
  TGFβ2:	VLSLYNTINP EASASPCCVS QDLEPLTILY YIGKTPKIEQ LSNMIVKSCK CS 112	126
  TGFβ3:	VLGLYNTLNP EASASPCCVP QDLEPLTILY YVGRTPKVEQ LSNMVVKSCK CS 112	127
  TGFβ2 specific:	S    I            S             I K   I

• [0240]

  TABLE 13
  Truncates of human TGFβ2nucleic acid ligand 14i-1.

  		SEQ
  		ID	BIND-
  NAME	SEOUENCEa	NO.	INGb	LENGTHc

  14i-1	GGGAGGACGAUGCGGAAGUAACGUUGUAGUAAAAUUCGUUCUCUC GGCAUUUGGCCAGACGACUCGCCCGA	72	1	71
  14i-1Δ5′d	GGAAGUAACGUUGUAGUAAAAUUCGUUCUCUCGGCAUUUGGCCAGACGACUCGCCCGA	128	>100	56
  14i-1Δ3′d	GGGAGGACGAUGCGGAAGUAACGUUGUAGUAAAAUUCGUUCUCUCGGCAUUUGGCCA	129	3	57
  141-1Δ5,3′d	GGAAGUAACGUUGUAGUAAAAUUCGUUCUCUCGGCAUUUGGCCA	130	>100	42
  14i-1t5-41	gGGAgGAUGCGGAAGUAACGUUGUAGUAAAAUUCcUUC	131	1	38
  14i-1t5-38	gGGAgGAUGCGGAAGUAACGUUGUAGUAAAAUUCc	132	>100	35
  14i-1t5-35	gGGAgGAUGCGGAAGUAACGUUGUAGUAAAAU	133	>100	32
  14i-1	gGGAgGAUGCGGAAGUAACGUUGUAGU UCcUUC	134	>100	33
  (ML-86)
  14i-1	gGGAgGAUGCGGAAGUAACGUUGUAGU	135	>100	27
  (ML-87)
  14i-1	gGgaGgAGUAACGUUGUAGU	136	>100	20
  (ML-89)

• [0241]

  TABLE 14
  Truncates of human TGβ2nucleic acid ligand 21a-4.

  		SEQ
  		ID	Bind-
  Name	Seguencea	NO.	ingb	Lengthc

  21a-4	GGGAGGACGAUGCGGCGUUGUUUAGUCGUAUGUAUAUACUAAGUCCGCUUGUCCCC AGACGACUCGCCCGA	86	1	71
  21a-4Δ5′d	GGCGUUGUUUAGUCGUAUGUAUAUACUAAGUCCGCUUGUCCCCAGACGACUCGCCCGA	137	>100	56
  21a-4Δ3′d	GGGAGGACGAUGCGGCGUUGUUUAGUCGUAUGUAUAUACUAAGUCCGCUUGUCCCCA	138	1	57
  21a-4Δ5,3′d	GGCGUUGUUUAGUCGUAUGUAUAUACUAAGUCCGCUUGUCCCCA	139	>100	42
  21a-4	ggGgaGCGGCGUUGUUUAGUCGUAUGUAUAUACUAAGUCCGCUU	140	1	44
  (ML-91)
  21a-4	ggGgaGCGGCGUUGUU       gaaa        AGUCCGCUU	141	>100	27
  (ML-92)
  21a-4	ggGgaGCGGCGUUGUUU   CGUAUGUAUAU   AAGUCCGCUU	142	>100	38
  (ML-108)
  21a-4	ggGgaGCGGCGUUGUUU      AUGUAU      AAGUCCGCUU	143	>100	33
  (ML-109)
  21a-4	ggGgaGCGGCGUUGUUUAGUCGUAUGUAUAUACUAAGUCCGC	144	1	42
  (ML-110)
  21a-4	ggGgaGCGGCGUUGUUUAGUCGUAUGUAUAUACUAAGU	145	30	38
  (ML-111)

• [0242]

  TABLE 15
  Biased SELEX conditions and results.

  Rounda	[RNA]b, nM	[TGFβ2], nM	RNAb/protein	[Competitor]	% Bound	% Background	Bound/background	Kd (nM)c

  34N7.21a-21round 0 nucleic acid

  870

  1a	1000	150	7	0	1.4	1.4	1.0	395
  2a	450	300	1.5	0	1.7	1.0	1.7	186
  3a	10	50	0.2	0	17.5	1.0	17.5	25
  4a	50	10	5	0	11.0	0.9	12.3	17
  4b	50	10	5	333 nM NX22284	2.2	1.3	1.7	8
  5a	8	1	8	0	1.4	0.9	1.5	1
  5b	8	1	8	100 nM NX22284	0.8	0.7	1.1	17
  6a	4	0.5	8	0	2.9	2.9	1.0	1
  6b	6	0.5	12	100 nM NX22284	1.8	1.3	1.4	1
  7a	5	0.25	20	0	0.5	0.14	3.4	1
  7b	5	0.25	20	200 nM NX22284	0.15	0.1	1.5	0.5
  				5mM tRNA
  8a
  	1	0.05	20	0	1.05	1.1	0.9	1
  8b	1	0.05	20	100 nM NX22284	0.6	0.5	1.2	3
  				5 mM tRNA
  9a	125	1	125	0	0.6	0.5	1.2	nd
  9b	0.9	0.01	90	0	0.15	0.14	1.0	nd

• [0243]

  TABLE 16
  Nucleic acid ligands isolated from round 5a of a human TGFβ2 biased SELEX.

  		SEQ
  		ID
  NAMEa	5′ FIXED                    SELECTEDb                  3′ FIXED	NO:	CHANGESc	BINDINGd

  putative structural element:    S1    B    S2    L        S2  S1

  21a-21:	GGGAGGACGAUGCGGUUCAGGAG  UACAG CUGUACUCCC CAGACGACUCGCCCGA	72	0	1.0
  1: (2)	GGGAGGACGAUGCGG GGUGAUUAUUACAGAGUAUGUAUAGCUGUACCCC CAGACGACUCGCCCGA	146	4	0.8
  2: (1)	GGGAGGACGAUGCGGAGGCGUUAUUAGAGAGUCUGUAUAGCUCUAGCCC CAGACGACUCGCC-GA	147	7	0.6
  4: (1)	GGGAGGACGAUGCGG GGAGGGUAUUACAGAGUAUGUAUAGCUGUACUCC CAGACGACUCGCCCGA	148	2	1.4
  6: (2)	GGGAGGACGAUGCGG GGAGGUUAUUAUAGAGUCUGUAUAGCUAUACCCC CAGACGACUCGCCCGA	149	3	1.6
  7: (1)	GGGAGGACGAUGCGG GAGGGUUAUUAUAGAGUCUGCAUAGCUAUACCCC CAGACGACUCGCCCGA	150	5	0.3
  9: (1)	GGGAGGACGAUGCGGUGAGAGUAUUACGGAGUAUGUAUAGCCGUACCCC CAGACGACUCGCCCGA	151	7	0.3
  10: (1)	GGGAGGACGAUGCGG GGGCAUUAUUUCAGAGUCUGUAUAGCUGUAGCCC CAGACGACUCGCCCGA	152	6	0.3
  11: (2)	GGGAGGACGAUGCGG GCGGAUUAUCACAGAGUAUGUAUAGCUGUGCCGC CAGACGACUCGCCCGA	153	8	0.4
  13: (1)	GGGAGGACGAUGCGGUGUGAAUAUUAGAGAGUCUGUAUAGCUCUACCCC CAGACGACUCGCCCGA	154	7	0.2
  14: (1)	GGGAGGACGAUGCGGCGGGAUUAUUACUGAGUCUGUAUAGCAGUACCCC CAGACGACUCGCCCGA	155	6	0.4
  15: (1)	GGGAGGACGAUGCGG GUGGAAUAUUACGGAGUCUGUAUAGCCGUACUCC CAGACGACUCGCCCGA	156	6	0.4
  17: (1)	GGGAGGACGAUGCGG GGGGACUAUUAGUGAGUCUGUAUAGCACUACCCC CAGACGACUCGCCCGA	157	8	0.8
  18: (1)	GGGAGGACGAUGCGG GUGGAUUAUUACAGCGUCUGUAUAUCUGUACCCC CAGACGACUCGCCCGA	158	6	1.0
  19: (2)	GGGAGGACGAUGCGG GCAGGUUAUUACAGAGUCUGUAUAGCUGUACUGC CAGACGACUCGCCCGA	159	2	1.0
  20: (1)	GGGAGGACGAUGCGG GGUAGAUAUCACUGAGUCUGUAUAGCAGUGUCCC CAGACGACUCGCCCGA	160	9	5.7
  21: (2)	GGGAGGACGAUGCGGAGGGAUUAUUACAGAGUCUGUAUAGCUGUACCCC CAGACGACUCGCCCGA	161	4	0.7
  22: (4)	GGGAGGACGAUGCGG GUGGAUUAUUACAGAGUCUGUAUAGCUGUACCCC CAGACGACUCGCCCGA	162	4	1.1
  25: (1)	GGGAGGACGAUGCGG GGGCGUUAUUACAGAGUCUGUAUAGCUGUAGCCC CAGACGACUCGCCCGA	163	4	1.0
  26: (1)	GGGAGGACGAUGCGG GGUGGUUAUUACACAGUAUGUAUAGGUGUACCCC CAGACGACUCGCCCGA	164	4	3.1
  28: (1)	GGGAGGACGAUGCGGAGGGAAUAUUACAGAGUAUGUAUAGCUGUACCCC CAGACGACUCGCCCGA	165	6	1.0
  29: (1)	GGGAGGACGAUGCGG GGAGUUUAUUACAGCGUCUGUAUAUCUGUAGCCC CAGACGACUCGCCCGA	166	5	1.0
  30: (1)	GGGAGGACGAUGCGGUGAGGUUAUUACAGAGUCUGUAUAGCUGUACUCC CAGACGACUCGCCCGA	167	1	2.4
  34: (1)	GGGAGGACGAUGCGG GGUGGUUAUUAGAGAGUCUGUAUAGCUCUACGCC CAGACGACUCGCCCGA	168	4	1.7
  35: (1)	GGGAGGACGAUGCGG GGGGAGUAUUAAAGAGUCUGUAUAGCUUUACCCC CAGACGACUCGCCCGA	169	6	0.8
  36: (1)	GGGAGGACGAUGCGG GGAGGAUAUUAUAGAGUCUGUAUAGCUAUACCCC CAGACGACUCGCCCGA	170	4	1.9
  invar-	UAU      GU UG AUA       C
  iant:

• [0244]

  TABLE 17
  Highest and lowest affinity TGFβ2 nucleic acid ligands from biased SELEX.

  		SEQ ID
  NAME
  	5′ FIXED        SELECTEDa                          3′ FIXED	NO.	BINDINGb	CHANGESc

  HIGHEST AFFINITY LIGANDS:

  13:	GGGAGGACGAUGCGGUGUGAAUAUUAGAGAGUCUGUAUAGCUCUACCCC CAGACGACUCGCCCGA	154	0.2	7
  14:	GGGAGGACGAUGCGGCGGGAUUAUUACUGAGUCUGUAUAGCAGUACCCC CAGACGACUCGCCCGA	155	0.4	6
  21:	GGGAGGACGAUGCGGAGGGAUUAUUACAGAGUCUGUAUAGCUGUACCCC CAGACGACUCGCCCGA	161	0.7	4
  35:	GGGAGGACGAUGCGG GGGGAGUAUUAAAGAGUCUGUAUAGCUUUACCCC CAGACGACUCGCCCGA	169	0.8	6
  putative structural elements: S1    B    S2    L        S2  S1
  21a-21:	GGGAGGACGAUGCGGUUCAGGAG  UACAG CUGUACUCCC CAGACGACUCGCCCGA	72	1.0	0

  LOWEST AFFINITY LIGANDS:

  36:	GGGAGGACGAUGCGG GGAGGAUAUUAUAGAGUCUGUAUAGCUAUACCCC CAGACGACUCGCCCGA	170	2.0	4
  30:	GGGAGGACGAUGCGGUGAGGUUAUUACAGAGUCUGUAUAGCUGUACUCC CAGACGACUCGCCCGA	167	2.4	1
  26:	GGGAGGACGAUGCGG GGUGGUUAUUACACAGUAUGUAUAGGUGUACCCC CAGACGACUCGCCCGA	164	3.1	4
  6:	GGGAGGACGAUGCGG GGAGGUUAUUAUAGAGUCUGUAUAGCUAUACCCC CAGACGACUCGCCCGA	149	3.3	3
  20:	GGGAGGACGAUGCGG GGUAGAUAUCACUGAGUCUGUAUAGCAGUGUCCC CAGACGACUCGCCCGA	160	5.7	9
  invariant:	UAU      GU UG AUA         C
  aNucleotides that differ from the starting sequence are shown in bold-faced lettering. A = 2′-OH A; C = 2′-F C; G = 2′-OH G; U = 2′-F U Putative structural elements: S1, stemi; B, bulge; S2, stem2; L, loop.
  bBinding is expressed as Kd(ligand)/Kd(21a-21). The Kdof 21a-21 is 1 nM
  cNumber of changes from staffing sequence.

• [0245]

  TABLE 18
  Substitution of 2′-OH purines with 2′-OCH3purines in NX22284 ligand.

  NAME	SEQUENCEa	SEO ID NO.	BINDINGb	LENGTHc	BIOACTIVITYd

  NX22284	GGAGGUUAUUACAGAGUCUGUAUAGCUGUACUCC[3′T]	115	1	34	1
  NX22304	ggaggUUaUUaCagagUCUgUaUagCUgUaCuCc[3′T]	171	>100	34	>100
  NX22355	GGAGGUUAUUaCagagUCUgUaUagCUgUaCUCC[3′T]	172	>100	34	>100
  NX22356	ggagGUUAUUACAGAGUCUGUAUAGCuGUACUCC[3′T]	173	1	34	1
  NX22357	GGAGgUUaUUaCAGAGUCUGUAUAGCUGUACUCC[3′T]	174	2	34	10
  NX22358	GGAGGUUAUUACagagUCUGUAUAGCUGUACUCC[3′T]	175	1	34	1
  NX22359	GGAGGUUAUUACAGAGUCUgUaUaGCUGUACUCY[3′T]	176	>100	34	>30
  NX22360	GGAGGUUAUUACAGAGUCUGUAUAgCUgUaCUCC[3′T]	177	1	34	1
  NX22374	GGAGGUUAUUACAGAGUCUgUAUAGCUGUACUCC[3′T]	178	25	34	>100
  NX22375	GGAGGUUAUUACAGAGCUGUaUAGCUGUACUCCC[3′T]	179	>100	34	>300
  NX22376	GGAGGUUAUUACAGAGUCUGUAUaGCUGUACUCC[3′T]	180	50	34	>100
  NX22377	ggaggUUaUUaCAGAGUCUGUAUAgCUgUaCucc[3′T]	181	1	34	1
  NX22383	ggaggUUaUUaCagagUCUGUAUagCUgUaCUCC[3′T]	182	500	34	>100
  NX22384	ggaggUUaUUaCagagUCUgUAUagCUgUaCUcc[3′T]	183	10000	34	>100
  NX22417	ggaggUUaUUaCagagUCUGUAUAgCUgUaCUCC[3′T]	184	1	34	10
  NX22420	ggaggUUAUUaCagagUCUGUAUAgCUgUaCuCc[3′T]	185	1	34	1
  NX22421	ggagGUUAUUACagagUCUGUAUAgCUgUacucc[3′T]	186	2	34	1
  NX22426	ggaga-UAUUaCagagUCUGUAUAgCUgUaCucc[3′T]	187	1	33	25
  NX22427	gg-ggUUAUUaCagagUCUGUAUAgCUgUaC-CC[3′T]	188	0.3	32	0.7

• [0246]

  TABLE 19
  Truncates and 2′-OCH3purine modifications of nucleicacid ligand #13 from a biased
  SELEX.

  NAME	SEOUENCEa	SEQ ID NO.	BINDINGb	LENGTHc	BIOACTIVITYd

  NX22385	UGUGAAUAUUAGAGAGUCUGUAUAGCUCUACCCC[3′T]	189	0.4	34	4
  NX22386	UgUgaAUaUUaGagagUCUGUAUagCUCUaCCCC[3′T]	190	3000	34	>100
  NX22387	UgUgaaUaUUagagagUCUgUAUagCUCUaCCCC[3′T]	191	3000	34	30
  NX22424	UgUgAAUAUUaGagagUCUGUAUAgCUCUaCCCC[3′T]	192	0.6	34	>100
  NX22425	UgUgaaUAUUagagagUCUGUAUAgCUCUaCCCC[3′T]	193	1.5	34	>100

• [0247]

  TABLE 20
  Pharmacokinetic properties of NX22323 in rats using
  a noncompartmental analysis.

  	Parameter	Units	Estimate

  	Cmax	(μg/mL)	27.1
  	AUClast	((μg * min)/mL)	3028.0
  	AUCINF	((μg * min)/mL)	3058.0
  	Beta t½	(min)	630.9
  	C1	(mL/(min * kg))	0.33
  	MRTINF	(min)	350.4
  	Vss	(mL/kg)	115.0
  	Vz	(mL/kg)	298.0

• [0248]

  TABLE 21
  Pharmacokinetic properties of NX22323 in rats
  using a compartmental analysis.

  Parameter	Units	Estimate	StdError	% Error

  Cmax	(μg/mL)	16.3	3.3	20.2
  AUCINF	((μg * min)/mL)	2486	274	11.0
  Alpha-t½	(min)	63.5	19.1	30.2
  Beta-t½	(min)	467.2	83.2	17.8
  A	(μg/mL)	14.63	3.21	21.9
  B	(μg/mL)	1.70	0.84	49.1
  C1	(mL/(min * kg)	0.402	0.044	11.0
  MRTINF	(min)	360.3	35.6	9.9
  Vss	(mL/kg)	144.9	23.1	15.9

• [0249]

  TABLE 22
  Binding and inhibitory activity of 2′-Omethyl- and Pegyl-modifications of lead TGFβ1
  truncate ligand CD70

  	SEQ ID NO.	Binding	Bioactivity

  ChD70

  GGGUGCCUUUUGCCUAGGUUGUGAUUUGUAACCUUCUGCCCA

  	216	+++	+++
  ChD70-m1	gggUgCCUUUUGCCUAGGUUGUGAUUUGUAACCUUCUGCCCA	194	+
  ChD70-m2	GGGUGCCUUUUgCCUaggUUGUGAUUUGUAACCUUCUGCCCA	195	++
  ChD70-m3	GGGUGCCUUUUGCCUAGGUUgUgaUUUgUAACCUUCUGCCCA	196	+++
  ChD70-m4	GGGUGCCUUUUGCCUAGGUUGUGAUUUGUaaCCUUCUgCCCa	197	++
  ChD70-m5	gGGUGCCUUUUGCCUAGGUUgUgaUUUgUAACCUUCUGCCCA	198	+++
  ChD70-m6	GgGUGCCUUUUGCCUAGGUUgUgaUUUgUAACCUUCUGCCCA	199	+++
  ChD70-m7	GGgUGCCUUUUGCCUAGGUUgUgaUUUgUAACCUUCUGCCCA		200	+++
  ChD70-m8	GGGUgCCUUUUGCCUAGGUUgUgaUUUgUAACCUUCUGCCCA	201	+
  ChD70-m9	GGGUGCCUUUUgCCUAGGUUgUgaUUUgUAACCUUCUGCCCA	202	+
  ChD70-m10	GGGUGCCUUUUGCCUaGGUUgUgaUUUgUAACCUUCUGCCCA	203	+++
  ChD70-m11	GGGUGCCUUUUGCCUAgGUUgUgaUUUgUAACCUUCUGCCCA	204	+++
  ChD70-m12	GGGUGCCUUUUGCCUAGgUUgUgaUUUgUAACCUUCUGCCCA	205	+++
  ChD70-m13	GGGUGCCUUUUGCCUAGGUUgUgaUUUgUaACCUUCUGCCCA	206	+++
  ChD70-m14	GGGUGCCUUUUGCCUAGGUUgUgaUUUgUAaCCUUCUGCCCA	207	+++
  ChD70-m15	GGGUGCCUUUUGCCUAGGUUgUgaUUUgUAACCUUCUgCCCA	208	+++
  ChD70-m16	GGGUGCCUUUUGCCUAGGUUgUgaUUUgUAACCUUCUGCCCa	209	+++
  ChD70-m17	gggUGCCUUUUGCCUaggUUgUgaUUUgUaaCCUUCUGCCCa3′-3′U	210	+++	+++
  ChD70-m18	gggUGCCUUUUGCCUaggUUgUgaUUUgUaACCUUCUGCCCa3′-3′U	211	+++
  ChD70-m19	gggUGCCUUUUGCCUaggUUgUgaUUUgUaaCCUUCUGCCC3′-3′U	212	++	−
  ChD70-m20	gggUGCCUUUUGCCUaggUUgU-----gUaaCCUUCUGCCCa3′-3′U	213	++
  ChD70-m21	gggUGCCUUUUGCCUaggUUg-------UaaCCUUCUGCCCa3′-3′U	214	++
  ChD70-m22	gggUGCCUUUUGCCUaggUU---------aaCCUUCUGCCCa3′-3′U	215	+++

• [0250]
• 1216171DNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 1 tcgggcgagt cgtctgnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnccgc 60 atcgtcctcc c 71232DNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 2 taatacgact cactataggg aggacgatgc gg 32316DNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 3 tcgggcgagt cgtctg 16488DNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 4 taatacgact cactataggg aggacgatgc ggnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60 nnnnnnnnnn nncagacgac tcgcccga 88588DNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 5 attatgctga gtgatatccc tcctgctacg ccnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60 nnnnnnnnnn nngtctgctg agcgggct 88671RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 6 gggaggacga ugcggnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnncagac 60 gacucgcccg a 71765DNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 7 gggaggacga tgcggnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnc agacgactcg 60 cccga 65882DNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 8 taatacgact cactataggg aggacgatgc ggnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60 nnnnnncaga cgactcgccc ga 82982DNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 9 attatgctga gtgatatccc tcctgctacg ccnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60 nnnnnngtct gctgagcggg ct 821065RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 10 gggaggacga ugcggnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnc agacgacucg 60 cccga 651127DNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 11 cgcaggatcc taatacgact cactata 271238DNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 12 ggcagaattc tcatctactt agtcgggcga gtcgtctg 381323DNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 13 agcggataac aatttcacac agg 231423DNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 14 gtgctgcaag gcgattaagt tgg 231519DNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 15 actttatgct tccggctcg 191619DNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 16 gccaaatgcc gagagaacg 191718DNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 17 ggggacaagc ggacttag 181818DNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 18 gggagtacag ctatacag 181915RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 19 ccgcaugcuc cuccc 152014RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 20 ucgggcgagu cgcg 142161RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 21 gggaggacga ugcgguccuc aaugaucuuu ccuguuuaug cuccccagac gacucgcccg 60 a 612271RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 22 gggaggacga ugcggaagua acguuuaagu aaaauucguu cucucgguau uuggccagac 60 gacucgcccg a 712371RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 23 gggaggacga ugcggaagua acguugaagu aaaauucguu cucucggcau uuggccagac 60 gacucgcccg a 712471RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 24 gggaggacga ugcgguccua accaucacaa ucucaauucu uauauuuucc cgccccagac 60 gacucgcccg a 712569RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 25 gggaggacga ugcggaaacc aaaagaccac aucuccauac ucacgcucug ccccagacga 60 cucgcccga 692671RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 26 gggaggacga ugcggauaga ucgguccgau aagucuuuca ucuuuaccug gcccccagac 60 gacucgcccg a 712771RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 27 gggaggacga ugcggaagua acguugaagu aaaauucguu cucucgguau uuggccagac 60 gacucgcccg a 712871RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 28 gggaggacga ugcggacgau ccuuuccuua acauuucauc auuucuccug ugccccagac 60 gacucgcccg g 712971RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 29 gggaggacga ugcgguccau caacaaucuu aucauuaugu uuuuccuucc cgccccagac 60 gacucgcccg a 713071RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 30 gggaggacga ugcgguccuc ugagccgauc uucuucacua cuucuuuuuc ugccccagac 60 gacucgcccg a 713171RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 31 gggaggacga ugcgguuccu caauucuucc aucuucauaa uguuucccuu ugccccagac 60 gacucgcccg a 713271RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 32 gggaggacga ugcggucuac ccuuuagcag uauuuguuuc caucguuguu ugccccagac 60 gacucgcccg g 713371RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 33 gggaggacga ugcggucuca acgaagaaca ucguuggaua cuguuugucc cgccccagac 60 gacucgcccg a 713471RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 34 gggaggacga ugcgguucag uuuccuucag uuuucguuuc uaauucuugu guccccagac 60 gacucgcccg a 713561RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 35 gggaggacga ugcggagcgg auuaauuagu cugacuucuu guccccagac gacucgcccg 60 a 613671RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 36 gggaggacga ugcggagaca ucuuugucuc gauuagucau guuccuuacc ugccccagac 60 gacucgcccg a 713769RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 37 gggaggacga ugcgguccuc uagcaagcag cuucucaucu uauuuuuccg ccccagacga 60 cucgcccga 693871RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 38 gggaggacga ugcggugcac agugauggau gacauuguau aacgguaugc guccccagac 60 gacucgcccg a 713970RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 39 gggaggacga ugcggaccua ucuuucuucc aagucauagu uuuacuuccc gccccagacg 60 acucgcccga 704071RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 40 gggaggacga ugcggaugag accuaaucau cgauccgcua ucuaaaaccu caccccagac 60 gacucgcccg a 714171RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 41 gggaggacga ugcgguccuc agacaaaucu uucuugaauc uuuccuuaac ugccccagac 60 gacucgcccg a 714270RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 42 gggaggacga ugcggaccga uucuccaacu ugacauuuau uccucuuucu gccccagacg 60 acucgcccga 704371RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 43 gggaggacga ugcgguccuc ugagccaauc uucuucgcua cuucuuuuuc ugccccagac 60 gacucgcccg a 714471RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 44 gggaggacga ugcggauucu uucuccaacg cuuuucacua ccuacauuuc ugccccagac 60 gacucgcccg a 714571RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 45 gggaggacga ugcggauccu auccucugaa uaucauuaaa ucaucuucuc cgccccagac 60 gacucgcccg a 714670RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 46 gggaggacga ugcgguucaa ucaucuucac ucucauuucc uuuuuccuac uccccagacg 60 acucgcccga 704771RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 47 gggaggacga ugcggcgaua gaaucuaguc guucuagaug aucugguacg ugccccagac 60 gacucgcccg a 714871RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 48 gggaggacga ugcgguagua auccuugucu uccauuucuc uuuacccuuu ugccccagac 60 gacucgcccg a 714961RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 49 gggaggacga ugcggcccau uaguccucau uaguccccug ugccccagac gacucgcccg 60 a 615071RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 50 gggaggacga ugcggcaucu uauccuccau caguuacucu ucguuauucc cgccccagac 60 gacucgcccg a 715170RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 51 gggaggacga ugcgguccaa auccucuucc cauguuagca uucagccuug uccccagacg 60 acucgcccga 705270RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 52 gggaggacga ugcgguuccg acaauuuccu ccaccauuag auuucuugcu gccccagacg 60 acucgcccga 705371RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 53 gggaggacga ugcggucuug auccuccuuu gugucuuucu uugucuuccc ugccccagac 60 gacucgcccg a 715470RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 54 gggaggacga ugcggaagua acguugaagu aaaauucguu cucucgguau uggccagacg 60 acucgcccga 705570RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 55 gggaggacga ugcgguccga ucaguuccuu cgauuaaucu ucuuuccugc cccccagacg 60 acucgcccga 705671RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 56 gggaggacga ugcggaaucc uucucccuga ugaauaugac cuuuuucuug cuccccagac 60 gacucgcccg a 715771RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 57 gggaggacga ugcggaugau cuuuaauguc ugguuugagg ucaaugcggg ugccccagac 60 gacucgcccg a 715871RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 58 gggaggacga ugcggagaug guacuccauc uccuuuaugu gcccaucgcu guccccagac 60 gacucgcccg a 715961RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 59 gggaggacga ugcgguccuc gauucuaauu uacuccuuuu ucccccagac gacucgcccg 60 a 616071RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 60 gggaggacga ugcggucuac ccuuuagcag uauuuguuuc caucguuguu ugccccagac 60 gacucgcccg a 716170RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 61 gggaggacga ugcggcacaa uauucuccuc uacuuccacg uauuuuccug uccccagacg 60 acucgcccga 706271RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 62 gggaggacga ugcgguccuc aaccuuagac uuucauuucu ucaguucuuc ugccccagac 60 gacucgcccg a 716371RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 63 gggaggacga ugcgguagug gucugucaaa ggaauagcua guaguguuug guccccagac 60 gacucgcccg a 716471RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 64 gggaggacga ugcggcaucu uccuuagcau accaguuuau uccuuucccu guccccagac 60 gacucgcccg a 716571RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 65 gggaggacga ugcggagcga caguauaguu aguacucuag cucuagugcu guccccagac 60 gacucgcccg a 716671RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 66 gggaggacga ugcggaccuc ucaugaucag caucucgcgu aaucacgguu caccccagac 60 gacucgcccg a 716771RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 67 gggaggacga ugcgguccgu acuccauuuc cuauuugauu ccuuuuccuc ugccccagac 60 gacucgcccg a 716871RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 68 gggaggacga ugcggaaccc acgaccuuac cuuaaucaug uauuucucuc ugccccagac 60 gacucgcccg a 716965RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 69 gggaggacga ugcggagaua augagugacg gugauuauag augcugcccc agacgacucg 60 cccga 657071RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 70 gggaggacga ugcgguuccu caauucuucc aucuucauaa uguuucccuu ugccccagac 60 gacucgcccg a 717160RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 71 gggaggacga ugcgguuccu uccaacguua ucuacuuucu gccccagacg acucgcccga 607271RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 72 gggaggacga ugcggaagua acguuguagu aaaauucguu cucucggcau uuggccagac 60 gacucgcccg a 717370RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 73 gggaggacga ugcggaagua acguuauagu aaaauucguu cucucgguau uggccagacg 60 acucgcccga 707471RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 74 gggaggacgg ugcggaagua acguuguagu aaaauucguu cucucggcgu uuggccagac 60 gacucgcccg a 717571RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 75 gggaggacga ugcggaagua acguuguagu aaaauucguu cucucggcgu uuggucagac 60 gacucgcccg a 717670RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 76 gggagacgau gcggaaguaa cguuguagua aaauucguuc ucucggcauu uggccagacg 60 acucgcccga 707771RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 77 gggaggacga ugcggaagua acguugaagu aaaauucguu cucucugcgu uuggucagac 60 gacucgcccg a 717870RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 78 gggaggacga ugcggaagua acguugaagu aaaauucguu cuccugguau uggccagacg 60 acucgcccga 707971RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 79 gggaggacga ugcggaagua acguugaagu aaaauucguu cucucggcau uuggccagac 60 gacucgcccg a 718070RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 80 gggaggacga ugcggaagua acguuguagu aaaauucguu cucuuggcau uugccagacg 60 acucgcccga 708171RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 81 gggaggacga ugcggaagua acguuaaagu aaaauucguu cucucggcgu uuggccagac 60 gacucgcccg a 718271RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 82 gggaggacga ugcggaagua acguugaagu aaaauucguu cucucggcgu uuggccagac 60 gacucgcccg a 718371RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 83 gggaggacga ugcggaagua acguuguagu aaaauucguu cucucgguau uuggccagac 60 gacucgcccg a 718470RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 84 gggaggacga ugcggaagua acguuguagu aaaauucguu cucuuggucu uggccagacg 60 acucgcccga 708570RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 85 ggaggacgau gcgaaguaac guuguaguaa aauucguucu cucgggcauu uggcagacga 60 cuucgcccga 708671RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 86 gggaggacga ugcggcguug uuuagucgua uguauauacu aaguccgcuu guccccagac 60 gacucgcccg a 718770RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 87 gggaggacga ugcgguucag gagguuauua cagagucugu auagcuguac uccccagacg 60 acucgcccga 708870RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 88 gggaggacga ugcgguucag gaggguauua cagagucugu auagcuguac uccccagacg 60 acucgcccga 708957RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 89 gguucaggag guuauuacag agucuguaua gcuguacucc ccagacgacu cgcccga 579056RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 90 gggaggacga ugcgguucag gagguuauua cagagucugu auagcuguac ucccca 569143RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 91 gguucaggag guuauuacag agucuguaua gcuguacucc cca 439236RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 92 ggagguuauu acagagucug uauagcugua cucccc 369334RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 93 ggagguuauu acagagucug uauagcugua cucc 349430RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 94 ggagguuauu acagagucug uauagcugua 309526RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 95 ggagguuauu acagagucug uauagc 269630RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 96 ggagguuauu acagagucug uauagccucc 309730RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 97 ggagguuauu agagucuaua gcuguacucc 309826RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 98 ggagguuauu agagucuaua gccucc 269933RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 99 ggagguuauu acagagucug uauagcugua cuc 3310032RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 100 ggagguuauu acagagucug uauagcugua cu 3210131RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 101 ggagguuauu acagagucug uauagcugua c 3110233RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 102 ggagguuauu acagagucug uauagcguac ucc 3310333RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 103 ggagguuauu acagagucug uauagcuguc ucc 3310432RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 104 ggagguuauu acagagucug uauagcuacu cc 3210533RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 105 ggagguuaua cagagucugu auagcuguac ucc 3310633RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 106 ggagguuauu acagaucugu auagcuguac ucc 3310732RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 107 ggagguuauu acaaguugua uagcuguacu cc 3210833RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 108 ggagguuauu acagaguugu auagcuguac ucc 3310932RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 109 gggguuauua cagagucugu auagcuguac cc 3211032RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 110 ggagguuauu acgagucugu auagcguacu cc 3211133RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 111 ggagauauua cagagucugu auagcuguac ucc 3311230RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 112 gggguuauuc agagucugua uagcugaccc 3011330RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 113 gggguuauua agagucugua uagcuuaccc 3011436RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 114 ggagguuauu acagagucug uauagcugua cucccc 3611534RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 115 ggagguuauu acagagucug uauagcugua cucc 3411637RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 116 ggagguuauu acagagucug uauagcugua cucccca 3711730RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 117 ggagguuauu acagagucug uauagcugua 3011833RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 118 gagguuauua cagagucugu auagcuguac ucc 3311932RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 119 agguuauuac agagucugua uagcuguacu cc 3212031RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 120 gguuauuaca gagucuguau agcuguacuc c 3112134RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 121 ggagguuauu acagagucug uauagcugua cucc 3412260PRTArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 122 Ala Leu Asp Thr Asn Tyr Cys Phe Ser Ser Thr Glu Lys Asn Cys Cys 1 5 10 15 Val Arg Gln Leu Tyr Ile Asp Phe Arg Lys Asp Leu Gly Trp Lys Trp 20 25 30 Ile His Glu Pro Lys Gly Tyr His Ala Asn Phe Cys Leu Gly Pro Cys 35 40 45 Pro Tyr Ile Trp Ser Leu Asp Thr Gln Tyr Ser Lys 50 55 6012360PRTArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 123 Ala Leu Asp Ala Ala Tyr Cys Phe Arg Asn Val Gln Asp Asn Cys Cys 1 5 10 15 Leu Arg Pro Leu Tyr Ile Asp Phe Lys Arg Asp Leu Gly Trp Lys Trp 20 25 30 Ile His Glu Pro Lys Gly Tyr Asn Ala Asn Phe Cys Ala Gly Ala Cys 35 40 45 Pro Tyr Leu Trp Ser Ser Asp Thr Gln His Ser Arg 50 55 6012460PRTArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 124 Ala Leu Asp Thr Asn Tyr Cys Phe Arg Asn Leu Glu Glu Asn Cys Cys 1 5 10 15 Val Arg Pro Leu Tyr Ile Asp Phe Arg Gln Asp Leu Gly Trp Lys Trp 20 25 30 Val His Glu Pro Lys Gly Tyr Tyr Ala Asn Phe Cys Ser Gly Pro Cys 35 40 45 Pro Tyr Leu Arg Ser Ala Asp Thr Thr His Ser Thr 50 55 6012552PRTArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 125 Val Leu Ala Leu Tyr Asn Gln His Asn Pro Gly Ala Ser Ala Ala Pro 1 5 10 15 Cys Cys Val Pro Gln Ala Leu Glu Pro Leu Pro Ile Val Tyr Tyr Val 20 25 30 Gly Arg Lys Pro Lys Val Glu Gln Leu Ser Asn Met Ile Val Arg Ser 35 40 45 Cys Lys Cys Ser 5012652PRTArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 126 Val Leu Ser Leu Tyr Asn Thr Ile Asn Pro Glu Ala Ser Ala Ser Pro 1 5 10 15 Cys Cys Val Ser Gln Asp Leu Glu Pro Leu Thr Ile Leu Tyr Tyr Ile 20 25 30 Gly Lys Thr Pro Lys Ile Glu Gln Leu Ser Asn Met Ile Val Lys Ser 35 40 45 Cys Lys Cys Ser 5012752PRTArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 127 Val Leu Gly Leu Tyr Asn Thr Leu Asn Pro Glu Ala Ser Ala Ser Pro 1 5 10 15 Cys Cys Val Pro Gln Asp Leu Glu Pro Leu Thr Ile Leu Tyr Tyr Val 20 25 30 Gly Arg Thr Pro Lys Val Glu Gln Leu Ser Asn Met Val Val Lys Ser 35 40 45 Cys Lys Cys Ser 5012858RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 128 ggaaguaacg uuguaguaaa auucguucuc ucggcauuug gccagacgac ucgcccga 5812957RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 129 gggaggacga ugcggaagua acguuguagu aaaauucguu cucucggcau uuggcca 5713044RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 130 ggaaguaacg uuguaguaaa auucguucuc ucggcauuug gcca 4413138RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 131 gggaggaugc ggaaguaacg uuguaguaaa auuccuuc 3813235RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 132 gggaggaugc ggaaguaacg uuguaguaaa auucc 3513332RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 133 gggaggaugc ggaaguaacg uuguaguaaa au 3213433RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 134 gggaggaugc ggaaguaacg uuguaguucc uuc 3313527RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 135 gggaggaugc ggaaguaacg uuguagu 2713620RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 136 gggaggagua acguuguagu 2013758RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 137 ggcguuguuu agucguaugu auauacuaag uccgcuuguc cccagacgac ucgcccga 5813857RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 138 gggaggacga ugcggcguug uuuagucgua uguauauacu aaguccgcuu gucccca 5713944RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 139 ggcguuguuu agucguaugu auauacuaag uccgcuuguc ccca 4414044RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 140 ggggagcggc guuguuuagu cguauguaua uacuaagucc gcuu 4414129RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 141 ggggagcggc guuguugaaa aguccgcuu 2914238RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 142 ggggagcggc guuguuucgu auguauauaa guccgcuu 3814333RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 143 ggggagcggc guuguuuaug uauaaguccg cuu 3314442RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 144 ggggagcggc guuguuuagu cguauguaua uacuaagucc gc 4214538RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 145 ggggagcggc guuguuuagu cguauguaua uacuaagu 3814665RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 146 gggaggacga ugcgggguga uuauuacaga guauguauag cuguaccccc agacgacucg 60 cccga 6514764RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 147 gggaggacga ugcggaggcg uuauuagaga gucuguauag cucuagcccc agacgacucg 60 ccga 6414865RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 148 gggaggacga ugcggggagg guauuacaga guauguauag cuguacuccc agacgacucg 60 cccga 6514965RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 149 gggaggacga ugcggggagg uuauuauaga gucuguauag cuauaccccc agacgacucg 60 cccga 6515065RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 150 gggaggacga ugcgggaggg uuauuauaga gucugcauag cuauaccccc agacgacucg 60 cccga 6515165RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 151 gggaggacga ugcggugaga guauuacgga guauguauag ccguaccccc agacgacucg 60 cccga 6515265RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 152 gggaggacga ugcgggggca uuauuucaga gucuguauag cuguagcccc agacgacucg 60 cccga 6515365RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 153 gggaggacga ugcgggcgga uuaucacaga guauguauag cugugccgcc agacgacucg 60 cccga 6515465RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 154 gggaggacga ugcgguguga auauuagaga gucuguauag cucuaccccc agacgacucg 60 cccga 6515565RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 155 gggaggacga ugcggcggga uuauuacuga gucuguauag caguaccccc agacgacucg 60 cccga 6515665RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 156 gggaggacga ugcgggugga auauuacgga gucuguauag ccguacuccc agacgacucg 60 cccga 6515765RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 157 gggaggacga ugcgggggga cuauuaguga gucuguauag cacuaccccc agacgacucg 60 cccga 6515865RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 158 gggaggacga ugcgggugga uuauuacagc gucuguauau cuguaccccc agacgacucg 60 cccga 6515965RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 159 gggaggacga ugcgggcagg uuauuacaga gucuguauag cuguacugcc agacgacucg 60 cccga 6516065RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 160 gggaggacga ugcgggguag auaucacuga gucuguauag cagugucccc agacgacucg 60 cccga 6516165RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 161 gggaggacga ugcggaggga uuauuacaga gucuguauag cuguaccccc agacgacucg 60 cccga 6516265RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 162 gggaggacga ugcgggugga uuauuacaga gucuguauag cuguaccccc agacgacucg 60 cccga 6516365RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 163 gggaggacga ugcgggggcg uuauuacaga gucuguauag cuguagcccc agacgacucg 60 cccga 6516465RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 164 gggaggacga ugcggggugg uuauuacaca guauguauag guguaccccc agacgacucg 60 cccga 6516565RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 165 gggaggacga ugcggaggga auauuacaga guauguauag cuguaccccc agacgacucg 60 cccga 6516665RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 166 gggaggacga ugcggggagu uuauuacagc gucuguauau cuguagcccc agacgacucg 60 cccga 6516765RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 167 gggaggacga ugcggugagg uuauuacaga gucuguauag cuguacuccc agacgacucg 60 cccga 6516865RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 168 gggaggacga ugcggggugg uuauuagaga gucuguauag cucuacgccc agacgacucg 60 cccga 6516965RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 169 gggaggacga ugcgggggga guauuaaaga gucuguauag cuuuaccccc agacgacucg 60 cccga 6517065RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 170 gggaggacga ugcggggagg auauuauaga gucuguauag cuauaccccc agacgacucg 60 cccga 6517134RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 171 ggagguuauu acagagucug uauagcugua cucc 3417234RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 172 ggagguuauu acagagucug uauagcugua cucc 3417334RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 173 ggagguuauu acagagucug uauagcugua cucc 3417434RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 174 ggagguuauu acagagucug uauagcugua cucc 3417534RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 175 ggagguuauu acagagucug uauagcugua cucc 3417634RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 176 ggagguuauu acagagucug uauagcugua cucc 3417734RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 177 ggagguuauu acagagucug uauagcugua cucc 3417834RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 178 ggagguuauu acagagucug uauagcugua cucc 3417934RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 179 ggagguuauu acagagucug uauagcugua cucc 3418034RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 180 ggagguuauu acagagucug uauagcugua cucc 3418134RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 181 ggagguuauu acagagucug uauagcugua cucc 3418234RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 182 ggagguuauu acagagucug uauagcugua cucc 3418334RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 183 ggagguuauu acagagucug uauagcugua cucc 3418434RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 184 ggagguuauu acagagucug uauagcugua cucc 3418534RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 185 ggagguuauu acagagucug uauagcugua cucc 3418634RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 186 ggagguuauu acagagucug uauagcugua cucc 3418733RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 187 ggagauauua cagagucugu auagcuguac ucc 3318832RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 188 gggguuauua cagagucugu auagcuguac cc 3218934RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 189 ugugaauauu agagagucug uauagcucua cccc 3419034RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 190 ugugaauauu agagagucug uauagcucua cccc 3419134RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 191 ugugaauauu agagagucug uauagcucua cccc 3419234RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 192 ugugaauauu agagagucug uauagcucua cccc 3419334RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 193 ugugaauauu agagagucug uauagcucua cccc 3419442RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 1-3 and 5 are 2′-OMe. 194 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4219542RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 12 and 16-18 are 2′OMe. 195 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4219642RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 21, 23-24 and 28 are 2′-OMe. 196 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4219742RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 30-31, 38 and 42 are 2′-OMe. 197 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4219842RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 1, 21, 23-24 and 28 are 2′-OMe. 198 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4219942RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 2, 21, 23-24 and 28 are 2′-OMe. 199 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4220042RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 3, 21, 23-24 and 28 are 2′-OMe. 200 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4220142RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 5, 21, 23-24 and 28 are 2′-OMe. 201 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4220242RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 12, 21, 23-24 and 28 are 2′-OMe. 202 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4220342RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 16, 21, 23-24 and 28 are 2′-OMe. 203 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4220442RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 17, 21, 23-24 and 28 are 2′-OMe. 204 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4220542RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 18, 21, 23-24, and 28 are 2′-OMe. 205 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4220642RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 21, 23-24, 28 and 30 are 2′-OMe. 206 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4220742RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 21, 23-24, 28 and 31 are 2′-OMe. 207 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4220842RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 21, 23-24, 28 and 38 are 2′-OMe. 208 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4220942RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 21, 23-24, 28 and 42 are 2′-OMe. 209 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4221042RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 1-3, 16-18, 21, 23-24, 28, 30-31 and 42 are 2′-OMe; linkage at positions 42 and 43 is 3′-3′. 210 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4221142RNAArtificial Sequencemodified_base(1)..(42)A′s and g′s at positions 1-3, 16-18, 21, 23-24, 28, 30 and 42 are 2′-OMe; linkage at positions 42 and 43 is 3′-3′. 211 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 4221241RNAArtificial Sequencemodified_base(1)..(41)A′s and g′s at positions 1-3, 16-18, 21, 23-24, 28 and 30-31 are 2′-OMe; linkage at positions 41 and 42 are 3′-3′. 212 gggugccuuu ugccuagguu gugauuugua accuucugcc c 4121337RNAArtificial Sequencemodified_base(1)..(37)A′s and g′s at positions 1-3, 16-18, 21, 23, 25-26 and 37 are 2′-OMe; linkage at positions 37 and 38 is 3′-3′. 213 gggugccuuu ugccuagguu guguaaccuu cugccca 3721435RNAArtificial Sequencemodified_base(1)..(35)A′s and g′s at positions 1-3, 16-18, 21, 23-24 and 35 are 2′-OMe; linkage at positions 35 and 36 is 3′-3′. 214 gggugccuuu ugccuagguu guaaccuucu gccca 3521533RNAArtificial Sequencemodified_base(1)..(33)A′s and g′s at positions 1-3, 16-18, 21-22, and 33 are 2′-OMe; linkage at positions 33 and 34 is 3′-3′. 215 gggugccuuu ugccuagguu aaccuucugc cca 3321642RNAArtificial SequenceDescription of Artificial Sequence Synthetic Sequence 216 gggugccuuu ugccuagguu gugauuugua accuucugcc ca 42

Claims (18)

What is claimed is:

1. A method of inhibiting a transforming growth factor β2 (TGFβ2) comprising contacting said TGFβ2 with a nucleic acid ligand of TGFβ2.

2. The method ofclaim 1, wherein the nucleic acid ligand of TGFβ2 is a ligand comprising a ligand having a nucleotide sequence selected from the group consisting of SEQ ID NOS:21-87, 89, 91-93, 109, 111, 114-116, 118-121, 129, 131, 138, 140, 144, 146-181, 184-189, 192, and 193.

3. The method ofclaim 1 wherein said nucleic acid ligand is conjugated to polyethylene glycol (PEG).

4. The method ofclaim 3 wherein said PEG has a molecular weight of about between 10-80 K.

5. The method ofclaim 3 wherein said PEG has a molecular weight of about 20-45 K.

6. The method ofclaim 1 wherein said ligand is

wherein

X=PEG, and

LIGAND=rGrGrArGrGfUfUrAfUfUrAfCrArGrArGfUfCfUrGfUfUrArGfCfUrGfUrAfCfUfCfC-3′-3′-dT (SEQ ID NO:115), wherein rG is 2′OH G, rA is 2′OH A, fU is 2′F U and fC is 2′F C.

7. A method for targeting a nucleic acid ligand to a site in a patient comprising TGFβ82 comprising:

covalently linking said nucleic acid ligand to a Non-Immunogenic, High Molecular 20 Weight Compound or Lipophilic Compound to form a Complex, and administering said Complex to said patient, whereby said nucleic acid ligand is targeted to a site in a patient comprising TGFβ2.

8. The method ofclaim 7, wherein the nucleic acid ligand of TGFβ2 is a ligand comprising a ligand having a nucleotide sequence selected from the group consisting of SEQ ID NOS:21-87, 89, 91-93, 109, 111, 114-116, 118-121, 129, 131, 138, 140, 144, 146-181, 184-189, 192, and 193.

9. The method ofclaim 7 wherein said nucleic acid ligand is conjugated to polyethylene glycol (PEG).

10. The method ofclaim 9 wherein said PEG has a molecular weight of about between 10-80 K.

11. The method ofclaim 9 wherein said PEG has a molecular weight of about 20-45 K.

12. The method ofclaim 7 wherein said ligand is

wherein

X=PEG, and

LIGAND=rGrGrArGrGfUfUrAfUfUrAfCrArGrArGfUfCfUrGfUfUrArGfCfUrGfUrAfCfUfCfC-3′-3′-dT (SEQ ID NO:1 15), wherein rG is 2′OH G, rA is 2′OH A, fU is 2′F U and fC is 2′F C.

13. A method for treating a TGF□2-mediated pathological conditions comprising administering a nucleic acid ligand capable of binding to TGF□2 to a patient in need thereof.

14. The method ofclaim 13, wherein the nucleic acid ligand of TGFβ2 is a ligand comprising a ligand having a nucleotide sequence selected from the group consisting of SEQ ID NOS:21-87, 89, 91-93, 109, 111, 114-116, 118-121, 129, 131, 138, 140, 144, 146-181, 184-189, 192, and 193.

15. The method ofclaim 13 wherein said nucleic acid ligand is conjugated to polyethylene glycol (PEG).

16. The method ofclaim 15 wherein said PEG has a molecular weight of about between 10-80 K.

17. The method ofclaim 15 wherein said PEG has a molecular weight of about 20-45 K.

18. The method ofclaim 13 wherein said ligand is

wherein

X=PEG, and

LIGAND=rGrGrArGrGfUfUrAfUfUrAfCrArGrArGfUfCfUrGfUfUrArGfCfUrGfUrAfCfUfCfC-3′-3′-dT (SEQ ID NO: 115), wherein rG is 2′OH G, rA is 2′OH A, fU is 2′F U and fC is 2′F C.

Images